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Abstract 
Aristolochene synthase from Penicillium roqueforti (PR-AS) is sesquiterpene synthase that 
catalyses the Mg2+-dependent conversion of farnesyl diphosphate FDP to (+)-aristolochene. 
Through the use of site directed mutagenesis, fluorinated FDPs and an aza-analogue of the 
eudesmane cation, the reaction was previously shown to involve germacrene A and 
eudesmane cation as intermediates. The subsequent series of rearrangements that 
transform the eudesmane cation to (+)-aristolochene have not been investigated previously. 
To probe the carbocationic nature of these 1,2-hydride and methyl shifts, new aza-
analogues were designed to mimic the geometric and electrostatic properties of postulated 
carbocation intermediates in the catalytic mechanism of PR-AS. Here is described the 
synthesis of both enantiomers of 10-aza-eremophilane in enantiomerically pure from the 
common precursor (4S)-limonene oxide and their analysis as inhibitors of PR-AS.  
The synthesis of (7R,4S,5S)-10-aza-eremophilane cation was accomplished in 8 steps, 
starting from a known keto ester that in turn was obtained by degradation of (-)-limonene 
oxide. An identical synthetic protocol was repeated from (4R)-limonene oxide to give the 
enantiomer of 10-aza-eremophilane cation. Inhibition studies with compound (7R,4S,5S)-10-
aza-eremophilane indicated that this ammonium salt acted as a moderate competitive 
inhibitor of PR-AS (Ki = 38 µM), and showed that eremophilane cation is likely a true 
intermediate on the pathway from FDP to aristolochene during PR-AS catalysis. The 
inhibition potency of 10-aza-eremophilane was increased by the addition of diphosphate PPi 
(Ki = 2.9 µM). This synergetic kinetic effect suggests that the possible involvement of PPi as a 
stabilizing anion for the eremophilane carbocation in PR-AS biosynthesis. Inhibition studies 
of the enantiomer of (7R,4S,5S)-10-aza-eremophilane cation, (7S,4R,5R)-10-aza-
eremophilane cation, which has incorrect stereocenteres, with PR-AS indicated that this 
ammonium salt was a poor inhibitor of PR-AS (Ki = 1.03 mM). The data obtained for this 
compound highlight the chiral environment of the active site of PR-AS, and more 
importantly supports the postulate that terpene synthases form a product-like contour at 
their active site that steers the carbocationic cascade catalyzed by PR-AS toward the 
production of a single enantiomer. 
    iv 
 
In the second part of the present work, progress was made towards the stereoselective 
synthesis of 5-aza-eudesmane cation. This teriary amine is a structural mimic of the 5-
eudesmane carbocation, another putative intermediate in the reaction cascade catalysed by 
PR-AS. However, this tertiary amine was not obtained with desired stereochemistry, 
nevertheless, two diastereoisomers of the desired compound were obtained. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    v 
 
TABLE OF CONTENTS 
 
DECLARATION          i 
ACKNOWLEDGEMENTS         ii 
ABSTRACT           iii 
LIST OF FIGURES          vii 
LIST OF SCHEMES           xi 
LIST OF TABLES          xv 
LIST OF ABBREVIATIONS          xv 
CHAPTER ONE INTRODUCTION         1 
1.1 General introduction to terpenes       2 
1.2 Importance and ecological role of terpenes       5 
1.3 Biosynthesis of terpenes        12 
1.3.1 Mevalonic acid (MVA) pathway      13 
1.3.2 Non-mevalonate (non-MVA) pathway      14 
1.4 Sesquiterpenes (C15)          16 
1.5 Terpene synthases          18 
1.6 Aristolochene synthase from Penicillium roqueforti      20 
1.7 Description of the reaction catalysed by aristolochene synthase    22 
1.8 Aza-analogues of highly reactive carbocations      27 
1.9  Quinolizidine alkaloids          34 
1.9.1  Synthesis of lupinine and related compounds       37 
1.10  2, 3, 4, 5-tetrahydropyridine and its derivatives      45 
1.11  Aim of this project          48 
CHAPTER TWO STEREOSELECTIVE SYNTHESIS OF 10-AZA-EREMOPHILANES  49  
2.1  Target molecules           50 
2.2  Eremophilane skeleton         50 
2.3  Retrosynthetic analysis         51 
2.4  Preparation of monocyclic lactam 183       54 
2.4.1  Beckmann rearrangement and lactamization      58 
2.5  Aza-Robinson annulation         63 
    vi 
 
2.6  Synthesis of 1-methyl-3, 4, 6, 7, 8, 9-hexahydroquinolizin-2-one (193)   65 
2.7  Synthesis of 4,5-dimethyl-1,2,4,6,7,8-hexahydroquinolizin-3-one (223)   67 
2.8  Imminium salts from enaminones such as 193      71 
2.9  Huang-Minlon modification of Wolff-Kishner reduction     75 
2.10  Stereoselective synthesis of of (7R,4S,5S)- 84       82 
2.11  Inhibition studies of PR-AS with ammonium salt 178     93 
2.12  Inhibition studies of PR-AS with ammonium salt (7R,4S,5S)-84   94 
2.13  Inhibition studies of PR-AS with ammonium salt (7S,4R,5R)-84   96 
2.14  Crystal structures of Aspergillus terreus aristolochene synthase (AT-AS)  
complexed with (7R,4S,5S)-84 and (7S,4R,5R)-84     97 
CHAPTER THREE APPROACHES TOWARDS THE SYNTHESIS OF  
5-AZA-EUDESMANE CATION          101 
3.1  Retrosynthetic analysis of 5-aza-eudesmane cation (83)    102 
3.2 Preparation of monocyclic imine 182        103 
3.2.1  Curtius rearrangement        105 
3.2.2       Cyclic imine-enamine ring formation                                                                   107 
3.3  Attempted stereospecific synthesis of (R)-1, 3-dibromobutane    108 
3.4  Synthesis of dehydroquinolizidinium salt 262       110 
3.5  Introduction of bridgehead methyl group to iminium salt 262   112 
3.6  Crystal structure of AT-AS complexed with amino cation 275    118 
3.7  Polonovski-Potier reaction of isomers 108 and 109     121 
3.7.1  Anti Polonovski-Potier inversion of bicyclic trans-fused quinolizidine 108  122 
3.7.2  Anti Polonovski-Potier inversion of quinolizidine 109   126 
3.8  Stereoselective synthesis of (-)-5-aza-eudesemane cation    128 
3.9  Another approach to the stereoselective synthesis of 5-aza-eudesmane cation 83 131 
3.10. Summary and future work        134 
CHAPTER FOUR EXPERIMENTAL         137 
4.1  General experimental          138 
4.2  Experimental           139 
REFERENCES            182 
APPENDIX            199 
 
    vii 
 
LIST OF FIGURES 
Figure 1.1: Structures of α-pinene (10), verbenone (11) and δ-limonene (12)   6 
Figure 1.2: Structures of E-β-farnesene (20) and (-)-germacrene A (21)    8 
Figure 1.3: Structures of gossypol (22), (+)-δ-cadinene (23), (+)-aristolochene (24)  
and PR-toxin (25)         9 
Figure 1.4: Structures of casbene (26) and paclitaxel (27)      10 
Figure 1.5: Structure of vitamin A (31)        11 
Figure 1.6: Examples of regular and irregular monoterpene skeletons    12 
Figure 1.7: Structure of lanosterol (30)        19 
Figure 1.8: Structures of fungal toxins thought to be derived from aristolochene (24)  20 
Figure 1.9: Ribbon diagram representation of the crystal structure of aristolochene  
Synthase from Penicillium roqueforti (1DGP.pdb).  
The red colour indicates the location of the two Mg-binding motifs  21 
Figure 1.10: Structures of 6, 7-dihydro-analogue of FDP (71) and dihydro-germacrene 
  A (72)          24 
Figure 1.11: Structures of fluorinated farnesyl diphosphates 73, 75, 76 and 79  
  and the fluorinated germacrene A analogues 74, 77 and 78    26 
Figure 1.12: Structures of 5-eudesmyl cation (69) and eremophilenyl cation (70)  
 and their aza-analogues 83 and 84 respectively      27 
Figure 1.13: Structures of eudesmane cation (68) and its aza-analogue 85    29 
Figure 1.14: Structures of PSPP (9) and (2R, 3S)-aziridine analogue (95)of PSPP    32 
Figure 1.15: Structures of 16-aza-ent-beyerane (102) and 16-aza-ent-trachylobane  
(103), proposed aza analogue mimics for the ent-beyeran-16-yl ion  
  (100) and protonated ent-trachylobane (104)      34 
 Figure1.16:  Structures of quinolizidines 105-112       34 
Figure 1.17: Structures of cermizine C (113), senepodine G (114) and cermizine (115)  35 
Figure 1.18: Structures of quinolizidine (116), lupinine alkaloid (117)  
  and epilupinine (118)         36 
 Figure 1.19: Conformations of 1-, 2-, 3-and 4-methylquinolizidines    44 
Figure 2.1: Structures of target molecules 178, (7R,4S,5S)-84 and (7S,4R,5R)-84 and  
   eremophilanyl cation (70)        50 
 
  
    viii 
 
Figure 2.2: Structure and numbering system of the eremophilane skeleton 179, 
   eremophilone (180) and quinolizidine (181)     50 
Figure 2.3: Retrosynthetic analysis of aza analogues 83 and 84    52 
Figure 2.4: Retrosynthetic analysis of compound 190     52 
Figure 2.5: Retrosynthetic analysis of enaminones 193 and 194 involving  
        aza-Robinson annulations        53 
Figure 2.6: Retrosynthetic analysis of 10-aza-eremophilane salt 84     53 
Figure 2.7: Structures of 2-piperidone (216) and lactam 183     63 
Figure 2.8: General scheme for the Robinson annulation reaction    64 
Figure 2.9: HMBC spectrum of unexpected bicyclic compound 225     69 
Figure 2.10: Conformations of enaminone 193      71 
Figure 2.11: Infra-red spectrum of amino ketone 223 showing Bohlmann bands  
at 2761-2927 cm-1        74 
Figure 2.12: Relative stereochemistry of the 4,5-dimethyl quinolizinone (223)  74 
Figure 2.13: 1-HNMR spectrum of 1,9-dimethyl-2,3,4,6,7,8-hexahydroquinolizidine (105) 
   in the region δH  = 0.5 – 2.5 ppm      80 
Figure 2.14: 1-HNMR spectrum of 1,9-dimethyl-2,3,4,6,7,8-hexahydroquinolizidinium salt 
(178) in the region δH  = 0.5 – 3.0 ppm       81 
Figure 2.15: Ball and stick representation of the X-ray crystal structure of the picrate 
  salt 243 (solved by Dr. Benson Kariuki)      82 
Figure 2.16: Comparison between the two thiolactams 195 and 196    83 
Figure 2.17: Comparison between the two Michael adducts 222 and 244   84 
Figure 2.18: 1H-NMR spectroscopic data for 193 and 194     85 
Figure 2.19: Comparison between aminoketones 223 and 197    87 
Figure 2.20: Trans-fused quinolizidine 197 in which the nitrogen lone-pair is trans to at 
  least two axial hydrogen atom (Bohlmann bands)    88 
Figure 2.21: Stereochemistry of amino ketone 197      88 
Figure2.22: Ball and stick representation of the X-ray crystal structure of the 
  perchlorate salt 247 (solved by Dr. Benson Kariuki)    89 
Figure 2.23: Ball and stick representation of the X-ray crystal structure of the picrate 
salt 260 (solved by Dr. Benson Kariuki)      92 
Figure 2.24: Ball and stick representation of the X ray crystal structure of the  
perchlorate salt 261 (solved by Dr. Benson Kariuki)    92 
 
    ix 
 
 
Figure 2.25: Lineweaver-Burk plots of initial rate versus the concentration of substrate 
 for AS catalysed turnover of FDP in the presence of 
 4,5 dimethyl- hexahydroquinolizidine. TFA salt (178) in A) the absence of 
 PPi (Ki = 2.86 mM) and (B) the presence of 250  µM PPi (Ki = 1.66 mM).  
 initial rates were determined at increasing concentrations of analogue  
 (0-25 µM). Assays were carried out (by Dr. Juan A. Faraldos) with purified 
 wild-type AS (100 nM) in assay buffer (20 mM Tris, 5 mM MgCl2, pH 7.5) 
 and at room temperature (22 °C) for 12 min.      94 
Figure 2.26: Inhibition of AS by ammonium salt (7R,4S,5S)-84: Lineweaver-Burk 
 plots of initial rates versus the concentration of substrate for AS 
 catalysed turnover of FDP in the presence of inhibitor (7R,4S,5S)-84 in 
 (A) the absence of PPi (Ki = 27.7 µM)  and  
 (B) the presence of 250 µM PPi (Ki = 2.9 µM).  
 Initial rates were determined at increasing concentrations of inhibitor 
  (0-25 µM). Assays were carried out (by Dr. Juan A. Faraldos) with purified  
 wild-type AS (100 nM) in assay buffer (20 mM Tris, 5 mM MgCl2, pH 7.5) 
  and at room temperature (22 °C) for 12 min.      95 
Figure 2.27: Inhibition of AS by ammonium salt (7R,4S,5S)-84: Dixon plots for 
 Inhibition of PR-AS by (7R,4S,5S)-84, in the absence of PPi, (7R,4S,5S)- 
 84 acted a modest competitive inhibitor of PR-AS with Ki = 38 µM  
 (right plot). The Ki of (7R,4S,5S)-84 dropped to 2.5 µM when  
 250 mM diphosphate (left plot) was added demonstrating a strong 
 synergistic inhibition. Assays were carried out by Dr. Juan A. Faraldos  96 
Figure 2.28: Ion-pair of eremophilane cation (70) with PPi and its analogue  
(7R, 4S, 5S)-84          96 
Figure 2.29: Lineweaver-Burk plots of initial rate versus the concentration of  
 substrate for AS catalysed turnover of FDP in the presence of (7S,4R,5R) 
 -84 in (A) the absence of PPi (Ki = 1.03 mM) and (B) the presence of 250 
µM PPi (Ki = 0.44 mM). Initial rates were determined at  
increasing concentrations of analogue (0, 16, 280, and 1568 µM). Assays 
were carried out (by Dr. Juan A. Faraldos) with, purified wild-type AS  
(100 nM) in assay buffer (20 mM Tris, 5 mM MgCl2,  pH 7.5) and 
at room temperature (22 °C) for 12 min     97 
Figure 2.30: Active site of AT-AS complexed with Mg2+-PPi and tertiary amino 
 cation (7R,4S,5S)-84. (a) Simulated annealing omit map of (7R,4S,5S)-84  
 bound to monomer A in the AT-AS-(7R,4S,5S)-84 complex. Analogue  
 (7R,4S,5S) 84) is shown in gray, and Atoms are shown in the following 
 colours: C = yellow (protein), O = red, N = blue, P = orange, S = yellow, Mg2+ 
 ions = silver spheres, solvent molecules = red spheres. Water molecule  
 "w" is trapped in the active site along with (7R,4S,5S)-84. (b) Superposition 
 of the AT-AS-(7R,4S,5S)-84 complex with the AT-AS-FSDP complex.  
 This structure was solved by the group of Prof. David W. Christianson, 
 University of Pennsylvania.        99 
    x 
 
 
Figure 2.31:  Active site of AT-AS complexed with Mg2+-PPi and tertiary amino  
 cation (7S,4R,5R)-84. (a) Simulation of tertiary amino cation  
 (7S,4R,5R)-84 bound to monomer A in the AT-AS-(7S,4R,5R)-84  
 complex. Analogue (7S,4R,5R)-84 is shown in gray, and atoms are shown 
 in the following colors: C = yellow (protein), O = red, N = blue, P = orange, 
 S = yellow, Mg2+ ions = silver spheres, solvent molecules = red spheres.  
 Water molecule "w" is trapped in the active site along with (7S,4R,5R)-84.  
 (b) Superposition of the AT-AS-(7S,4R,5R)-84 complex with the  
 AT-AS-FSDP complex. This structure was solved by the group of Prof.  
 David W. Christianson, University of Pennsylvania.    100 
 
Figure 3.1: Retrosynthetic analysis of 5-aza-edesmane cation (83)     102 
Figure 3.2: Positions of α-double bond and β-oxygen with respect to the methyl 
 group          103 
Figure 3.3: Structures of imines 165 and 182      108 
Figure 3.4: General scheme for the stereospecific synthesis of amine 266   108 
Figure 3.5: Stereochemistry of amine 108        114 
Figure 3.6: Ball and stick representation of the X-ray crystal structure of the  
 perchlorate salt 273 (solved by Dr. Benson Kariuki)    115 
Figure 3.7: Stereochemistry of amine 109        115 
Figure 3.8: Ball and stick representation of the X-ray crystal structure of the  
 perchlorate salt 274 (solved by Dr. Benson Kariuki)    116 
Figure 3.9: Conformations of 1-, 2-, 3- and 4- methylquinolizidines    116 
Figure 3.10: Comparison of coupling constant of CH3CH doublets between 
distereoisomers 108 and 109       117 
Figure 3.11: Stepwise mechanism in AT-AS biosynthesis     119 
Figure 3.12: Active site of AT-AS complexed with Mg2+-PPi and tertiary amino cation  
 275 (a) Simulated annealing omit map of 275 bound to monomer A in the  
 AT-AS-275 complex. Analogue 275 is shown in gray, and Atoms are  
 shown in the following colours: C = yellow (protein), O = red, N = blue,  
 P = orange, S = yellow, Mg2+ ions = silver spheres, solvent molecules 
 = red spheres. Water molecules "w" is trapped in the active site along with 
  275 (b) Superposition of the AT-AS-275 complex with the AT-AS-FSDP  
 complex. This structure was solved by the group of Prof. David W.  
 Christianson, University of Pennsylvania.     120 
Figure 3.13: Polonovski-Potier inversion of isomer 109      122 
Figure 3.14: Structures of trans-quinolizidine-N-oxide 282 and cermizine C N-oxide (283) 123 
    xi 
 
Figure 3.15: Stereochemistry of amine N-oxide 282      123 
Figure 3.16: Structures of 5-eudesmane cation (290) and its ananlogue (-)-5-aza- 
 eudesmane cation (292)       128
             
 
LIST OF SCHEMES 
Scheme 1.1: Biosynthesis of the prenyl diphosphates     3 
Scheme 1.2: Head to tail condensation between IDP (3) and DMADP (2) to 
  produce geranyl diphosphate (4).      4 
Scheme 1.3: Biosynthesis of squalene (7)       5 
Scheme 1.4: Biosynthesis of artemisinin (13)      7 
Scheme 1.5: Presumed biosynthesis of parthenolide (17)     7 
Scheme 1.6: Generation of cholesterol (28) from FDP (5)     11 
Scheme 1.7: Mevalonic acid pathway to IDP (3) and DMADP (2)    14 
Scheme 1.8: The non-mevalonate pathway to IDP (3) and DMADP (2)   15 
Scheme 1.9: Biosynthesis of selected sesquiterpenes from FDP    17 
Scheme 1.10: Proposed reaction catalysed by aristolochene synthase PR-AS  22 
Scheme 1.11: Conversion of DMADP (2) to isoprene (1) through a concerted reaction  
  Pathway         23 
Scheme 1.12: Proposed mechanism for the conversion of 12, 
   13-difluorofarnesyl diphosphate (79) to 12,13-difluoro- 
  (E,E)-α-farnesene (81) and 12,13-difluoro-(E)-β- farnesene (82).  26 
Scheme 1.13: Stepwise versus concerted processes in aristolochene biosynthesis   28 
Scheme 1.14: Stereoselective synthesis of 4-aza-eudesmane cation (85) Reagents: 
   (i) 1 methyl acrylate, 2. Aq H+, (ii) ethylene glycol, cat H+, (iii) Aq NH3, 
   (iv) 1. LiAlH4,  2. 10% HCl,  (v) Na, anh. EtOH, (vi) H2CO, NaCNBH3,  
   (vii) HCl, Et2O           30 
Scheme 1.15: Aza analogues for studies of trichodiene (94) biosynthesis   31 
Scheme 1.16: Aza-analogues for studies of BDPS      32 
Scheme 1.17: Biosynthesis of ent-kaurene (101)      33 
Scheme 1.18: General procedure for synthesis of quinolizidine (116)   37 
Scheme 1.19: Asymmetric synthesis of (+)-lupinine by Goldberg    38 
Scheme 1.20: Synthesis of both enantiomers 1-menthoxycarbonyl-1-(10)- 
   dehydroquinolizidines(-)-123-a and (+)-123-b    38 
Scheme 1.21: Boekelheide’s method for the synthesis of 1- and 3-substituted 
  quinolizidines         39 
    xii 
 
Scheme1.22: Conversion of 2-thiopiperidone to lupinine as reported by Gerrans  40 
Scheme 1.23: Robinson annulations using Nazarov’s reagent to synthesis  
  (±)-epilupinine (118) reported by Hiroki      40 
Scheme 1.24: Synthesis (±)-lupinine (117) reported by Hiroki    41 
Scheme 1.25: Synthetic sequence for conversion of quinolizidine  
  (116) to 10-methylquinolizidine (148)     42 
Scheme 1.26: Stereoselective synthesis of (±)-cermizine C (113) and  
  (±)-epi-cermizine C (152)        43 
Scheme 1.27: Routes to quinolizidines methiodide salts 158 and 160     44 
Scheme 1.28: Structure and deprotonation of 2-methyl-2, 3, 4, 5-tetrahydropyridine  
 (165)          45 
Scheme 1.29: Synthesis of cyclic enamines 168 and 169     46 
Scheme 1.30: Evans’ procedure for the synthesis of bicyclic enamines alkaloids  
  171 and 172          46 
Scheme 1.31: One pot syntheses of 175-177 using Evans’ procedure   47 
Scheme 1.32: Carbocations proposed to be involved in aristolochene biosynthesis  
 and the aza-analogues 83 and 84 targeted for synthesis   48 
Scheme 2.1: Base-catalysed hydrolysis of (-)-limonene oxide (187) to  
   diastereomeric diol 199        55 
Scheme 2.2: Acid-catalysed hydrolysis of epoxide 200     55 
Scheme 2.3: Stereoselective oxidation of diol 199 to cis-202 and trans-202  56 
Scheme 2.4: Mechanism of oxidation diol 199 to hydroxy ketone 202 by  
  chlorochromate anion        57 
Scheme 2.5: LTA-oxidative cleavage mechanism of α-hydroxy ketone 202  
 to form keto ester 198         58 
Scheme 2.6: Formation of oxime 204        59 
Scheme 2.7: Mechanism of the Beckmann rearrangement of oxime 205 to  
 acetamide 209         60 
Scheme 2.8: Intramolecular cyclization reaction of keto acid 211 to bicyclic 
-lactone 210           61 
Scheme 2.9: Beckmann rearrangement of oxime 212 to 213 by the Mehta’s procedure  61 
Scheme 2.10:Rearrangement of oxime tosylate 214 under basic condition to 189 and 
 215          62 
Scheme 2.11: Beckmann rearrangement of oxime 204 to acetamide 189    62 
Scheme 2.12: Cyclisation reaction of acetamide 189 to lactam 183    63 
 
    xiii 
 
Scheme 2.13: Danishefsky and Heathcock methods for the preparation of 
indolizinones and quinolizinones via distinct aza-Robinson 
annulations reactions        64 
Scheme 2.14: Mechanism of thiation of -valerolactam 216 with Lawesson’s reagent   66 
Scheme 2.15: Michael alkylation of thiolactam 195 with EVK (185)    66 
Scheme 2.16: Mechanism of aza-Robinson annulation to give quinolizinone 193   67 
Scheme 2.17: 1,4-Addition reaction of Me2CuLi to octalone 224     68 
Scheme 2.18: Ring expansion reaction of enaminone 193      68 
Scheme 2.19: Proposed mechanism of expansion ring reaction of 194    70 
Scheme 2.20: Activation of cis-trans enaminone 226 toward 1,4-addition   71 
Scheme 2.21: Reaction of enaminone 193 with acetyl chloride   72 
Scheme 2.22: Introduction of an angular methyl group to enaminone through  
 iminium salt 233 to generate  
 4,5-dimethyl-1,2,4,6,7,8-hexahydroquinolizin-3-one (223)    73 
Scheme 2.23: Formation of amine thioketal 234      75 
Scheme 2.24: Formation of tosyl hydrazone 235      76 
Scheme 2.25: Proposed mechanism of Shapiro reaction of 235 to give 236  77 
Scheme 2.26: Conversion of aminoketone 223 to diastereoisomers of amino alcohol 
237 and 238 and subsequently to tosylate salt 239     78 
Scheme 2.27: Fernandez procedures to remove ketone functionality from 240  78 
Scheme 2.28: Mechanism of the Huang-Minlon reduction of amino ketone  
223 to amine 105        79 
Scheme 2.29: Synthesis of bicyclic tertiary amine 105 and its TFA salt 178   80 
Scheme 2.30: Preparation of picrate salt 243 for X-ray crystallography  
(performed by Dr. Juan A. Faraldos)      81 
 Scheme 2.31: Conversion of lactam 183 to thiolactam 196      82 
Scheme 2.32: Formation of Michael adduct 244       83 
Scheme 2.33: Aldol condensation of thioiminium salt generating 
enaminone 194 and by-product 245       85 
Scheme 2.34: Conversion of enaminone 194 to amino ketone 197     87 
Scheme 2.35: Conversion of amino ketone 197 to final free amine 106    88 
Scheme 2.36: Formation of (7R,4S,5S)- 84 and perchlorate salt 247  
(carried out by Dr. Juan A. Faraldos)      89 
 
Scheme 2.37: Stereospecific synthesis of bicyclic tertiary amine (7R,4S,5S)- 
4,5-dimethyl-7-(prop-1-en-2-yl) decahydroquinolizidine (106)  90 
 
    xiv 
 
Scheme 2.38: Stereoselective synthesis of bicyclic tertiary amine 107 and   
(7S,4R,5R)-84         91 
Scheme 2.39: Picrate 260 and perchlorate 261 salts of amine 107   
(carried out by Dr. Juan A. Faraldos)      91 
Scheme 3.1: Epoxidation of (-)-limonene (263) to (-)-limonene oxide (187)   104 
Scheme 3.2: Conversion of (-)-limonene oxide (187) to keto acid 211    104 
Scheme 3.3: Synthesis of keto acid 211 by oxidation of diol 199 with Jones’ reagent  105 
Scheme 3.4: Mechanism of the Curtius rearrangement of keto acid 211    106 
Scheme 3.5: Cyclisation of urethane 186 to imine 182      107 
Scheme 3.6: Intramolecular cyclisation of urethane 186 to cyclic imine 182 in  
74% yield         108 
Scheme 3.7: Conversion of (S)-1, 3-butanediol (188) to racemic 1, 3-dibromobutane  109 
Scheme 3.8: Proposed mechanism for conversion of chiral diol 188 to racemic 1,3 
dibromobutane         110 
Scheme 3.9: Reaction of cyclic imine 182 with racemic 1, 3-dibromobutane  111 
Scheme 3.10: Possible elimination reaction mechanisms of alkylated compound 269  111 
Scheme 3.11: Conversion of iminium salt 262 to diastereoisomeric amines  
 108 and 109         112 
Scheme 3.12: The configuration and conformational possibilities of  
   4, 10-dimethyl quinolizidines 272, 109, 108 and 266    113 
Scheme 3.13: Formation of perchlorate salt 273 (carried out by Dr. Juan A. Faraldos) 114 
Scheme 3.14: Formation of perchlorate salt 274 (carried out by Dr. Juan A. Faraldos) 116 
Scheme 3.15: Stereoselective synthesis of trans-fused-quinolizidine 108  and cis-fused  
 quinolizidine 109         118 
Scheme 3.16: General scheme of Polonovski-Potier reaction of N-oxide 276  121 
Scheme 3.17: Synthesis of trans-fused-quinolizidine-N-oxide 282    122 
Scheme 3.18: Synthesis of iminium ion 112       124 
Scheme 3.19: Synthesis of iminium ion 112 and comparison with (-)-senepodine G (114) 124 
Scheme 3.20: Reduction of iminium ion 112 with NaBH4     125 
Scheme 3.21: Stereospecifically addition of hydride to (-)-senepodine G (114) 
 and (±)-epi-senepodine G (156)       125 
Scheme 3.22: Synthesis of amine-N-oxide 280      126 
Scheme 3.23: Conversion of cis-N-oxide 280 to iminium ion 285 and isomerization to  
 unexpected conjugated iminium ion 286     127 
Scheme 3.24: Biosynthesis of 5-epi-aristolochene (287)     128 
    xv 
 
Scheme 3.25: Stereoselective synthesis of trans-quinolizidine 110 and  
 cis-quinolizidine 111        130 
Scheme 3.26: Preparation of 5-aza-eudesmane cation (292) and cis-quinolizidinium 
  salt 300 (carried out by Dr. Juan A. Faraldos)     130 
Scheme 3.27: An alternative approach to the synthesis of bicyclic amine 266  131 
Scheme 3.28: Synthesis of imine acetal 302 and attempts to introduce  
 methyl group to 302        132 
Scheme 3.29: General strategy to activate imine acetal 302 as nitrone  
 305 towards addition of methyl magnesium bromide   133 
Scheme 3.30: Epoxidation of vinylic group of imine acetal 302 to  
 epoxides 307 and 308        133 
 
 
 
LIST OF TABLES 
Table 2.1: Attempts to improve the yield of enaminone 194    86 
 
 LIST OF ABBREVIATIONS 
 
[α]    Specific rotation 
Aq    Aqueous 
Amp    Ampicillin 
Ar    Unspecified aryl substituent 
AS    Aristolochene synthase 
AT-AS    Aristolochene synthase from Aspergillus terreus 
BuLi    Butyl lithium 
c                                 Concentrated 
CoA                        Coenzyme A 
mCPBA                 meta chloroperoxybenzoicacid 
DBU                       1, 8-diazabicyclo[5.4.0]undec-7-ene 
    xvi 
 
DCM                    Dichloromethane 
DEPT                        Distortionless Enhancement by Polarisation Transfer 
DIBAL                   Diisobutylaluminium hydride 
DMAPP                 Dimethylallyl diphosphate 
DPPA                   Diphenylphosphoryl azide 
DMF                       Dimethylformamide 
DMSO                Dimethyl sulfoxide 
EI                           Electron impact 
FDP                          Farnesyl diphosphate 
HMBC                     Heteronuclear multiple-bond correlation spectroscopy 
HRMS                     High resolution mass spectrometry  
HSQC                      Heteronuclear single-quantum correlation  
HOAc                       Acetic acid 
h                             Hours 
i                              iso 
IR                        Infra Red 
IDP                         Isopentenyl diphosphate 
J                  Coupling constant (in Hz) 
KM                                Michaelis constant 
LDA                     Lithium diisopropyl amide 
LTA             Lead tetraacetate 
M                  Molar 
Me                      Methyl 
MeLi                   Methyl lithium 
MEP                     Methylerythritol phosphate 
min                     Minutes 
m.p.                  Melting point             
MS                  Mass spectrometry 
    xvii 
 
MVA                  Mevalonic acid 
MTO                 Methyltrioxorhenium 
MW                   Molecular weight 
n                         normal 
NADPH              Reduced nicotinamide adenine dinuleotide phosphate 
NMR                  Nuclear Magnetic Resonance 
nOe                    Nuclear Overhauser effect 
NOESY             Nuclear Overhauser effect spectroscopy 
OD                   Optical density 
p                     para  
PCC               Pyridinium chlorochromate 
Ph                  Phenyl 
PPi                   Inorganic diphosphate  
PR-AS    Aristolochene synthase from Penicillium roqueforti 
PTSA               para-Toluenesulfonic acid 
R                     Unspecified substituent 
TFA                  Trifluoroacetic acid 
TFAA                Trifluoroacetic anhydride 
THF                Tetrahydrofuran 
TLC                 Thin layer chromatography 
TsCl                  para-Toluene sulfonyl chloride 
TMSCl              Trimethylsilyl chloride  
TEAS                 5-epi-Aristolochene synthase from Nicotiana tabacum 
UHP    Urea hydrogen peroxide 
 
    0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    1 
 
 
 
 
 
 
 
 
 
CHAPTER ONE 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
    2 
 
1.1 General introduction to terpenes 
Terpenes are a group of small molecule natural products that are widespread in nature. 
They are produced in all forms of life but are particularly prevalent in the plant kingdom, 
that generates more than half their number which currently exceeds 30,000 identified 
compounds.1 The term terpene originates from “turpentine”, a fluid obtained through 
steam distillation of resin obtained from pine trees. Terpenes are a large and varied class 
of hydrocarbons, when they are modified biochemically, such as through oxidation or 
rearrangement of the carbon skeleton, the resulting compounds are generally referred to 
as terpenoids.  
The majority of these compounds are secondary metabolites and in most cases the actual 
role they play in the organism that produces them are unidentified. They are often not 
essential for viability of the organism. Instead, they play important roles, for example, in 
communication or defence.2 There is also a small group of terpenoids which are used in 
primary metabolism, such as the phytol side chain of chlorophyll.3  
The terpenoids form a large and structurally diverse family of natural products derived 
formally from C5 isoprene units
4 (1) joined in a head-to-tail fashion. Dimethylallyl 
diphosphate (DMADP, 2) and isopentenyl diphosphate (IDP, 3) are biological equivalents of 
isoprene and are universal precursors of the isoprenoids in all living organisms (Scheme 
1.1).5 Typical structures contain carbon skeletons represented by (C5)n, and are classified as 
hemiterpenes (C5) (Scheme 1.1), monoterpenes (C10), sesquiterpenes (C15), diterpenes 
(C20), sesterterpenes (C25), triterpenes (C30) and tetraterpenes (C40). All these acyclic 
precursors can then be modified to generate acyclic, monocyclic or multicyclic products.6,7  
The head to tail condensation of IDP (3) and DMADP (2) catalysed by geranyl diphosphate 
synthase yields geranyl diphosphate (GDP, 4) the universal precursor of all monoterpenes. 
This process involves ionization of the DMADP to give an allylic carbocation that adds to 
the double bond of IDP, to form a new carbocation that is quenched by selective proton 
elimination (Scheme 1.2).8 With the specific prenyl transferase, this model electrophilic 
reaction can be further extended to produce further linear isoprenoid diphosphates by 
sequential addition of IDP units. Farnesyl diphosphate (FDP, 5), and geranylgeranyl 
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diphosphate (GGDP, 6) arise by the addition of one molecule of IDP to either geranyl or 
farnesyl diphosphate or the loss of one molecule of diphosphate ion. They are, the 
universal precursors of all sesqui- and diterpenes found in nature. All the double bonds in 
these linear precursors display E-stereochemistry.9 These linear diphosphates are further 
processed by terpene synthases to give rise to cyclic and acyclic terpenoids. 
 
Scheme 1.1: Biosynthesis of the prenyl diphosphates 
 
    4 
 
 
 
 
Scheme 1.2: Head to tail condensation between IDP (3) and DMADP (2) to produce 
geranyl diphosphate (4). 
 
Triterpenes (C30) are not formed by an extension of the process of adding IDP to the 
growing chain. Instead, two molecules of FDP (5) are joined head to head to yield the 
hydrocarbon squalene (7). Squalene synthase (SS) catalyses the 1`-1 condensation 
between two molecules of farnesyl diphosphate (5) via a tertiary cyclopropyl carbinyl 
intermediate, presequalene diphosphate PSDP (9) (Scheme 1.3) to yield squalene (7). 
While the formation of the tetraterpenes skeleton, for example phytoene (8) (Scheme 1.1), 
involves coupling of two molecules of geranylgeranyl diphosphate GGDP (6).10  
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Scheme 1.3: Biosynthesis of squalene (7) 
1.2 Importance and ecological role of terpenes 
Apart of their huge array of structural diversity, terpenoids also have varied biological 
activity in nature. For example, plants produce a wide range of this family of molecules for 
very different purposes, such as for attraction of insects, for the inhibition of the growth of 
competitor plants in resource-limited areas or for antimicrobial and antifungal 
properties.11 
Monoterpenoids are usually found in the essential oils of citrus and other plants.12 They 
have a high economic value as flavours and fragrances. However, recently, more medical 
and ecological functions have been allocated to this group of terpenoid compounds. α-
Pinene (10) (Figure 1.1) has been discovered as sex pheromone attracting the female 
cotton boll weevil.13 The primary oxidation product of α-pinene is verbenone (11), which 
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has an important role in the control of the southern pine bark beetle. Recent publications 
have revealed that verbenone also has antimicrobial properties.14 δ-Limonene (12) has 
been used as a medicinal compound, it is extracted from orange peel oil and has 
chemopreventative activity against some cancer cell lines.13 
 
Figure 1.1: Structures of α-pinene (10), verbenone (11) and δ-limonene (12) 
 
All terpenoids derive from a small number of linear isoprenoid diphosphate precursors. 
The 15-carbon compound farnesyl diphosphate FDP (5) is the universal precursor to all 
sesquiterpenes in plants, bacteria and fungi.15-18 Sesquiterpenoids have been used as 
traditional medicines for thousands of years and more recently modified sesquiterpenoids 
as therapeutic agents.19 For example artemisinin (13), an endoperoxide-containing 
sesquiterpene lactone from the Chinese-Vietnamese plant-Artimisia annua L. (sweet 
wormwood) has been used in China as a traditional anti-malaria and antipyretic drug.20 The 
biosynthesis of artemisinin is believed to involve the cyclization of farnesyl diphosphate 
FDP (5) to amorpha-4,11-diene (14), which is further oxidized to an dihydroartemisinic acid 
(16), an advance precursor of artemisinin (Scheme 1.4).21 
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Scheme 1.4: Biosynthesis of artemisinin (13) 
 
Parthenolide (17) (Scheme 1.5) is another sesquiterpene lactone present in several 
medicinal plants that has been used in folk medicine for its anti-inflammatory or analgesic 
properties. It is also used as the antimigraine agent in Feverfew and as a traditional herbal 
remedy for the relief of arthritis, toothache and menstrual difficulties.10 Germacryl cation 
(18), which results from a 1,10-cyclisation of FDP (5), is the precursor of germacrene A-
derived sesquiterpenes such as parthenolide. Compound 17 is actually classified as 
germacranolide, the suffix “olide” referring to the lactone group. Whilst the details of the 
pathway are not known, a series of simple oxidative transformations can produce the α,β-
unsaturated lactone and epoxide groupings (Scheme 1.5).10 
 
Scheme 1.5: Presumed biosynthesis of parthenolide (17) 
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While some sesquiterpenoids (e.g. 13 and 17) have medicinal properties useful for 
humans, the vast majority of these secondary metabolites are efficiently exploited by the 
organism that produce them. Aphids, for example, when attacked or irritated produce 
defensive secretions from their cornicles, known as volatile alarm pheromones, that cause 
other aphids in the area to disperse. While the most common alarm pheromone identified 
for aphids is the acylic E-β-farnesene (20) (Figure 1.2),22 termites use the macrocycle (-)-
germacrene A (21) as their preferred semiochemical.23  
 
 
Figure 1.2: Structures of E-β-farnesene (20) and (-)-germacrene A (21) 
Plants and microorganisms also produce sesquiterpenes to their advantage. Gossypol (22), 
a sesquiterpene dimer derived from δ-cadinene (23) is used by cotton plants as a defensive 
phytoalexin.24 similarly, fungi, when under stress, produce a blend of defensive 
sesquiterpenoid mycotoxins, used as deterrents against competing organisms. 
Aristolochene (24) (Figure 1.3) is the biochemical precursor of several fungal toxins 
including the potentially lethal PR- toxin (25).25  
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Figure 1.3: Structures of gossypol (22), (+)-δ-cadinene (23), (+)-aristolochene (24) and PR 
toxin (25) 
 
As with other groups of terpenes, diterpenes have quite a few different uses both in nature 
and in medicine. Casbene (26) (Figure 1.4),26 a macrocyclic hydrocarbon, has been 
reported to appear at much higher levels in castor bean seedlings when the plant is under 
fungal attack than in sterile conditions. With both antibacterial and antifungal properties, 
this diterpene is considered to be a phytoalexin.26 
Of particular interest in therapeutic terms is the diterpene-derivative paclitaxel (TaxolTM) 
(27) (Figure 1.4),27 which is extracted from the pacific yew tree and has remarkable 
antitumour activity and antileukemic activity. One common characteristic of cancer cells is 
their rapid rate of cell division. In order to accommodate this, the cytoskeleton of a cell 
undergoes extensive restructuring. Paclitaxel is an effective treatment for aggressive 
cancers, due to its adverse affect on the process of cell division by preventing this 
restructuring by binding to tubulin. It is most commonly used to treat ovarian, breast and 
non-small cell lung cancer.27  
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Figure 1.4: Structures of casbene (26) and paclitaxel (27) 
 
Cholesterol (28) and other steroids are considered as triterpenes even though they possess 
(C27-C30) skeletons. This is because they are derived from the C30 linear precursor, 
squalene (7), which is derived from two molecules of FDP (5) (Scheme 1.3). Oxidation by 
squalene monooxygenase of one of the terminal double bonds of squalene gives 2,3-
squalene oxide (29), which undergoes enzyme-catalyzed cyclisation to afford lanosterol 
(30), and is then elaborated into cholesterol (28) and other steroids (Scheme 1.6).28 
Cholesterol is the source of sexual hormones, bile acid and vitamin D in animals. It is also 
involved in controlling calcium and phosphorus metabolism. Another important function is 
the maintenance of membrane fluidity and permeability.28 
Carotenoids comprise the family of naturally occurring pigments derived from the C40 
linear precursor phytoene (8) (Scheme 1.1).29 Carotenoids are central for the absorption of 
light in photosynthetic organisms due to their highly conjugated structures. They are also 
the precursors of the essential growth factor retinol also known as vitamin A (31) (Figure 
1.5), which has important functions for example in the vision process, for resistance to 
infectious disease and bone remodelling.30,31 
 
    11 
 
 
Scheme 1.6: Generation of cholesterol (28) from FDP (5). 
 
 
Figure 1.5: Structure of vitamin A (31). 
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1.3 Biosynthesis of terpenes 
Isoprene, namely 2-methyl-1,3-butadiene (1) was first discovered during distillation of 
natural rubber in a low-boiling fraction, and identified during the degradation of terpentine 
oil and cyclic monoterpenes. The initially postulated “isoprene rule” by Wallach stated that 
most terpenoids could be hypothetically constructed by repetitive joining of isoprene (1) 
units.32 In 1953 Leopold Ruzicka postulated the “biogenetic isoprene rule” stating that the 
carbon skeleton of terpenes is composed of isoprene units linked either in a regular (head 
to tail) or irregular arrangement.33 For example, a number of natural monoterpene 
structures contain carbon skeletons which, although obviously derived from isoprene C5 
units, do not seem to fit the regular head-to-tail coupling mechanism (Figure 1.6).10 
 
Figure 1.6: Examples of regular and irregular monoterpene skeletons 
 
Even though the isoprene unit is the structural feature characteristic of all terpenes nature 
utilizes two C5 diphosphates, dimethylallyl diphosphate (DMADP, 2) and isopentenyl 
diphosphate (IDP, 3) (Scheme 1.1),34 as the actual biological building blocks from which 
terpenes are derived. Isopentenyl diphosphate (IDP, 3) and dimethylallyl diphosphate 
(DMADP, 2) are the substrates of isoprenyl diphosphate synthases, a family of terpenes 
enzymes that mediate their condensation giving rise, to geranyl diphosphate (GDP, C10), 
farnesyl diphosphate (FDP, C15), and geranyl geranyl diphosphate (GGDP, C20) (Scheme 1.1) 
by the iterative addition of IDP. There are two pathways leading to IDP and DMADP, the 
mevalonate pathway and a recently discovered mevalonate-independent pathway via 
deoxyxylulose phosphate.35  
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1.3.1 Mevalonic acid (MVA) pathway 
The mevalonic acid pathway is usually used by mammals, higher plants, fungi and even 
some bacteria.36 This pathway starts with three molecules of acetyl-CoA (32). The first two 
units of acetyl-CoA react in a Claisen condensation reaction catalysed by acetoacetyl-CoA 
synthase which release coenzyme A to afford acetoacetyl-CoA (33) (Scheme 1.7). A third 
molecule of acetyl-CoA is subsequently added in an aldol-like manner with the help of β-
hydroxy-β-methylglutaryl-CoA (HMG-CoA) synthase yielding HMG-CoA (34).36 Next, HMG-
CoA reductase catalyses the reduction of the thioester group of 34 to give the primary 
alcohol functionality of mevalonic acid (36). Two equivalents of NADPH cofactor are 
required in this transformation. The first NADPH reduces HMG-CoA to its corresponding 
aldehyde (mevaldic acid, 35), and the second further reduces the newly formed carbonyl 
group to (3R)-mevalonic acid (MVA, 36).37 The two hydroxyl groups of (3R)-mevalonic acid 
are then diphosphorylated by three molecules of ATP to yield mevalonic acid triphosphate 
(38). The final product IDP (3) arises from the decarboxylation of mevalonic acid 
triphosphate. IDP (3) and DMADP (2) are interconvertible by stereospecific isomerisation. It 
has been shown by tritium-labelling experiment that only the pro-R hydrogen of 3 at C2 is 
involved in the isomerisation process.38 
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1.3.2 Non-mevalonate (non-MVA) pathway 
The non-MVA pathway was discovered at the end of the last century by Rohmer and co-
workers.39,40 This pathway takes place in plastids and has also been named as the 
pyruvate/glyceraldehyde-3-phosphate pathway or MEP pathway. Pyruvate (39) and D-
glyceraldehyde-3-phosphate (40) (Scheme 1.8) are the starting compounds and 2-C-
methyl-D-erythritol-4-phosphate (MEP, 43) is an important intermediate of this alternative 
metabolic pathway leading to the formation of isopentenyl diphosphate (IDP) and 
dimethylallyl diphosphate (DMADP). 
 
Scheme 1.7: Mevalonic acid pathway to IDP (3) and DMADP (2). 
 
This route starts by a thiamine diphosphate (TPP) mediated decarboxylation of pyruvate 
(39) that affords an enamine that further reacts with glyceraldehydes-3-phosphate (40) to 
give 1-deoxy-D-xylulose-5-phosphate (DXP, 41). After a pinacol-like rearrangement of DXP, 
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the resulting intermediate is reduced with NADPH by DXP-reductoisomerase affording 2-C-
methyl-D-erythritol-4-phosphate (MEP, 43).40 MEP reacts with cytidine triphosphate CTP 
and is then phosphorylated with one equivalent of ATP to yield 2-phospho-4-
cytidinediphosphate-2-C-methylerythritol (45), which is converted to 2-C-methyl-D-
erythritol-2,4-cyclodiphosphate (46).40 Afterwards, IDP (3) and DMADP (2) are synthesized 
following a reduction-dehydration step that an electron transport chain.41 
 
 
Scheme 1.8: The non-mevalonate pathway to IDP (3) and DMADP (2) 
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1.4 Sesquiterpenes (C15) 
Addition of a further molecule of IDP to geranyl diphosphate in an extension of the 
isoprenyl diphosphate synthase reaction leads to the sesquiterpene precursor, farnesyl 
diphosphate FDP (5). FDP can then be further transformed to linear and cyclic 
sesquiterpenes.41 The first step for the majority of enzymatic formation of sesquiterpenes 
is belived to involve the ionization of FDP (5) to the transoid farnesyl cation (50) (Scheme 
1.9).7 The cyclisation of farnesyl cation may occur from the distal double bond to generate 
either the ten-(E,E-germacradienyl cation) (18) or eleven-membered ring (trans-humulyl 
cation) (51). However, due to the E-geometry of the C2-C3 double bond of FDP, a 1,6-
cyclisation is prevented by steric constraints.18 To achieve 1,6-cyclisation, sesquiterpene 
synthases generate nerolidy cation (52) by isomerisation of the C2-C3 double bond to 
generate the cisoid isomer (53) of the nerolidyl cation, thereby permitting the cyclisation 
from either the central or distal double bond to form the six-(bisabolyl cation) (54) or 
seven-(cycloheptanyl cation) (56), as well as ten and eleven membered rings; -Z,E-
germacradienyl cation (55) and -cis-humulyl cation (57) respectively (Scheme 1.9).10 
Further cyclisations, hydride shifts, methyl migrations (Wagner-Meerwein rearrangements) 
may occur following the generation of initial cyclic carbocation prior to termination of the 
reaction by deprotonation or nucleophilic capture.42,43 
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Scheme 1.9: Biosynthesis of selected sesquiterpenes from FDP10 
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1.5 Terpene Synthases 
Terpene synthases (often also called terpene cyclases) are metal ion-dependent enzymes 
that catalyse the conversion of a given universal polyisoprenoid precursor (eg. GDP, FDP or 
GGDP) to one (or more) cyclic terpene products. Structural biology work has shown that 
class I terpene synthases posses two specific binding motifs that anchor the metal ions 
essential for catalysis.44 These metal ions coordinate to the diphosphate leaving group and 
trigger the heterocyclic cleavage of the C-O diphosphate ester bond that leads to the 
formation on an allylic carbocation.44 Often, a series of intramolecular cyclisations, methyl 
and hydride shifts and other rearrangements  occur to produce the final products after 
proton loss or water capture. The divalent metals are mostly Mg2+ or Mn2+, with Mg2+ 
being used most often.45,46  
Terpene synthases, especially those from different kingdoms of life forms, share little 
amino acid sequence similarity among them (in many instances below 25-35%).47 For 
example, despite producing almost identical hydrocarbons, the fungal aristolochene 
synthase from Penicillium roqueforti (PR-AS) and the plant epi-aristolochene synthase from 
Nicotiana tabacum (TEAS) only share 16% sequence similarity.48 Interestingly, the crystal 
structures of all sesquiterpene synthase solved up to date have shown that these proteins 
all share a common fold, which has been named the class I terpene fold, usually containing 
ten to twelve α-helices arranged in an anti-parallel fashion.49 The shape of catalytic active 
site varies between the different synthases but is always nested deep within this α-helical 
barrel.49  
Usually, the catalytic cavity of terpene synthases is surrounded by about 5 helices, which 
are connected by loops.50 The loops are relatively short at the bottom of the active site but 
long at the top, making the shape of the active site somewhat conical.51 The active site of 
terpene synthases provides a chiral molecular environment (or template) that enforces the 
unique conformation of the substrate that leads to the often exclusive  enzymatic 
product.47 Indeed, terpene synthases display striking accuracy regarding stereo- and regio-
specificity as exemplified by lanosterol synthase, an enzyme that produces only one isomer 
of lanosterol (30) (Figure 1.7) among the 128 possible steroisomers.51 
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Figure 1.7: Structure of lanosterol (30) 
 
Terpene synthase can be classified into two groups according to their general reaction 
mechanism.17 While class I terpene synthases such as mono- and sesquiterpene synthases 
initiate their reaction cascades by diphosphate ionisation, class II terpene synthases 
feature a protoned-initiated cyclisation mechanism involving a double bond or an 
epoxide.52 As mention earlier, class I terpene synthases contain two specific metal binding 
sites, namely the DDXX(D/E), found at the entrance of the active site. 44, 53 In contrast, class 
II terpene synthase contain only one DXDD metal binding motif.52 Some terpene synthases 
contain structural features of both class I and II types. For example, the C-terminal catalytic 
domain of tobacco 5-epi-aristolochene synthase belongs to the class I terpenoid fold , 
whereas N-terminal domain belongs to class II terpenoid fold but has unknown 
function.50,54 
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1.6 Aristolochene Synthase from Penicillium roqueforti 
Aristolochene synthase is a class I sesquiterpene synthase that produces aristolochene 
from FDP (5). Aristolochene, the C15 bicyclic eremophilane-type sesquiterpene55 produced 
by aristolochene synthase has been isolated from several sources. While plants and 
animals prefer the (-)-enantiomer,56 fungal sources such as Penicillium roqueforti and 
Aspergillus terreus produce (+)-aristolochene.55,57 The formation of aristolochene catalyzed 
by aristolochene synthase in Penicillium roqueforti is thought to represent the first step in 
the biosynthesis of a large group of sesquiterpenoid fungal toxins, the most poisonous of 
which is the bis-epoxide PR-toxin (25)58 (Figure 1.8). 
 
 
Figure 1.8: Structures of fungal toxins thought to be derived from aristolochene (24) 58 
 
Aristolochene synthase was first isolated and purified from the fungus Penicillium 
roqueforti in 1989.59 The X-ray crystal structure of the apo-enzyme at 2.5 Å resolution was 
solved in 2000.48 The crystal structure of recombinant PR-AS showed the typical α-helical 
class I terpene synthase fold with two Mg2+-binding mofits (Figure 1.9).17,48 Aristolochene 
synthase (PR-AS) is a monomeric sesquiterpene cyclase with 342 amino acid residues and a 
molecular weight of 38000.48 Like other sequiterpene synthases, both Mg2+ and Mn2+ can 
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be used as cofactors of the reaction, although Mn2+ can act as an inhibitor at high 
concentration.59 The enzyme’s structure consists of 11 α-helices, six of which form the 
hydrophobic active site cavity. Based on the X-ray crystallographic analyses, it was 
identified that some of amino acid residues (Phe-178, Phe-112, Trp-334) in the active site 
were involved in stabilising various carbocation intermediates.60-63 The fungal 
aristolochene synthase from Aspergillus terreus (AT-AS) also catalyses the conversion of 
farnesyl diphosphate to (+)-aristolochene as a single sesquiterpene product.25 Its molecular 
weight is 36000, which is less than PR-AS. Apart from this, the amino acid sequence of AT-
AS is 61% identical with that of PR-AS.48 Recent work on X-ray crystal structures of AT-AS 
by Christianson et al. demonstrated that it has a tetrameric quaternary structure, in which 
each subunit adopts the α-helical class I terpene synthase fold with the active site in a 
solvent-exposed conformation.49 However, solution of the X-ray crystal structure of its 
complex with inorganic diphosphate and Mg2+ ions (resolved to 2.15 Å) revealed that one 
subunit was bound to three Mg2+ ions and PPi and was stabilised in the “closed” 
conformation required for catalysis.49 There are two metal binding motifs in AT-AS, the 
DDLLE motif beginning with D90 and the NSE motif beginning with N219.49 
 
Figure 1.9: Ribbon diagram representation of the crystal structure of aristolochene 
synthase from Penicillium roqueforti (1DGP.pdb). The red colour indicates the location of 
the two Mg-binding motifs. 
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1.7 Description of the reactions catalysed by aristolochene 
synthase 
The first step in the reaction cascade (Scheme 1.10) catalysed by aristolochene synthase is 
the loss of the diphosphate group from farnesyl diphosphate (5). Upon binding of three 
magnesium ions, diphosphate expulsion from the C1 position of FDP is triggered by the 
intramolecular attack of the distal C10,C11 π-bond on C1 in a concerted reaction that 
occurs with inversion of configuration at C1.55,64 Deprotonation of the resulting germacryl 
cation (18) leads to the germacrene A (21).65,66,67,68 Protonation of germacrene A by an 
unidentified active site acid48,49,66,67 and electron flow from the C2-C3 π-bond to C6 leads to 
the formation bicyclic eudesmane cation (68).48 Residue Y92 was initially suggested to act 
as an acid in the formation of the eudesmane cation (68).48,63,66,67 However, after Felicetti 
and Cane removed the hydroxyl group of tyrosine, generating a Y92F mutant, this still 
produced aristolochene, but in low amount.25 The positive charge on the eudesmane 
cation is thought to be stabilised by the π-system of W334.60 Successive 1,2-hydride shift 
and methyl migration followed by loss of HS on C8 complete biosynthesis of (+)-
aristolochene (24).55,65 
 
Scheme 1.10: Proposed reaction catalysed by aristolochene synthase PR-AS 
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Based on the X-ray crystal structure of isoprene synthase bound to a substrate analogue 
(dimethylallyl-S-thiolodiphosphate),69and due to the nearly physiological pKa of H2P2O7
2-/ 
HP2O7
3- pair, it was suggested that the enzyme bound diphosphate leaving group could 
serve as the general base in a syn-periplanar elimination (Scheme 1.11).69 
 
Scheme 1.11: Conversion of DMADP (2) to isoprene (1) through a concerted 
reaction pathway 
Several aromatic residues are usually found in the active site of terpene synthases, and 
cation-π interactions involving the quadrupole moment of the aromatic ring are thought to 
stabilize cationic intermediates along the biosynthetic pathway.70,71 The electrostatic 
component arises from interactions of the quadrupole moments of the aromatic rings, 
which are produced by the uneven distribution of charge. Greater electron density 
concentrates on the face of the ring, resulting in reduced electron density on the edge of 
the ring.70,71 
FDP analogues have been used to study the complex reaction mechanism of PR-AS, Cane 
and co-workers synthesised four 2H labelled FDP analogues at position C12, C13 and C8, 
which enable them to locate the site of the final deprotonation at C12.65 In addition Cane 
et al found good evidence for the intermediacy of germacrene A during catalysis.72 The 
incubation of the 6,7-dihydro-analogue of FDP (71) with AS generates the abortive 
cyclisation product, dihydrogermacrene A (72). This was confirmed by a direct GC/MS 
comparison with a synthetic sample.72According to the proposed mechanism of AS, the 
cyclisation step to form eudesmane cation would be prevented because of the loss of the 
C6-C7 double bond in this 6,7-dihydro-analogue of FDP causing dihydro-germacrene A (72) 
to accumulate (Figure 1.10).72 
 
    24 
 
 
Figure 1.10: Structures of 6,7-dihydro-analogue of FDP (71) and dihydro-
germacrene A (72) 
At Cardiff University, the cationic reaction mechanism of the PR-AS, the route to 
aristolochene was probed with fluorinated farnesyl diphosphate. 2-Fluorofarnesyl 
diphosphate (73) was synthesised and incubation with aristolochene synthase resulted in 
the formation to 2-fluorogermacrene A (74). These results have shown that 2-F-FDP (73) 
was a poor substrate, and also suggest the absence of farnesyl cation (50) during the 
cyclisation pathway (Figure 1.11).73 
Incubation of 6- and 14-fluoro farnesyl diphosphate 75 and 76 with PR-AS produced the 
corresponding fluorinated germacrene A analogues 77 and 78. These results provided 
compelling evidence of intermediacy of germacrene A (21) during PR-AS catalysis (Figure 
1.11).68 
Incubation of the 12, 13-difluorofarnesyl diphosphate (79) (Figure 1.11) with PR-AS did not 
give any products as judged by GC-MS analysis.64 The steady-state kinetic parameters of 
purified AS were measured in the presence of different amounts of 12,13-difluorofarnsyl 
diphosphate and radiolabelled [1-3H]-FDP showing that 79 was a reversible competitive 
inhibitor of AS, with an inhibition constant (Ki = 0.8 ± 0.2 µM) comparable to the Michaelis 
constant of FDP (KM = 2.3 µM),
64  suggesting that the initial cyclisation during AS catalysis 
generates germacryl cation (18) in a concerted process and also ruling out the possible 
existence of the farnesyl cation (50) in the enzymatic reaction catalysed by PR-AS,  due to 
the electronic effects of fluoro substituents. The electrophilic attack of C1 by the C10, C11 
π-bond would be inhibited if farnesyl cation 80 was generated in the first place. Thus, the 
accumulation of the 12,13-difluorofarnesyl cation would go through an elimination, 
forming 12,13-difluoro-(E,E)-α-farnesene (81) and 12,13-difluoro-(E)-β-farnesene (82)64 
(Scheme 1.12).  
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The formation of eudesmane cation (68) has been inferred by site-directed mutagenesis 
experiments. X-ray crystallographic analysis reveals that this cation 68 could be established 
by W334 through cation-π interaction. Tryptophan 334 was mutated with the aliphatic 
amino acids valine and leucine, which led to accumulate of germacrene A, therefore 
suppressing the native aristolochene activity of this enzyme.60  
A recent mutagenesis study with non-canonical residues has shown the importance of 
cation π- interactions as the means of carbocation stabilisation during PR-AS catalysis. In 
particular, when Trp334 was replaced with unnatural phenylalanines [W334p-(Cl)Phe, 
W334p-(CF3)Phe and W334p-(NO2)Phe] harbouring para-substituents with increasing 
electron-withdrawing properties, accumulation of germacrene A (21) was observed. The 
amount of 21 generated as a proportion of the hydrocarbon products proved to be directly 
proportional to the electron withdrawing power of the para substituent. These results 
provided strong evidence for the stabilising role played by Trp334 during AS-catalysis since 
they demonstrate that reduction in the cation-π stabilising ability of the aromatic amino 
acid side chains leads to a reduced propensity, in this case, to form the eudesmane 
cation.74 Taken together, these studies have provided compelling evidence supporting a 
cyclisation cascade involving at least two discrete intermediates: the neutral hydrocarbon 
germacrene A (21) and the highly reactive eudesmane cation (68) (Scheme 1.10). However, 
little is known about the last three steps (Scheme 1.10) leading to aristolochene from the 
enzyme-bound eudesmane cation (68).  
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Figure 1.11: Structures of fluorinated farnesyl diphosphates 73, 75, 76 and 79 and the 
fluorinated germacrene A analogues 74, 77 and 78 
 
 
Scheme 1.12: Proposed mechanism for the conversion of 12,13-difluorofarnesyl 
diphosphate (79) to 12,13-difluoro-(E,E)-α-farnesene (81) and 12,13-difluoro-(E)-β-
farnesene (82) 
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1.8 Aza-analogues of highly reactive carbocations 
Since the carbocations involved in terpene chemistry are highly unstable intermediates 
that cannot be isolated, their transient existence within the active sites of terpene 
synthases can be inferred indirectly through the use of FDP analogues or mutagenesis (as 
discussed above). A complementary approach to study the complex cationic reactions 
catalysed by terpene synthases consist of the use of stable aza-analogues of the putative 
carbocations. To probe the carbocationic nature of the 1,2-hydride and methyl shifts, two 
novel aza-analogues (83 and 84, Figure 1.12) have been designed for synthesis and 
evaluation of their capacity as inhibitors of PR-AS. These compounds were designed to 
mimic the geometric and electrostatic properties of postulated carbocation intermediates 
69 and 70 in the catalytic mechanism of PR-AS.  
 
Figure 1.12: Structures of 5-eudesmyl cation (69) and eremophilenyl cation (70) and 
their aza-analogues 83 and 84 respectively 
 
There are four possible pathways to determine the mechanism of the last transformations 
in PR-AS biosynthesis (Scheme 1.13): stepwise, concerted/stepwise, stepwise/concerted 
and concerted processes. In the stepwise mechanism, the enzymatic reaction goes through 
two carbocations 69 and 70 from eudesmane cation (68). While, in the fully concerted 
pathway, the transformation of eudesmane cation (68) to aristolochene (24) take place in 
one step. The other two possible mechanisms are partway between these two extremes. 
Therefore, the kinetic evaluation of the two analogues 83 and 84 as inhibitors of PR-AS 
should provide us with evidence about the existence of the putative carbocationic 
intermediates 69 and 70 on the pathway from FDP (5) to aristolochene (24) during PR-AS 
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catalysis. Hence, this study could be enable us to confirm the mechanism of the later steps 
in the catalytic cascade of PR-AS.  
 
Scheme 1.13: Stepwise versus concerted processes in aristolochene biosynthesis 
Aza-analogues of terpenes are nitrogen containing terpenoids that resemble postulated 
carbocationic intermediates in terpene biosynthesis. In particular, they are designed to 
mimic the geometric and electrostatic properties of presumed carbocationic species, but 
since they cannot be turned-over by the enzyme, they act as tightly bound inhibitors. The 
absence of the empty p-orbitals required to undergo the usual transformations of highly 
reactive carbocations generated by terpene synthases make them useful active site probes 
of these enzymes and as a consequence they are, for the most part, competitive inhibitors 
of these enzymes. Indeed aza-analogues have been reported as inhibitors of mono-,75,76 
sesqui-77 and diterpene synthases,78,79 as well as inhibitors of squalene and oxidosqualene 
synthases.80-83 This concept has proven useful in the design of enzyme inhibitors aimed at 
suppressing sterol biosynthesis.84-87 Aza-analogues presenting a positive charge at a 
position identical to that of the sp2-carbon in the carbocationic HEI (high energy 
intermediate). Hence, the trigonal carbcationic center is replaced by a tetrahedral 
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positively charged nitrogen.82 The replacement of the sp2 hybridised carbon of the 
proposed intermediate with a sp3 hybridised nitrogen atom allows for a stable molecule to 
be synthesised in the laboratory providing a somewhat imperfect geometric model of the 
carbocation to study the cationic chemistry characteristic of terpene synthases. The 
positive charge has been shown to be distributed over the hydrogens carried by the α-
carbons and the nitrogen atom being negatively charged. Thus, the alkyl ammonium group 
appears as a large, positively charged surface, with the nitrogen atom buried in the 
center.88 
Our group recently provided an approach to identify eudesmane cation (68) by employing 
the aza analogue 8589 that effectively mimics the topological and electrostatic properties 
of eudesmane cation (68) (Figure 1.13).  
 
Figure 1.13: Structures of eudesmane cation (68) and its aza-analogue 85 
 
Aza analogue 85 was synthesised in seven steps starting from chiral enamine 86 (Scheme 
1.14), which was then alkylated with methyl acrylate to produce Michael adduct 87 as the 
only regioisomer. Protection of the ketone group of 87 as an acetal, and then reaction with 
NH4OH afforded primary amide 88. Reduction of amide 88 was achieved by using LiAlH4, to 
the corresponding primary acetal amine and subsequent cyclisation to Schiff base 89 was 
induced by use of aqueous acid. Reduction of Schiff base 89 was carried out using sodium 
in ethanol and then reductive N-alkylation with formaldehyde in the presence of NaBH3CN 
produced N-methyl trans-decahydroquinoline (91). This was exposed to hydrochloric acid 
in diethyl ether to yield ammonium salt 85.89 
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Scheme 1.14: Stereoselective synthesis of 4-aza-eudesmane cation (85)89 Reagents: (i) 
1. methyl acrylate, 2. Aq H+, (ii) ethylene glycol, cat H+, (iii) Aq NH3, (iv) 1. LiAlH4, 2. 10% 
HCl, (v) Na, anh. EtOH, (vi) H2CO, NaCNBH3, (vii) HCl, Et2O 
 
Inhibition studies of PR-AS with ammonium salt 8589 have shown that the compound 85 
was clearly bound in the active site of the enzyme, with binding affinity (Ki = 0.34 µM) 
almost identical to that displayed by FDP (KM = 2.3 µM) in both, the absence and presence 
of inorganic diphosphate (PPi). Consequently compound 85 is an excellent mimic of the 
postulated eudesmane cation 68, providing therefore strong evidence for the formation of 
this highly reactive intermediate in the active site of the enzyme.89 
Some aza analogues have been synthesized in both enantiomeric forms. The different 
inhibition data for the two enantiomers gives enantioselective information for the 
inhibitors in the enzyme active site. For example, Coates and co-workers reported the 
synthesis of both enantiomers of aza analogues R and S-93 for trichodiene synthase studies 
(Scheme 1.15).77 Although both of the enantiomers are inhibitors of trichodiene synthase, 
no significant difference was found in the affinity of the enantiomers for the enzyme (Ki 
=2.6 µM for the R isomer and 2.9 µM for the S isomer). Hence, the ability of trichodiene 
synthase to bind both enantiomers of 93 with identical affinity is consistent with notion 
that the active site of this synthase is permissive rather than restrictive with respect to 
these particular enantiomeric pair of aza-analogues.77 
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Scheme 1.15: Aza analogues for studies of trichodiene (94) biosynthesis 
 
Another example, squalene synthase (SS) catalyses the 1`-1 condensation between two 
molecules of farnesyl diphosphate (5) via tertiary cyclopropyl carbinyl intermediate, 
presequalene diphosphate PSDP (9) (Figure 1.14) to yield squalene (7).80 Because of its key 
position in the cholesterol biosynthetic pathway, squalene synthase is an attractive target 
for pharmacological intervention to reduce serum cholesterol level. Thus, Coates and co-
workers reported the synthesis and characterization of two enantiopure aziridine 
analogues (-)-(2R, 3S)-95- and (+)-(2S, 3R)-95-diphosphates of PSDP (9) (Figure 1.14) and 
their evaluation as inhibitors of recombinant yeast squalene synthase.90 These studies 
revealed that the (-)-(2R, 3S)-95- diphosphate enantiomer matching the configuration of 
PSDP (9) showed better inhibition (IC50 1.17 ± 0.08 µM) than other enantiomer (+)-(2S, 3R)-
95-diphosphate in the absence and the presence of inorganic diphosphate (16-fold and 4-
fold, respectively).90  
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Figure 1.14: Structures of PSDP (9) and (2R,3S)-aziridine analogue (95) of PSDP 90 
Due to their kinetic behaviour, aza analogues of cationic intermediates have been used in 
X-ray crystallographic studies of terpene synthases and useful structural information has 
been obtained. Christianson, Croteau and Coates reported 2-azabornane (97) and 7-aza-
7,8-dihydrolimonene (96), two inhibitors of bornyl diphosphate synthase (BDPS) as 
crystallisation aids (Scheme 1.16). The X-ray structures of the enzyme-aza analogue 
complexes obtained at 2.0 Å resolution,75 providing key mechanistic interferences 
regarding the cyclisation sequence of geranyl diphosphate including the position, the 
orientation of the substrate, and the interaction between the substrate and the key active 
site amino acid residues.  
 
Scheme 1.16: Aza-analogues for studies of  BDPS75 
It is worth noting that in practice, the inhibition studies of aza-analogues are performed in 
both the presence and absence of inorganic diphosphate (PPi), since the effectiveness of 
some aza-analogues is enhanced by the presence of PPi. The effect of PPi on the 
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experiment can provide insight into the role of PPi as a stabilising counter ion in the 
enzymatic mechanism. For example, ent-kaurene synthase catalyses the conversion of 
geranylgeranyl diphosphate (GGDP, 6) through copalyl diphosphate (CDP, 99) to ent-
kaurene (101) (Scheme 1.17).91 The secondary carbocation ent-beyeran 16-yl cation (100) 
is a key branch intermediate in the proposed mechanistic scheme. In order to evaluate this 
mechanistic hypothesis, Roy and co-workers synthesised the aza analogues of 16-aza-ent-
beyerane (102) and 16-aza-ent-trachylobane (103) that mimic the ent-beyeran-16-yl ion 
(100) and protonated ent-trachylobane (104)91 (Figure 1.15). These aza-analogues 102 and 
103 have inhibited ent-kaurene synthase with inhibition constants of IC50  = 1 x 10
-7 and 1 x 
10-6 M similar in value to the binding constant of the ent-copalyl diphosphate substrate (KM 
= 3 x 10-7 M). Indeed, these two analogues showed strong synergism in the presence of 1 
mM inorganic PPi (IC50 = 4 x 10
-9 and 2 x 10-8 M). The strong synergy displayed by these 
compounds with PPi suggested a large stabilization of the corresponding carbocationic 
intermediate, by ion pairing with the (PPi.Mg) released in the first ionization of copalyl 
diphosphate substrate (99).91 
 
 
Scheme 1.17: Biosynthesis of ent-kaurene (101) 
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Figure 1.15: Structures of 16-aza-ent-beyerane (102) and 16-aza-ent-trachylobane (103), 
proposed aza analogue mimics for the ent-beyeran-16-yl ion (100) and protonated ent-
trachylobane (104)91 
 
1.9 Quinolizidine alkaloids 
The synthetic bicyclic tertiary amines 105-111 and iminium ion 112 (Figure 1.16) belong to 
the quinolizidine family of alkaloids and previous routes for the synthesis of these bicyclic 
amines are presented below. 
 
Figure 1.16: Structures of quinolizidines 105-112 
Quinolizidine alkaloids represent about 2% of the 7000 known plant alkaloids. The lupin 
alkaloids responsible for the toxic properties associated with Lupinus, are characterized by 
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a quinolizidine skeleton. Quinolizidine alkaloids are mainly found in plants of the 
Leguminosae family. They prevent or repel feeding of herbivores, and are toxic to them 
through a variety of mechanisms. A number of plants (Laburnum, Cytisus, Lupinus) contain 
significant quantities of these alkaloids and are known to be responsible for human 
poisoning.10 
Further examples of natural products containing the quinolizidine skeleton are cermizine C 
(113), senepodine G (114) and cermizine D (115) (Figure 1.17). These compounds are so-
called Lycopodium alkaloids because this plant produces a number of alkaloids that have 
unique structures and biological activities, such as acetylcholine esterase (AchE) inhibitory 
activity. Thus, Lycopodium alkaloids have been attractive targets for organic and medicinal 
chemistry.92 
 
Figure 1.17: Structures of cermizine C (113), senepodine G (114) and cermizine (115)92 
 
The quinolizidine or octahydroquinolizidine structure (116) is a central framework in 
numerous important natural products, representing the simplest member of the family, 
with only one substituent at the C1 position, as shown for lupinine alkaloids (117) and 
epilupinine (118) (Figure 1.18).93 Lupinine carries the hydroxymethyl group in an axial 
position. By comparison with the decalins the preferred conformation of the lupinine 
structure is expected to be that in which the rings are trans-fused because this minimises 
1,3-diaxial interactions. 93 Thus, despite the axial opposition between the hydroxymethyl 
group, axial hydrogen atoms and axial lone-pair in lupinine, the trans-conformation must 
still be important. In this instance the intramolecular hydrogen bonding between the 
nitrogen atom and the hydroxyl group occurs to favour the trans-conformation. While, 
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epilupinine (118) bears the hydroxymethyl group in equatorial position, or this 
configuration is associated with the preferred trans-fused conformation.93  
Bohlmann has shown that a prominent infrared band at 2800-2700 cm-1 occurs in the 
spectra of trans-fused quinolizidines, in which the nitrogen lone-pair is trans to at least two 
axial hydrogen atoms on carbon atoms adjacent to nitrogen.94 This characteristic 
absorption is seen at 2750 cm-1 in the infrared spectrum of quinolizidine and (-)-lupinine 
(117).  
The lower frequency of the trans-bands compared with the normal C-H region was due to 
charge delocalization of the nitrogen lone pair of electrons to the axial C-H bonds. In the 
trans-fused quinolizidine system, all three axial C-H bonds should take part in this 
delocalization. The axial C-H bonds on both C-1 and C-9 (116, Figure 1.18) have the same 
symmetry and force constants, so vibrational coupling can occur, and two bands appear at 
2800 and 2700 cm-1 respectively. The first is due to asymmetric, and the second due to 
symmetric, stretching vibrations.93,94 
 
Figure 1.18: Structures of quinolizidine (116), lupinine alkaloid (117) and epilupinine (118) 
 
The predominance of the trans-fused conformation has also been demonstrated by 1H- 
and 13CNMR spectroscopy.93 Quinolizidines having the cis ring fusion either show much 
weaker or no Bohlmann bands at all.93 
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1.9.1 Synthesis of lupinine and related compounds 
The azabicyclic skeleton of quinolizidine is an important structural subunit present in 
numerous alkaloids. The wide range of biological activities found in this family of natural 
products make them ideal targets for total synthesis. Quinolizidine (116) was prepared by 
Boekelheide and Rothchild.95 For this synthesis, 1,1-dicarbethoxy-3-(2-pyridyl)-propane 
(121) was prepared by Michael addition of diethyl malonate (120) to vinyl pyridine (119) 
(Scheme 1.18). The preparation of 4-quinolizidone (122) was carried out by means of 
Raney nickel hydrogenation of 1,1-dicarbethoxy-3-(2-pyridyl)-propane (121) in dioxane 
solution at 125-150 °C under hydrogen pressure according to the procedure reported by 
Bohlman and co-workers.96 The lactam 122 was then converted in high yield to 
quinolizidine (116) by the action of lithium aluminium hydride (Scheme 1.18). 
 
Scheme 1.18: General procedure for synthesis of quinolizidine (116)95,96 
The absolute configuration of (-)-lupinine (117) was established by X-ray diffraction97 as 
(1R,10R)-1-hydroxymethyquinolizidine.93,97 Synthesis of (-)-lupinine has been carried out 
directly, without a separate resolution step. Reductions of (-)-and (+)-1-menthoxycarbonyl-
1-(10)-dehydroquinolizidines-123 with NaBH4 yielded (-) and (+)-menthoxycarbonyl 
quinolizines-124 (Scheme 1.19). Subsequent treatment with lithium aluminium hydride 
afforded (+)-and (-)-lupinines-117 in 10% yield.98 The enantiomeric 1-menthoxycarbonyl-1-
(10)-dehydroquinolizidines (-)-123-a and (+)-123-b were prepared separately (Scheme 
1.20) by reaction of 1(10)-dehydroquinolizidine (125) with enantiomerically pure menthyl 
chloroformates (-)-126-a and 126-b. The later compound was obtained via reaction of 
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enantiomeric menthol 127-a and 127-b with phosgene (Scheme 1.20).98 The 
dehydroquinolizidine 125 was prepared by dehydrogenation of quinolizidine (116) with 
mercuric acetate as reported by Leonard and co-workers.99 
 
Scheme 1.19: Asymmetric synthesis of (+)-lupinine by Goldberg98 
 
Scheme 1.20: Synthesis of both enantiomers of 1-menthoxycarbonyl-1-(10)-
dehydroquinolizidines (-)-123-a and (+)-123-b98 
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Another synthesis of lupin alkaloids was described by Boekelheide and co-workers.100 It 
was shown that ɣ-(2-pyridyl)-butyronitriles (129) (Scheme 1.20) upon mild hydrogenation 
over platinum in the presence of acid, underwent cyclisation to afford quinolizidine 
derivatives (130-132, Scheme 1.21). Since the requisite ɣ-(2-pyridyl)-butyronitriles (129) 
was synthesised from either 2-vinylpyridine (128) or ethyl 2-pyridyl acetate, these two 
steps were useful for preparing 1- and 3-substituted quinolizidines, compounds which are 
of interest because of their relationship to the lupin alkaloids.100 
 
Scheme 1.21: Boekelheide’s method for the synthesis of 1- and 3-substituted 
quinolizidines.100 
 
Gerrans reported another approach to the synthesis of various substituted pyrrolizidine, 
indolizidine and quinolizidine ring systems.101 The key steps of this approach involved the 
selective use of the ambident nucleophilicity of the vinylic urethane group at the α- and γ-C 
atoms 135 (Scheme 1.22). 2-Thiopiperidone (133) was treated with ethyl acrylate in the 
presence of catalytic amount of NaH to give the N-alkyl derivative 134, which was then 
treated with ethyl bromoacetate and Et3N/Ph3P to give the vinylic urethane 135. The 
saturated ester group of 135 was selectively reduced with LiAlH3OEt to give the alcohol 
136, which on treatment with NaH/p-TsCl followed by warming in CH3CN, afforded directly 
the bicyclic vinylogous urethane 137. Conversion of compound 137 to rac-lupinine (117) 
was achieved by using NaBH4 followed by LiAlH4.
101 
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Scheme1.22: Conversion of 2-thiopiperidone to lupinine as reported by Gerrans.101 
In a different approach, epilupinine (118) was synthesized starting from cyclic thioimidate 
(138) that underwent Robinson annulation using methyl 3-oxo-4-pentenoate (Nazarov’s 
reagent).102,103 Reaction of cyclic thioimidate (138) with Nazarov’s reagent (139) in the 
presence of HgCl2 to give quinolizidine 140 (Scheme 1.23). Stereospecific reduction of 140 
with diisobutylaluminum hydride (DIBAL) gave saturated β-ketoester 141 and then 
complete reduction of the ketone by using Mozingo’s methodology104 followed by 
reduction of the ester group with LiAlH4 afforded (±)-epilupinine (120). 
 
Scheme 1.23: Robinson annulations using Nazarov’s reagent to synthesis (±)-epilupinine 
(118) reported by Hiroki et al 102 
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The conversion of the quinolizidine product 140 to lupinine (117) was also described 
(Scheme 1.24).102 Thianation of the ketone group with Lawesson’s reagent produced 
enaminothioketone 144 which was then desulfurised with Raney Ni to give enaminoester 
145. Stereospecific reduction of 145 was achieved with sodium borohydride to afford 
methyl lupinate 146 and subsequent conversion to (±)-lupinine (117) was completed by 
reduction with LiAlH4.
102 
 
Scheme 1.24: Synthesis of (±)-lupinine (117) reported by Hiroki et al. 102 
 
Oxidation of quinolizidine (116) with mercuric acetate yielded Δ1(10)-dehydroquinolizidine 
(125, Scheme 1.25) that yielded upon treatment with perchloric acid the Δ5(10)-
dehydroquinolizidinium salt (147). Subsequently introduction of a bridgehead methyl 
group at the C10 position was performed. The formation of 10-methylquinolizidine (148) 
was achieved by treatment of dehydroquinolizidinium salt (147) with methyl magnesium 
iodide (Scheme 1.25).99 
Enamines and iminium salts can be distinguished using IR spectroscopy. The IR spectrum of 
enamine 125 showed an absorption at 1625 cm-1, while the perchlorate salt 147 absorbed 
intensively and sharply at 1696 cm-1. The shift of infrared absorption frequency to higher 
value from enamine to its iminium salt has been shown to be characteristic of α, β-
unsaturated amines (enamines).105 
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Scheme 1.25: Synthetic sequence for conversion of quinolizidine (116) to 10-
methylquinolizidine (148)99 
 
In order to synthesise disubstituted quinolizidine, recent efforts have established a 
procedure for the conjugate addition of lithiated methyl pyridines 149 to enone 150 
(Scheme 1.26).106 The utility of this reaction was demonstrated by the concise synthesis of 
(±)-cermizine C (113) and (±)-epi-cermizine C (151). To carry the synthesis forward, the 1,4-
addition product 152 was protected as the acetal 153 (Scheme 1.26). Catalytic 
hydrogenation of compound 153 gave a 1: 1 ratio of the diastereomers 154 and 155 that it 
was possible to separate by chromatography. Separately, exposure of each diastereomer 
to acid yielded the unstable alkaloids (±)-senepodine G (114) and (±)-epi-senepodine G 
(156). Reduction of each with NaBH4 afforded the alkaloids (±)-cermizine C (113) and (±)-
epi-cermizine C (151).106 
Methiodide salts (158, 160, Scheme 1.27) of quinolizidines have been prepared in two 
ways, firstly by direct quaternisation of quinolizidine with methyl iodide and secondly by 
cyclisation of 2-4`-iodobutyl-1-methylpiperidine (157).93 The 1H-NMR spectra of these 
compounds indicated that the compound formed by direct quaternisation has the trans-
fused ring structure. However, the free bases, quinolizidine, 1-, 2- and 3-
methylquinolizidine, all exist predominantly in the trans-fused ring conformation with an 
equatorial methyl group except 4-methylquinolizidine93 (Figure 1.19), which would not be 
expected to hinder the approach of a quaternising reagent, so, the resulting methiodide 
salts would all be expected to preserve the trans-ring fusion and the equatorial C-methyl 
group. In general, quaternisation of methylquinolizidnes that contain the trans-fused 
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conformation with an axial methyl group on the same side of the molecule as the nitrogen 
lone pair lead to products with the cis-ring configuration.93 
 
Scheme 1.26: Stereoselective synthesis of (±)-cermizine C (113) and (±)-epi-cermizine C 
(151).106 
    44 
 
 
  Scheme 1.27: Routes to quinolizidines methiodide salts 158 and 160. 
 
 
Figure 1.19: Conformations of 1-, 2-, 3- and 4-methylquinolizidines 
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1.10 2, 3, 4, 5-Tetrahydropyridine and its derivatives 
2,3,4,5-Tetrahydropyridine and its derivatives have also attracted attention as key 
precursors for the synthesis of some alkaloids.107 2-Methyl-3,4,5,6-tetrahydropyridine 165 
exist as two tautomers (Scheme 1.28). Compounds such as 2-methyl-3,4,5,6-
tetrahydropyridine (165) are readily converted to a lithium derivative 166 with LDA that 
could react with an electrophile to further functionalise this ring (Scheme 1.28).107  
 
Scheme 1.28: Structure and deprotonation of 2-methyl-2,3,4,5-tetrahydropyridine (165)107 
 
Indeed, the cyclic enamines as versatile synthetic intermediates have played an important 
role in the design of numerous alkaloid syntheses. For example, Evans and co-workers108 
have developed a general method for the synthesis of cyclic enamines from structurally 
varied imine anions. This method is generally applicable to the synthesis of Δ2-
tetrahydropyridine derivatives. Deprotonation at the α-position of imines 167 using LDA at 
low temperature in anhydrous conditions afforded an imine anion that was then alkylated 
with alkyl dihalides to produce cylic enamines 168 and 169 (Scheme 1.29).108 
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Scheme 1.29: Synthesis of cyclic enamines 168 and 169108 
 
The above annulation sequence was then applied to the synthesis of 2-methyl-Δ1-
tetrahydropyridine (165) and Δ1(9)-octahydroquinoline (170), which were further 
transformed into bicyclic quinolizidines 171 and 172 respectively (Scheme 1.30).108 
 
 
Scheme 1.30: Evans’ procedure for the synthesis of bicyclic enamines alkaloids 171 and 
172108 
This methodology was later applied to the synthesis of 1,2,3,4,5,6,7,8-octahydro-1,6-
naphthyridines (175-177) (Scheme 1.31),109 another type of important nitrogen-containing 
bicyclic structures with potential biological activity, as predicted by the PASS 
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programme.110 The computer software package PASS (prediction of activity spectra for 
substances) is used to rapidly predict various biological activities for selected compounds. 
These are pharmacological effects, mechanisms of action, mutagenicity and 
carcinogenicity.110 PASS prediction is based on the analysis of structure-activity 
relationships of the training set including a great number of non-congeneric compounds 
with different biological activities. PASS once trained is able to predict many types of 
activity for a new substance. Compounds (175-177) may possess psychotropic, neuroleptic, 
spasmolytic and analgesic activities. Kinetic deprotonation of imine 173 with LDA in 
anhydrous conditions (Scheme 1.31), followed by consecutive alkylation with 1-bromo-3-
chloro propane afforded 174. The reaction mixture was then heated under reflux to effect 
final ring closure to (175-177).109 
 
 
Scheme 1.31: One pot syntheses of 175-177 using Evans’ procedure.109 
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1.11 Aim of this project 
To further explore the reaction mechanism of PR-AS, the aim of this project was to 
synthesise of two novel aza-analogues, 5-aza-eudesmane cation (83) and 10-aza-
eremophilene (84), designed to mimic the geometric and electrostatic properties of the 
carbcationic intermediates 69 and 70, postulated to be involved in the last steps of 
Aristolochene biosynthesis. The kinetic evaluation of these two analogues 83 and 84 with 
PR-AS should provide us with evidence about the existence of the putative carbocationic 
intermediates 69 and 70 on the pathway from FDP (5) to aristolochene (24) catalysed by 
PR-AS. Moreover, the study of the binding affinity of these aza analogues with PR-AS 
should further our understanding of the mechanism of action of this class of enzyme and 
be applicable to other system. 
 
Scheme 1.32: Carbocations proposed to be involved in aristolochene 
biosynthesis and the aza-analogues 83 and 84 targeted for synthesis 
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CHAPTER TWO 
STEREOSELECTIVE SYNTHESIS OF 10-AZA 
EREMOPHILANES 
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2.1 Target molecules 
In this chapter, the synthesis of three analogues 178, (7R,4S,5S)-84 and (7S,4R,5R)-84 
(Figure 2.1) and their kinetic evaluation with PR-AS are described. These quinolizidine 
analogues possess the typical eremophilane skeleton of sesquiterpenes such as 
aristolochene and epi-aristolochene, with two vicinal methyl groups. These salts mimic the 
putative carbocations such as 70 (Figure 2.1) involved in sesquiterpene biosynthesis.  
 
 
 
Figure 2.1: Structures of target molecules 178, (7R,4S,5S)-84 and (7S,4R,5R)-84 and 
eremophilanyl cation (70) 
 
2.2 Eremophilane skeleton 
The biogenetically interesting eremophilane class of sesquiterpenes possess the basic 
carbon skeleton 179 showed in Figure 2.2. Eremophilone 180, a sesquiterpene ketone 
isolated by Simonsen and co-workers in 1932 represented the first eremophilane-type 
sesquiterpene. 111 The most characteristic feature of these compounds are the cis-vicinal 
methyl groups at C4 and C5 in ring A, and the C7-isopropyl side chain in ring B. The 
numbering system normally employed for this class of compounds is shown in Figure 2.2.  
 
Figure 2.2: Structure and numbering system of the eremophilane skeleton 179, 
eremophilone (180) and quinolizidine (181) 
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Eremophilane compounds are historically interesting in that they pose a disagreement with 
the original isoprene rule, which stated that, in case of sesquiterpenes, three isoprene 
units must be joined by head-to-tail linkages.32 In this case however, the methyl group on 
C5 breaks this rule – it would be on on C-10 in eremophilane 179, but it has migrated to C-
5 during PR-AS catalysis. 
2.3 Retrosynthetic analysis  
Retrosynthetic analysis is the process of disconnecting a target molecule through a 
sequence of gradually simpler structures which leads to simple or commercially available 
starting materials. The transformation of a molecule to a synthetic precursor is 
accomplished by the application of a “transform”, the theoretical reverse of a synthetic 
reaction to a target structure. The precursor species from which the target may be 
assembled are called synthons.112  
Since the aza analogues 83 and 84 are structural mimics of the 5-eudesmane (69) and 
eremophilane (70) cations respectively, two proposed intermediates in the biosynthesis of 
PR-AS, the former would be potential inhibitors of PR-AS (Figure 2.3). The target molecules 
83 and 84 were subjected to the disconnection process, giving the simpler precursors 182 
and 183. Each of the precursors so generated was then examined in the same way, and the 
process was repeated until simple or commercially available structure resulted. (4S)-
limonene oxide (187) was chosen as the starting material for both aza analogues 83 and 84 
as it is commercially available in both enantiomeric forms and possesses  the required 4S-
isopropylidene group. 
The Robinson annulation consists of an initial Michael alkylation followed by an aldol 
condensation. The product of a Robinson annulation is a six-membered ring containing an 
α, β-unsaturated ketone. For example, compound 190 (Figure 2.4) may be formed by a 
combination of a Michael addition and an aldol reaction. The C=C bond in the ring is 
derived from the aldol reaction, while another new bond is created by the Michael 
reaction. Thus, the synthetic precursors of this transformation are compounds 191 and 
192.113 
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Figure 2.3: Retrosynthetic analysis of aza analogues 83 and 84 
 
Figure 2.4: Retrosynthetic analysis of compound 190  
The aza-Robinson annulation was decided upon for the synthesise enaminones 193 and 
194 (Figure 2.5), one of the key intermediates en route to the tertiary amines 105 and 106. 
Enaminone 193 was used in pilot experiments and synthesised by aza-Robinson annulation 
aimed at the construction of the ring A of aza analogue 84 (Figure 2.1). Retrosynthetic 
analysis of enaminone 193 led to the synthetic precursors, piperidone-2-thione (195) and 
ethyl vinyl ketone (185), while the retrosynthetic analysis of enaminone 194 involved (4S)-
(prop-1-ene-2yl) piperidine-2-thione (196) and ethyl vinyl ketone (185).  
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Figure 2.5: Retrosynthetic analysis of enaminones 193 and 194 involving aza-
Robinson annulations  
For the synthesis of the quinolizidine 84, enaminone 194 could be synthesised by aza-
Robinson annulation between thiolactam 196 and ethyl vinyl ketone (EVK) 185 via tandem 
Michael alkylation and aldol condensation (Figure 2.6). Lactam 183 could be obtained via 
cyclisation of acetamide 189, which would be obtained via keto ester 198 through 
degradation of limonene oxide (187) and subsequent Beckmann rearrangement of 198.  
 
Figure 2.6: Retrosynthetic analysis of 10-aza-eremophilane salt 84 
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2.4 Preparation of monocyclic lactam 183 
The first stage of this synthesis is the preparation of lactam 183. Among the synthetic 
intermediates, the acyclic keto ester 198 is a very important one, since it allows the 
regioselective introduction of nitrogen at the keto position via a Beckmann rearrangement. 
The preparation of keto ester 198 has been reported before by Kido and co-workers114 and 
the same procedures were followed. Reaction of (-)-limonene oxide (187) with KOH (5 
equivalents), H2O and DMSO for 24 h afforded a distereomeric mixture of diols 199 in 70% 
yield (Scheme 2.1). The mixture of epimers was carried forward to the next reaction 
without purification. In accordance with a standard SN2 reaction (Scheme 2.1), the 
hydrolysis of limonene oxide under basic conditions took place through the nucleophilic 
attack at the least substituted position of the epoxide. Interestingly, Wolinsky and Chane 
115 reported epoxide ring opening procedure with the structurally similar limonene 1,2-
epoxide 200 under acid-catalysis with 1% H2SO4 in acetone which afforded a single anti diol 
201-a, that was different from the diols 201-b and 201-c obtained by Mori et al. using a 
similar procedure (Scheme 2.2).116 The main difference between these two methods is the 
concentration of the acid catalyst. When concentrated HClO4 was used, the reaction 
proceeded through a carbocation intermediate (SN1 reaction), and subsequent attack by 
H2O gave cis and trans diol isomers 201-b and 201-c. On the other hand, when diluted 
sulfuric acid was used at rt, nucleophilic epoxide ring opening is favoured via a SN2 –like 
reaction, and a different diol isomer 201-a was then formed. So, the hydrolysis of (-)-
limonene oxide (187) in this study was most likely following the mechanism of the 
Wolinsky procedure.  
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Scheme 2.1: Base-catalysed hydrolysis of (-)-limonene oxide (187) to diastereomeric diol 
199 
 
Scheme 2.2: Acid-catalysed hydrolysis of epoxide 200 
 
The 1H-NMR spectrum of the diol 199 was consistent with that reported in the literature.114 
Compared to epoxide 187, the chemical shift for the C-3 methine proton was shifted down 
field from 3.45 to 3.75 ppm, due to the greater deshielding effect of the newly formed 
hydroxyl group. The IR spectrum of diol 199 showed two bands, one sharp at 3600 cm-1 
owing to O-H stretching, and another one as a broad band at 3400 cm-1 owing to the 
intramolecular hydrogen bonded O-H. The 13C-NMR spectrum of diol 199 showed the 
expected two signals at 71.3 and 73.9 ppm assignable to carbons directly attached to 
oxygen.  
The second step en route to the target was the stereoselective oxidation of diol 199 to 
hydroxy ketone 202. This transformation was achieved using 5 equivalents of pyridinium 
chlorochromate (PCC), in DCM.114 TLC analysis of the reaction mixture showed the 
    56 
 
presence of two compounds in 1:3 ratio, due to the presence of two disteroisomers of 
hydroxy ketone 202 (Scheme 2.3). After purification by flash chromatography on silica gel, 
hydroxy ketone 202 was isolated in 75% yield.  
 
Scheme 2.3: Stereoselective oxidation of diol 199 to cis-202 and trans-202 
Although PCC is commercially available, it could be made by mixing chromium trioxide with 
pyridine and hydrochloric acid as shown in Scheme 2.4. The oxidizing component of PCC 
203 is the chlorochromate anion, CrClO3
-. Oxidation of the secondary alcohol of diol 199 is 
a two step process. The first step involves the formation of chromate ester, which later 
undergoes an elimination reaction to generate hydroxy ketone 202 (Scheme 2.4). 
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Scheme 2.4: Mechanism of oxidation diol 199 to hydroxy ketone 202 by chlorochromate 
anion 
The 1H-NMR spectrum of the hydroxy ketone 202 is consistent with that in the 
literature.114 The IR spectrum displayed a broad band at 3350 cm-1 for the O-H stretch and 
a sharp band at 1710 cm-1 assignable to carbonyl group.  
The third step involved further oxidation of hydroxy ketone 202 en route to 198. Reaction 
of hydroxy ketone 202 with lead tetraacetate (LTA) 114 in methanol at 0 °C afforded keto 
ester as a less polar compound than the starting material as judged by TLC. The crude 
mixture contained Pb(OAc)2 salt, therefore, this mixture was filtered through a bed of 
alumina before extraction, thus ensuring the proper removal of toxic Pb(OAc)2.  The 
residue was purified by flash chromatography on silica-gel to give 198 in 74% yield. 
Mechanistically, the first step of this reaction starts with the nucleophilic attack of the 
alcohol group at Pb(IV) to form an unstable Pb(OAc)3 ester (Scheme 2.5) and a molecule of 
acetic acid (AcOH). Next the nucleophilic attack of the carbonyl group by methanol is 
accompanied by the cleavage of a carbon-carbon bond with the elimination of a second 
molecule of acetic acid and Pb(OAc)2. 
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Scheme 2.5: LTA-oxidative cleavage mechanism of α-hydroxy ketone 202 to form keto 
ester 198 
The 1H-NMR spectrum of compound 202 displayed characteristic absorbances for the 
methyl ketone (CH3C=O) at 2.15 ppm and the methoxy group at 3.65 ppm, both as sharp 
singlets. The 13C-NMR spectrum of 202 showed two signals at 209.9 and 173.6 ppm arising 
from the carbonyl groups of the ketone and ester respectively. In addition, in agreement 
with structure 202, the IR spectrum of 202 displayed two bands at 1710 and 1725 cm-1 
owing to the carbonyl stretches of the ketone and ester respectively.  
2.4.1 Beckmann rearrangement and lactamization 
Following the retrosynthetic scheme, the next objective was to regioselectively introduce 
the amine functionality at the keto site of 198 and induce cyclization to form lactam 183. 
For this purpose, 198 was converted to oxime 204 by treatment with hydroxyl amine 
hydrochloride and pyridine.117 Flash chromatography on silica gel afforded the pure oxime 
204 in 80% yield (Scheme 2.6). 
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Scheme 2.6: Formation of oxime 204 
1H-NMR spectroscopic analysis revealed the presence of the oxime as an E/Z mixture of 
isomers in a 3:1 ratio. The major isomer displayed three singlets at δH 1.69, 1.79 and 3.59 
owing to the E-(CH3C=CH2), E-(N=CCH3) and E-(CH3COO) respectively. Similarly, the 
corresponding protons of the minor isomer resonated at δH 1.62, 1.78 and 3.58 ppm.  
Formally, the Beckmann rearrangement is an acid-catalysed rearrangement of an oxime to 
an amide, in which the OH group of the ketoxime R1R2C=NOH (eg. 205) activated as 
tosylate to make it good leaving group (Scheme 2.7).118 The OH group of an oxime can also 
become a leaving group either by protonation or coordination to a Lewis acid. Thus, 
oximes activated in this fashion undergo [1,2]-rearrangement of the group that is attached 
to the C=N bond in the trans position with regard to the O atom in the oxime and 
simultaneous N-O heterolysis. The reactive nitrilium cation 207 formed in this manner is 
then captured by water to form an imidocarboxylic acid 208, which tautomerizes 
immediately to the observed amide 209.118 
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Scheme 2.7: Mechanism of the Beckmann rearrangement of oxime 205 to acetamide 209. 
 
In an attempt to synthesise acetamide 189 in one step, keto ester 198 was treated with 
hydroxyl-O-sulfonic acid (NH2OSO3H) in the presence of acetic acid under reflux.
119 
However, instead of the expected acetamide 189, an unwanted product 210 was 
generated (Scheme 2.8).115 Hence, keto ester 198 underwent an extremely facile 
intramolecular ester-olefin cyclization reaction with involving a carboxylic acid group 
generated in situ from 198. This result indicates that the condensation of hydroxyl-O-
sulfonic acid with keto group of 198 in a slow process compared to the observed 
intramolecular cyclisation. 
To demonstrate the intermediacy of acid 211 in the process, keto ester 198 was hydrolysed 
to keto acid 211 using 6N LiOH, and then the above experiment was repeated with keto 
acid 211 to give the same bicyclic product 210 (Scheme 2.8). The two signals of the vinylic 
group assignable to the starting material 198 at 4.6 and 4.7 ppm in the 1H-NMR spectrum 
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were replaced by one olefinic signal at 5.4 ppm (CH=C in cyclic lactone), and a new signal at 
1.4 ppm was assignable to the angular methyl group of lactone 210. 
 
Scheme 2.8: Intramolecular cyclization reaction of keto acid 211 to bicyclic -lactone 210 
 
Using a compound similar to keto ester 198, Mehta and co-workers reported that 
treatment of oxime 212 with para-toluenesulfonyl chloride in pyridine led to the smooth 
formation of the rearranged compound 213 in 57% yield after 24 h at room temperature 
(Scheme 2.9).117  In our case, the same procedure with oxime 204 produced only the 
oxime-tosylate (3: 1) 214 in 86% yield, no rearrangement was obtained even when DMAP 
was added as a catalyst (Scheme 2.10).  
 
Scheme 2.9: Beckmann rearrangement of oxime 212 to 213 by the Mehta’s procedure117 
Furthermore, when oxime tosylate 214 was heated under reflux with triethyl amine in 80% 
of aqueous ethanol, two rearranged compounds 189 and 215 were obtained. 
Unfortunately, the undesired amide 215 was obtained in 70% yield although a small 
amount of the desired amide 189 in 25% yield was isolated (Sheme 2.10). The alkyl group 
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that migrates is generally anti- to the tosylate leaving group, so, it was inferred that oxime 
tosylate 214 was syn- rather than anti-configured, thus explaining the formation of 
compound 215.120 
 
Scheme 2.10: Rearrangement of oxime tosylate 214 under basic condition to 189 and 215 
Gratifyingly, when oxime 204 was heated at reflux with p-TsCl in pyridine for 6 h, 
acetamide 189 was obtained in 53% yield albeit contaminated with a small amount (20%) 
of 215, which was separated from the desired compound by flash chromatography on 
silica-gel. This procedure was optimised by changing the temperature and time. Indeed, 
when oxime 204 was treated with p-TsCl in pyridine at room temperature for 7 days in the 
dark under an N2 atmosphere, acetamide 189 was obtained in 90% yield (Scheme 2.11).  
 
Scheme 2.11: Beckmann rearrangement of oxime 204 to acetamide 189  
Hydrolysis of acetamide 189 under basic conditions (30% NaOH) produced a -
aminoaliphatic carboxylic acid, followed by adjustment of reaction to pH 6, and heating to  
130 °C drove the equilibrium toward the formation of -lactam 183 as white crystals in 77% 
yield after purification (Scheme 2.12).121a 
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Scheme 2.12: Cyclisation reaction of acetamide 189 to lactam 183 
1H-NMR and 13C-NMR spectroscopic analysis of lactam 183 revealed signals of this 
compound at δH 6.3-6.4 (a broad singlet, NH), 3.27-3.28 (m, CH2N), 2.37-2.46 (m, CH2CO). 
These values are in good agreement with those previously reported for -valerolactam 216 
at δH 6.7, 3.28-3.33 and 2.31-2.44 (Figure 2.7).
121b  
 
Figure 2.7: Structures of 2-piperidone (216) and lactam 183 
The -valerolactam 216 was used in pilot experiments via aza-Robinson annulation aimed 
at the construction of the ring A of aza analogue 84 (Figure 2.1).  
2.5 Aza-Robinson annulation 
The Robinson annulation was introduced in 1935 by Robert Robinson and William Sage 
during their landmark synthesis of sterol.113 They demonstrated a unique and 
unprecedented condensation between enolates and α,β-unsaturated ketones (Figure 2.8). 
The findings have not only proven an important method for the synthesis of steroidal 
frameworks; but, since their discovery, have been used in the synthesis of other complex, 
diverse and important compounds.113 
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Figure 2.8: General scheme for the Robinson annulation reaction 
Bicyclic indolizinones and quinolizinones have been prepared previously by Danishefsky, 
who used a Rh(II) catalyzed reaction between α-diazoketones and thiolactams to bring 
about the key ring closure reaction122,123 (Scheme 2.13, 1). However, the use of 
diazomethane for the preparation of the α-diazoketone could restrict the scope of this 
methodology to small scale synthesis. Recently, to solve this problem, a novel synthetic 
strategy towards the development of aza-Robinson annulations–type reaction on a large 
scale has been reported. This variant involves the conversion of a thiolactam into an 
iminium ion, which then undergoes intramolecular attack by the internal enolate on the 
side chain (Scheme 2.13, 2). This methodology was first described by Heathcock124and then 
applied by others.123,125 
 
Scheme 2.13: Danishefsky and Heathcock methods for the preparation of indolizinones and 
quinolizinones via distinct aza-Robinson annulations reactions. 
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2.6 Synthesis of 1-methyl-3,4,6,7,8,9-hexahydroquinolizin-2-one 
(193) 
As mentioned above, the formation of the ring A of compound 84 was first assessed using 
-valerolactam 216 following a modification of the protocol described by Heathcock.124 
Since the lactam 216 itself is not active enough to undergo a cyclisation reaction, activation 
of the carbonyl group was needed. Some approaches to activate this amide functionality 
involved its transformation into imino ethers, thiolactams, or thiolactam ethers. On the 
other hand, another approach consists of the use of a more active α, β-unsaturated ketone 
such as the Nazarov reagent. Lawesson’s reagent was used to obtain the more reactive 
thiolactam 195 in 85% yield.126 Mechanistically, the conversion of -valerolactam 216 to 
the corresponding thiolactam 195 is depicted in Scheme 2.14. Lawesson’s reagent 221 
upon heating decomposes via breakdown of the central phosphorus/sulphur four-
membered ring to yield two reactive dithiophosphine ylides R-PS2 (Scheme 2.14). The 
reaction of this ylide with carbonyl of lactam 216 gives rise to the thiaoxaphosphetane 
intermediate. The driving force of this reaction is the formation of a stable P-O bond. The 
1H-NMR and 13C-NMR data of thiolactam (195) were consistent with those found in the 
literature.126  
Michael reaction between the deprotonated thiolactam and ethyl vinyl ketone (EVK) in the 
presence of anhydrous potassium carbonate and 18-crown-6 gave the Michael adduct 222 
in 87% yield (Scheme 2.15).123 Crown ethers are useful as phase transfer catalysts (PTC), 
that facilitate the migration of a reactant from one phase to another where reaction 
actually occurs. In this case, the use of 18-crown-6 allows the use of K2CO3 as the base 
necessary for the alkylation. 
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Scheme 2.14: Mechanism of thiation of -valerolactam 216 with Lawesson’s reagent  
 
 
Scheme 2.15: Michael alkylation of thiolactam 195 with EVK (185) 
Cyclisation of the Michael adduct 222 to the bicyclic enaminone 193 was achieved in an 
aldol condensation, through the generation of the thioiminium ion by treatment with 
Me2SO4 via an SN2 reaction. DBU was used as a sterically hindered and non nucleophilic 
base in the second step of the aldol condensation to give enaminone 193 in 78% (Scheme 
2.16).123,127 
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Scheme 2.16: Mechanism of aza-Robinson annulation to give quinolizinone 193 
 
The 1H-NMR spectroscopic data of bicyclic enaminone obtained was in good agreement 
with those reported by Guarna and co-workers.124 Enaminone 193 displayed signals at δ 
3.36 (t, 2H, CH2N) in ring A, 3.22 (t, 2H, CH2N) in ring B, 2.51 (dd, 2H, CH2C=C), 1.73 (s, 3H, 
CH3C=C). The IR spectrum showed a band at 1715 cm
-1 for the C=O stretch with a 
conjugated alkene C=C double bond, and another weaker band at 1657 cm-1 arising from 
the C=C stretch. 
2.7 Synthesis of 4,5-dimethyl-1,2,4,6,7,8-hexahydroquinolizin-3-
one (223) 
In principle, the crucial introduction of the angular methyl group at C5 should be readily 
achieved by the use of dimethylcopper lithium, which is prepared from methyl lithium and 
copper iodide (molar ratio 2: 1). Piers and Keziere have reported that the reaction of 
octalone 224 with an excess of dimethylcopper lithium yielded eremophil-11-ene-3-one 
180 in 77% yield (Scheme 2.17).128 It should be noted that the stereoselective conversion 
of octalone 224 into eremophilene type 180 is of particular significance, since this reaction 
provides a simple and efficient method to install the vicinal dimethyl system found in 
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eremophilane-type sesquiterpenes. Methyl lithium alone would give the expected 1,2 
addition rather than 1,4-addition, however, in the presence of copper salt the required 
conjugate, Michael-like addition was induced.  
 
 
Scheme 2.17: 1,4- addition reaction of Me2CuLi to octalone 224 
To our surprise, the reaction of enaminone 193 with an excess of dimethyl copper lithium 
gave an unexpected ring expansion reaction, yielding compound 225 (Scheme 2.18). 1H-
NMR, 13C-NMR, 2D-NMR and HR-MS experiments were used to identify and structurally 
characterize this compound. 
 
 
Scheme 2.18: Ring expansion reaction of enaminone 193 
The 1H-NMR spectrum of compound 225 revealed signals at δ 2.9-3.07 (m, 2H, CH2N), 2.3-
2.7 (m, 2H, CH2N), 2.21-2.29 (m, 1H, CH3CH), 1.70-1.72 (m, 1H, CH), and 0.99 (d. 3H, 
CH3CH). The HMBC spectrum of amino ketone 225 showed three significant correlations 
peaks for the CH3 protons on C-4 at 0.99 ppm with CH of C-5 at 67 ppm, correlation with 
the carbonyl carbon C=O at 210 ppm and correlation with C-4 at 55 ppm, and did not show 
any correlation peak between protons of CH3 and C5 of CH2 in structure B. These results 
confirmed the structure of this compound is A and not B (Figure 2.9).  
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Figure 2.9: HMBC spectrum of unexpected bicyclic compound 225 
 
A plausible mechanism is depicted in Scheme 2.19, this ring-expansion reaction could take 
place via the intermediacy of a copper (III) β-adduct, the a key intermediate proposed for 
the classical 1,4-addition of dimethyl lithium cuprate to enones.129 The formation of this 
complex involves binding of copper to the π-system. 
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Scheme 2.19: Proposed mechanism of expansion ring reaction of 193 
Since the C-methylation of enaminone 193 was unsuccessful with Me2CuLi, alternative 
strategies were tried to increase the reactivity of the β-position. Chloro silanes have 
frequently been used to trap the enolates formed by conjugate addition of organocuprate 
reagents to α, β-unsaturated carbonyl compounds.129 TMSCl accelerates cuprate-enone 
conjugate addition by increasing the electron deficiency of the α,β-double bond. In this 
case, however, no reaction was observed when TMSCl was added to mixture of enaminone 
and dimethylcopper lithium. Boron trifluoride etherate (BF3.OEt2) has also been used as a 
Lewis acid, 130 aimed at activating 193 toward Michael alkylation. Unfortunately again, the 
addition of BF3.OEt2 to the reaction mixture at -78 °C, did not give the desired compound 
223. Furthermore, changing the copper (I) salt and the nucleophile, did not lead to any 
reaction as observed by TLC analysis or NMR spectroscopy. For example, when enaminone 
was added to a mixture of copper (I) bromide dimethyl sulphide complex (CuBr. SMe2), 
MeLi and BF3.OEt2 at -78 °C, or MeLi was replaced with MeMgBr, the reactions only 
afforded unreacted starting material.130 
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2.8 Iminium salts from enaminones such as 193 
Since the term enaminone refers to any compound containing the conjugated N-C=C-
C=O,131 it should be possible to convert enaminone to an iminium salt by using a strong 
Bronsted acid such as trifluoroacetic acid (TFA). This conversion allows 1,4-addition of 
methyl group to iminium salt. Although, in acyclic enaminone, there are four possible 
isomers as depicted in Figure 2.10, enaminone 193 display a cis-trans conformation.  
 
Figure 2.10: Conformations of enaminone 193 
As expected, Mayers and co-workers132 found that the reaction of cis-trans enaminone 226 
with methyl magnesium bromide gave the enamine alcohol 227 in high yield, as a 
consequence of an exclusive 1,2-addition. However, with methyl magnesium iodide 10% of 
the 1,4 addition product 228 was obtained together with unreacted starting material and a 
mixture of unidentified compounds (Scheme 2.20). In contrast, the conversion of the 
enaminone 226 to its O-acetyl iminium salt 229 allows preparation of amino ketone 228 in 
a useful yield of 60 to 65% yield.132 
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Scheme 2.20: Activation of cis-trans enaminone 226 toward 1, 4-addition 133 
Following Mayers and co-workers strategy, the reaction of enaminone 193 with 1.2 
equivalents of acetyl chloride in dry THF133 gave a mixture (2:1) of O-acetyl iminium salt 
230 and N-acetyl enaminone salt 231 after 5 min in 90% as total yield (Scheme 2.21). 
Resonances arising from both 230 and 231 were visible in the 1H-NMR spectrum of 
acetylated iminum salt mixture. The major compound was the unwanted N-acylated salt in 
66% yield and the minor compound was O-acylated salt (33%). The signals assigned to 230 
were: δ 1.72 (CH3C=C), 2.0 (CH3CON), 3.1-3.2 (CH2N) in ring A, 3.70-3.72 (CH2N) in ring B, 
and the signals assigned to 231 were:  δ 1.89, 2.23, 3.92 and 4.10 for CH3C=C-O, CH3COO, 
CH2N, CH2N respectively. 
 
 
Scheme 2.21: Reaction of enaminone 193 with acetyl chloride 
 
Comparing the nucleophilicity of a carbonyl group C=O and that of a tertiary amine, it is 
expected that of the enolate anion and the amine would have comparable nucleophilic 
reactivity. In addition, conformational analysis of bicyclic enaminone indicates that the 
three substituents of the N atom at the bridgehead position in the most stable cis-trans 
conformation are locked by the bicyclic skeleton, thus the lone pair electrons of the 
nitrogen atom are more exposed to the electrophiles (CH3COCl, MeI etc) than normal 
tertiary free amines, which can freely rotate their alkyl substituents. This explains the 
larger amount of the N-acylate salt 230. In addition, the reaction of O-methylated iminium 
salt 232 with methyl magnesium bromide, did not give the 1,4-addition product 223 after 
24 h at room temperature (Scheme 2.23). Similarly, The TFA iminium salt 233, which was 
prepared from 193 with TFA in high yield (90%) at room temperature, did not react with 
excess of MeMgBr at room temperature. Fortunately, when the temperature was 
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increased to 66 °C (refluxing THF), the formal 1,4-conjugate addition of MeMgBr took place 
giving racemic amine 223 in 65% yield (Scheme 2.22). 
It is known that 10-quinolizidines with a trans ring fusion display characteristic absorption 
bands in the 2800-2700 cm-1 region of the infrared spectrum. These absorptions, termed 
the Bohlmann bands (discussed in chapter one) result from a specific interaction between 
the nitrogen lone pair and at least two axial hydrogens.94 Quinolizidines with cis ring fusion 
either show much weaker or no Bohlmann bands at all. The amino ketone 223 showed 
Bohlmann bands at 2761-2927 cm-1, thus indicating, that it was most likely in the trans-
configuration (Figure 2.11). 
 
 
Scheme 2.22: Introduction of an angular methyl group to enaminone through iminium salt 
233 to generate 4,5-dimethyl-1,2,4,6,7,8-hexahydroquinolizin-3-one (223) 
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Figure 2.11: Infra-red spectrum of amino ketone 223 showing Bohlmann bands at 2761-
2927 cm-1 
The 1H-NMR and 13C-NMR spectroscopic analyses of 4,5-dimethyl quinolizidine-3-one (223) 
confirmed the structure of 223 with characteristic 1H-NMR signals at δ 0.72 [3H, s, C(CH3)], 
0.87 (3H, d, (CH3)CH), 2.18-2.22 (1H, CH(CH3), 2.63-2.85 (4H, m, 2CH2N). The relative cis-
orientation of the two vicinal methyl groups at C4 and C5 of 223 was unambiguously 
established by nOe-measurements. Irradiation of the methyl doublet at δ 0.87 ppm led to 
nOe enhancements (3%) of the CH3 singlet at 0.72 ppm, likewise a nOe-enhancement was 
observed for CH3 doublet (4%) when the CH3 singlet at 0.72 ppm was irradiated. Thus, 
allowing both methyl groups to be assigned as syn relative to each other (Figure 2.12).  
 
Figure 2.12: Relative stereochemistry of the 4,5-dimethyl quinolizinone (223) 
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2.9 Huang-Minlon modification of the Wolff-Kishner reduction 
The final step en route to quinolizidine 105 was the removal of the ketone group in 223. 
There are several well-established methodologies for the selective removal of the ketone 
carbonyl function. All of them require activation of the ketone first, followed by different 
types of metal reductions. Among others, conversion of a ketone to its thioketal followed 
by Raney Ni reduction is a commonly used method. Formation of thioketal is usually 
catalysed by acetic acid or BF3.OEt2. Indeed, when the amino ketone 223 was treated with 
ethanedithiol in the presence of 3 equivalents of BF3.OEt2, amino thioketal 234 was 
produced in good yield 80% (Scheme 2.23).134 The condensation reaction between 
ethanedithiol  and and amino ketone 223 took place with nucleophilic attack of the 
carbonyl group of 223 by a thiol group of  ethandithiol followed by elimination of water to 
give compound 234. 1H-NMR,13C-NMR and DEPT spectra where in full agreement with the 
structure of 234. Heating of 234 with Raney-Ni in refluxing ethanol for 2-4 h,134 did not give 
the desired compound 105 (Scheme 2.23), even though an excess of Raney-Ni was added. 
It is uncertain what caused the failure of this desulfurization reduction. Quite a few 
modifications of this reaction were tried unsuccessfully. Clearly, another strategy was 
needed for this reduction. 
 
Scheme 2.23: Formation of amine thioketal 234 
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Tosyl hydrazones of aldehydes and ketones are readily obtained as crystalline compounds 
and easily purified. It has been previously shown that tosyl hydrazones react with bases at 
high temperature yielding p-toluensulphinic acid, nitrogen and alkanes.135 Reaction of 
amino ketone 223 with MeC6H4SO2NHNH2 in EtOH at reflux temperature for 24 h gave the 
tosyl hydrazone derivative 235 in good yield (79%) (Scheme 2.24).136 The condensation 
reaction took place through the nucleophilic attack of the carbonyl group of 223 by the 
NH2 group of tosyl hydrazide, followed by elimination of water to yield compound 235. 
However, attempts to reduce tosyl hydrazone 235 with lithium aluminium hydride (LiAlH4) 
and sodium borohydride (NaBH4) were unsuccessful at room temperature. When the 
reaction time and temperature of the LiAlH4 reduction was increased, tosyl hydrazone 235 
reacted via Shapiro elimination to afford the enamine 236 (Scheme 2.25).  
  
 
Scheme 2.24: Formation of tosyl hydrazone 235. 
However, in the Shapiro reaction the tosyl hydrazone group of 235 is used as the leaving 
group in the elimination reaction. The LiAlH4 abstracts the first proton from hydrazone 235 
and then the less acidic proton to produce a carbanion (Scheme 2.26). The carbanion 
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proceeds in an elimination reaction to create the C=C double bond, followed by expulsion 
of N2 and the resulting vinyl amine reacts with water to give the enamine 236.  
These results indicated that the direct activation of the ketone group followed by 
reduction was not compatible with the functionalities of the molecule. Thus, a different 
strategy was needed to perform this transformation. It was envisioned that the C=O bond 
could be reduced in a two-step sequence by transformation to alcohol, then, after 
activation as tosylate, the alcohol might be reduced by LiAlH4 to give the desired 
compound 105.  
 
 
Scheme 2.25: Proposed mechanism of Shapiro reaction of 235 to give 236. 
Reduction of amino ketone 223 with lithium aluminium hydride in dry THF provided the 
diastereoisomers of amino alcohol 237 and 238 (9:1) in 90% total yield (Scheme 2.26). Both 
isomers are suitable for the following transformation, since this stereocenter will be erased 
after the reduction. The subsequent derivatisation of this epimeric mixture with tosyl 
chloride provided an epimeric mixture of tosylate salts 239, that did not react with LiAlH4 
to yield the expected product 105 (Scheme 2.26). 
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Scheme 2.26: Conversion of aminoketone 223 to diastereoisomers of amino alcohol 237 
and 238 and subsequently to tosylate salts 239. 
 
Fernandez has reported another example of a related reduction of amino ketone 240 to 
compound 241, using a mixture of potassium hydroxide, hydrazine hydrate and ethylene 
glycol at reflux, which afforded the amine 241 in 90% yield (Scheme 2.27).137 
 
 
Scheme 2.27: Fernandez procedure to remove the ketone functionality from 240138 
Huang and Minlon reported a modification of the Wolff-Kishner reduction.138 This 
procedure consists of refluxing the carbonyl compound in a moderate amount of 
diethylene or triethylene glycol, 85% hydrazine hydrate and three equivalents of sodium or 
potassium hydroxide. When these conditions (the Huang-Minlon modification), were 
applied to 223, the final amine 105 was obtained in 74% yield (Scheme 2.28). The 
mechanism of this reaction first involved the formation of the hydrazone 242 (Scheme 
2.28) in a mechanism that is analogous to the formation of an imine. Successive 
deprotonations eventually result in the expulsion of nitrogen gas.  
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Spectroscopic (IR and NMR) and mass spectrometric analyses confirmed the structure of 
amine 105. The 13C-NMR spectrum of amino ketone 223 showed the characteristic signal at 
210 ppm for a ketone C=O group, a signal that disappeared in 13C-NMR of amine 105, also 
in the IR spectrum of amine 105 the stretching band of C=O at 1720 cm-1 also disappeared. 
The final amine 105 was stored at -20 °C under a nitrogen atmosphere. 
 
 
Scheme 2.28: Mechanism of the Huang-Minlon reduction of amino ketone 223 to amine 
105. 
For the kinetic studies with PR-AS, the final amine 105 was treated with 1 equivalent of TFA 
to yield the stable TFA salt 178 in 74% yield. 1H-NMR and 13C-NMR spectra of the salt 
showed a nice separation of all signals, as expected for the deshielding effect of TFA 
(Figures 2.13 and 2.14). The successful synthetic sequence leading to the bicyclic amine 
105 and its salt 178 is summarised in Scheme 2.29. 
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Scheme 2.29: Synthesis of bicyclic tertiary amine 105 and its TFA salt 178 
 
Figure 2.13: 1-HNMR spectrum of 1,9-dimethyl-2,3,4,6,7,8-hexahydroquinolizidine (105) in 
the region δH  = 0.5 – 2.5 ppm 
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Figure 2.14: 1-HNMR spectrum of 1,9-dimethyl-2,3,4,6,7,8-hexahydroquinolizidinium salt 
(178) in the region δH  = 0.5 – 3.0 ppm  
The relative configuration of the final ammonium salt was unambiguously verified by X-ray 
crystallography (Figure 2.15) using the picrate salt 243 (Scheme 2.30). 
 
Scheme 2.30: Preparation of picrate salt 243 for X-ray crystallography (performed by Dr. 
Juan A.Faraldos) 
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Figure 2.15: Ball and stick representation of the X-ray crystal structure of the picrate salt 
243 (solved by Dr. Benson Kariuki) 
2.10 Stereoselective synthesis of (7R,4S,5S)-84 
Following the same synthetic sequence developed for the unsubstituted lactam 216, 
lactam 183 was converted to quinolizidine 106 in six steps and 87% overall yield. 
Thiolactam 196 was obtained after purification and recrystallisation from i-PrOH in 77% as 
white crystals (Scheme 2.31).126  
 
Scheme 2.31: Conversion of lactam 183 to thiolactam 196 
The structure of 196 was verified by 1H-NMR spectroscopy. The 1H-NMR spectrum of 
thiolactam 196 was however slightly different from thiolactam 195, due to the presence of 
chiral isopropylidene substituent on C7 as shown in Figure 2.16. 
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Figure 2.16: Comparison between the two thiolactams 195 and 196 
 
Michael alkylation of thiolactam 196 with ethyl vinyl ketone in dry THF, anhydrous 
potassium carbonate and a catalytic amount of 18-crown-6 gave the Michael adduct 244 in 
85% yield (Scheme 2.32).123 The 1H-NMR spectrum of the Michael adduct was in 
agreement with the chemical shifts recorded to the Michael adduct of the parent 
compound 222 as shown in Figure 2.17.  
 
 
Scheme 2.32: Formation of Michael adduct 244 
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Figure 2.17: Comparison between the two Michael adducts 222 and 244 
Next, 244 was activated for the intramolecular aldol condensation by treatment with 
dimethyl sulphate, generating in this manner the more reactive thioiminium ion, that 
further reacted with DBU to give the desired enaminone 194 in 54% as best yield after 
optimization (Scheme 2.33).123 The low yield of enaminone 194 was a result of this enone 
undergoing isomerization under these conditions, which resulted in the formation of by-
product 245. Several modifications were tried to improve the yield of the reaction. First, 
Me2SO4 and DBU were distilled under reduced pressure and N2 atmosphere, secondly DBU 
was replaced with other bases, such as Et3N, 2,6-lutidine and 2,4,6-collidine. 
As shown in Table 2.1, with the exception of 2,4,6-collidine, all bases could be used to 
generate the enolate that ultimately yielded the enaminone 193 after intramolecular 
cyclisation. However, no improvement of the yield was observed. When, the Michael 
adduct 244 was treated with dimethyl sulphate followed by treatment with triethylamine, 
the yield of enaminone 194 went down to 29% (Table 2.1). Since the isomerization of the 
enaminone 194 to the side-product 245 occurred at high temperature (boiling toluene, 
140-150 °C), the solvent was changed to benzene, and the yield of enaminone rise up to 
54%, by using Et2O, the yield was slightly lower 41% as shown in Table 2.1. 
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Scheme 2.33: Aldol condensation of thioiminium salt generating enaminone 194 and by-
product 245 
For comparison, the characteristic 1H-NMR resonances of compounds 193 and 194 are 
given in Figure 2.18. 
 
Figure 2.18: 1H-NMR spectroscopic data for 193 and 194  
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Attempt Michael adduct Solvent Bases Enaminone 
Yield of 
enaminone 
Yield of by-
product 
1. 
 
toluene DBU 
 
78%  
2. 
 
toluene Et3N 
 
45%  
3. 
 
toluene 
2,6-
lutidine 
 
56%  
4. 
 
toluene 
2,4,6-
collidine 
No reaction   
5. 
 
toluene DBU 
 
37% 62% 
6. 
 
toluene Et3N 
 
29% 68% 
7. 
 
Et2O DBU 
 
41% 51% 
8. 
 
benzene DBU 
 
54% 44% 
 
Table 2.1: Attempts to improve the yield of enaminone 194 
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In same manner as the parent compound 193, conversion of enaminone 194 to its salt 246 
allowed the introduction of the angular methyl group, after reaction with methyl 
magnesium bromide to provide the vicinal dimethyl system 197 found in eremophilane-
type sesquiterpenes in a useful yield of 64% (Scheme 2.34). 
 
Scheme 2.34: Conversion of enaminone 194 to amino ketone 197 
A combination of 1D and 2D-NMR experiments revealed that compound 197 was produced 
as single diastereoisomer. The 1H-NMR spectrum of 197 displayed signals at δ 0.71 (s, 3H, 
CCH3), 0.90 (d, J = 7.0 Hz, 3H, CHCH3), 2.62-2.69 (m, 2H, COCH2CH2N), 2.80-2.86 (m, 2H, 
CH2CH2N). These values are in good agreement with those of the parent compound 223, 
which displayed signals at δ 0.72 [3H, s, C(CH3)], 0.87 [3H, d, J = 6.5 Hz, (CH3)CH], 2.42-2.64 
(2H, m, COCH2CH2N), 2.61-2.85 (4H, m, COCH2CH2NCH2) (Figure 2.19).  
 
Figure 2.19: Comparison between aminoketones 223 and 197 
 
The bicyclic amino ketone 197 showed Bohlmann bands at 2930-2793 cm-1 in the IR 
spectrum, which confirm this amino ketone 197 posses a trans- ring fusion configuration 
(Figure 2.20).94  
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Figure 2.20: Trans-fused quinolizidine 197 in which the nitrogen lone-pair is trans to at 
least two axial hydrogen atom (Bohlmann bands) 
The stereochemistry of compound 197 was confirmed by nOe-measurements (Figure 2.21). 
Irradiation of the CH3 singlet at δ 0.71 ppm led to nOe enhancements of the CH3 doublet 
(C4) (2%) at 0.91 ppm, and CH methane on C7 at 2.10 ppm (3.1%).  A nOe was also 
observed for the protons of the CH3 singlet (4.6%) at 0.71 ppm when the CH3 doublet  was 
irradiated, thus allowing the methyl at C4 to be assigned as syn relative to CH3 at C5 and 
confirmed the trans-fused ring configuration. 
 
Figure 2.21: Stereochemistry of amino ketone 197 
Conversion of the amino ketone 197 into the final amine 106 was carried out through 
Huang-Minlon reduction. Thus, after refluxing 197 in a mixture of potassium hydroxide, 
hydrazine hydrate, and ethylene glycol for 3 h, water was distilled off and the residue was 
heated to 180 °C for 3 h to yield 106 in 74% yield (Scheme 2.35).137,138 The 13C-NMR 
spectrum of amino ketone 197 showed characteristic signal at 210 ppm for ketone group 
C=O, which disappeared in 13C-NMR of final amine 106. The free amine 106 was stored at -
20 °C under nitrogen atmosphere. 
 
Scheme 2.35: Conversion of amino ketone 197 to final free amine 106 
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Amine 106 was treated with TFA to afford 10-aza-eremophilane salt (7R,4S,5S)-84 in 70% 
yield (Scheme 2.36). The absolute configuration of the final ammonium salt was 
unambiguously verified by X-ray crystallography (Figure 2.22). For this purpose, another 
salt, was prepared by treating free amine with perchloric acid in EtOH to give perchlorate 
salt 247 (Scheme 2.36). The synthetic sequence leading to the bicyclic amine 106 is 
summarised in Scheme 2.37. 
 
Scheme 2.36: Formation of (7R,4S,5S)-84 and perchlorate salt 247 (carried out by Dr. Juan 
A. Faraldos).  
 
 
Figure 2.22: Ball and stick representation of the X-ray crystal structure of the perchlorate 
salt 247 (solved by by Dr. Benson Kariuki) 
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Scheme 2.37: Stereospecific synthesis of bicyclic tertiary amine (7R,4S,5S)-4,5-dimethyl-7-
(prop-1-en-2-yl) decahydroquinolizidine (106) 
(7S,4R,5R)-84 was synthesised starting from R-(+)-limonene oxide (248) following the same 
synthetic sequence previously described for (7R,4S,5S)-84. The synthetic sequence leading 
to the bicyclic amine 107 and (7R,4S,5S)-84 is summarised in Scheme 2.38. As before, For 
X-ray crystallography, the picrate salt 260 was prepared from the free amine 107 and picric 
acid, while perchlorate salt 261 was synthesised from reaction of free amine 107 and 
perchloric acid in ethanol (Scheme 2.39). These conversions were carried out by Dr. Juan A. 
Faraldos, Cardiff Unniversity. The absolute configuration of the final ammonium salts 260 
and 261 were unambiguously verified by X-ray crystallography (Figures 2.23 and 2.24).  
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Scheme 2.38: Stereoselective synthesis of bicyclic tertiary amine 107 and (7S,4R,5R)-84. 
 
Scheme 2.39: Picrate 260 and perchlorate 261 salts of amine 107 (carried out by Dr. Juan A. 
Faraldos) 
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Figure 2.23: Ball and stick representation of the X-ray crystal structure of the picrate salt 
260 (solved by Dr. Benson Kariuki) 
 
 
 Figure 2.24: Ball and stick representation of the X-ray crystal structure of the 
perchlorate salt 261 (solved by Dr. Benson Kariuki) 
After obtaining the three novel aza-analogues, 178-(4S,5S), (7R,4S,5S)-84 and its mirror 
image (7S,4R,5R)-84, the next task was to evaluate them as potential inhibitors with 
aristolochene synthase. The analogue (7R,4S,5S)-84 was expected to bind well to the active 
site of enzyme, since it was designed to mimic the eremophilane cation (70) involved in 
aristolochene biosynthesis. As introduced in the first chapter, many mechanistic details of 
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the cyclisation of FDP by aristolochene synthase from P. roqueforti have been studied, 
previously through the analysis of the reaction products generated by AS-mutants and FDP 
analogues. However there are still some mechanistic details that need further 
investigation. In particular regarding the reaction sequence from eudesmane cation that 
lead to the final hydrocarbon compound. Thus, in order to explore this, the three 
analogues were kinetically evaluated in the presence of fixed amounts of enzymes a 
described by Lineweaver-Burk.139   
2.11 Inhibition studies of PR-AS with ammonium salt 178 
The kinetic evaluation of these analogues was performed by Dr. Juan A. Faraldos (Cardiff 
University). In short, the kinetic steady state parameters of purified recombinant AS were 
measured in the presence of varying amounts of ammonium salt 178 by incubation with 
[1-3H]FDP and monitoring the formation of tritiated, hexane extractable products. A 
double reciprocal plot indicated that the ammonium salt 178 lacking the isopropylidene 
unit was weak an inhibitor of PR-AS. The measured Ki of 2.86 ± 0.35 mM (no PPi) (Figure 
2.25) was 5000-fold higher than the Michaelis-Menten constant for FDP (KM = 0.53 ± 0.21 
µM). Even in the presence of PPi (250 µM), ammonium salt 178 was weak an inhibitor of 
PR-AS [Ki of 1.66 ± 0.15 mM, (Figure 2.25)]. Since the aza-analogue ((7R,4S,5S)-84, Figure 
1.12) was intended to mimic the topological and electrostatic properties of carbocation 70 
presumably involved in the last step (Scheme 1.10) of aristolochene biosynthesis, the aza-
analogue 178 is an imperfect mimic, because it lacks an isopropylidene group.  
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Figure 2.25: Lineweaver-Burk plots of initial rate versus the concentration of substrate 
for AS catalysed turnover of FDP in the presence of 4,5-dimethyl-
hexahydroquinolizidine.TFA salt (178) in (A) the absence of PPi (Ki = 2.86 ± 0.35 mM) 
and (B) the presence of 250 µM PPi (Ki = 1.66 mM ± 0.15). Initial rates were 
determined at increasing concentrations of analogue (0-25 µM). Assays were carried 
out (by Dr. Juan A. Faraldos) with purified wild-type AS (100 nM) in assay buffer (20 
mM Tris, 5 mM MgCl2, pH 7.5) and at room temperature (22 °C) for 12 min. 
2.12 Inhibition studies of PR-AS with ammonium salt (7R,4S,5S)-84  
Inspection of the the kinetic plots (Figure 2.26 and Figure 2.27), obtained for compound 
(7R,4S,5S)-84 and PR-AS revealed that this ammonium salt acted as moderate competitive 
inhibitor with a Ki = 27.7 ± 2.4 µM in the absence of PPi (Figure 2.26), Ki  = 38 ± 4.1 µM (by 
Dixon plot, Figure 2.27). This was concluded because the individual plots intersect on the y-
axis, indicating that Vmax remains constant in the presence of inhibitor, this is characterisitic 
of  inhibitors that competes for the same binding site on the enzyme as the substrate.The 
measured Ki was 72-fold higher than the Michaelis-Menten constant measured for FDP (KM 
= 0.53 ± 0.21 µM).  
The inhibition potency of aza-analogues often increases by the addition of diphosphate 
PPi.77,91 In order to mimic the complex of PR-AS with 10-aza-eremophillane cation, 
(7R,4S,5S)-84  in the presence of PPi, the inhibition constant of ammonium salt for the PR-
AS was measured in the presence of 250 µM of PPi. The Ki dropped to 2.5 ± 0.7 µM when 
PPi (250 µM) was added to the incubation mixture, hence it enhanced the effective 
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inhibition by a factor of 15.2 (Figures 2.26 and 2.27). This synergetic kinetic effect suggests 
the possible involvement of PPi in the stabilization of carbocation 70 (Figure 2.28) in 
aristolochene biosynthesis. This observation is consistent with the general strategy that 
has been suggested in terpene synthases, based on several crystal structures of terpene 
synthases aza analogues complexes.76 Namely that stabilise carbocations generated during 
catalysis by the formation of carbocation-diphosphate ion pairs.91 Compound (7R,4S,5S)-84 
mimic of eremophilane cation 70 binds moderately well to PR-AS in the presence of 
diphosphate. This could be a consequence of the possibility that the final carbocation 
intermediate in this terpenoid cyclisation reaction may be oriented toward the PPi anion, 
which may play a key role in quenching the final carbocation intermediate. 
 
        
  
Figure 2.26: Inhibition of AS by ammonium salt (7R,4S,5S)-84: Lineweaver-Burk plots of 
initial rate versus the concentration of substrate for AS catalysed turnover of FDP in the 
presence of inhibitor (7R,4S,5S)-84 in (A) the absence of PPi (Ki = 27.7 ± 2.4 µM) and (B) the 
presence of 250 µM PPi (Ki = 2.9 ± 0.3 µM). Initial rates were determined at increasing 
concentrations of inhibitor (0-25 µM). Assays were carried out (by Dr. Juan. A. Faraldos) 
with purified wild-type AS (100 nM) in assay buffer (20 mM Tris, 5 mM MgCl2, pH 7.5) and 
at room temperature (22 °C) for 12 min. 
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Figure 2.27: Inhibition of AS by ammonium salt (7R,4S,5S)-84: Dixon plots for inhibition of 
PR-AS by (7R,4S,5S)-84, in the absence of PPi, (7R,4S,5S)-84 acted a modest competitive 
inhibitor of PR-AS with Ki = 38 µM ± 4.1 (right plot). The Ki of (7R,4S,5S)-84 dropped to 2.5 ± 
0.7 µM when 250 mM diphosphate (left plot) was added demonstrating a strong synergistic 
inhibition. Assays were carried out by Dr. Juan A. Faraldos. 
 
Figure 2.28: Ion-pair of eremophilane cation (70) with PPi and its analogue (7R,4S,5S)-84 
 
2.13 Inhibition studies of PR-AS with ammonium salt (7S,4R,5R)-84 
Inspection of the the kinetic plots (Figure 2.29), obtained for compound (7S,4R,5R)-84 and 
PR-AS revealed, as somewhat expected, that this salt did not bind strongly to the active 
site of PR-AS either in the presence (Ki = 0.44 ± 0.18 mM) or absence (Ki = 1.03 ± 0.21 mM) 
of PPi (Figure 2.29). This enzymatic enantiomeric discrimination of aza-analogs highlights 
the chiral environment of the active site of PR-AS and provides evidence for a product-like 
    97 
 
contour of this cavity that ultimately steers the electrophilic reaction cascade toward the 
production of a single enantiomer.  
       
                     
Figure 2.29: Lineweaver-Burk plots of initial rate versus the concentration of substrate for 
AS catalysed turnover of FDP in the presence of (7S,4R,5R)-84 in (A) the absence of PPi (Ki = 
1.03 ± 0.21 mM) and (B) the presence of 250 µM PPi (Ki = 0.44 ± 0.18 mM). Initial rates 
were determined at increasing concentrations of analogue (0, 16, 280, and 1568 µM). 
Assays were carried out (by Dr. Juan A. Faraldos) with purified wild-type AS (100 nM) in 
assay buffer (20 mM Tris, 5 mM MgCl2, pH 7.5) and at room temperature (22 °C) for 12 
min. 
 
2.14 Crystal structures of Aspergillus terreus aristolochene 
synthase (AT-AS) complexed with (7R,4S,5S)-84 and (7S,4R,5R)-84 
Our Inhibition studies with the mechanistically similar PR-AS have shown that only the aza-
analog [(7R,4S,5S)-84] possessing the stereochemistry of the postulated carbocation binds 
efficiently to the active site, with the opposite enantiomer (7S,4R,5R)-84 binding poorly.  
More recent studies have reported the X-ray crystal structures of AT-AS complexed with 
amino analogues (7R,4S,5S)-84, (7S,4R,5R)-84 (and 275, chapter three).140 Surprisingly, the 
active site of AT-AS was sufficiently flexible to accommodate analogues (7R,4S,5S)-84, 
(7S,4R,5R)-84 and analogue 275 with partially or completely incorrect stereochemistry 
(Figure 2.30 a), (Figure 2.31 a). These studies show that the analogue (7R,4S,5S)-84 binds in 
a region that is encircled by the faces of three aromatic residues Y61, F81 and F147 (Figure 
2.31). Therefore, the binding of aza analogue (7R,4S,5S)-84 with the correct stereocenters 
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to mimic eremophilane cation (70) suggest that Y61, F81 and F147 are ideally positioned to 
stabilise carbocation intermediates in the AT-AS reaction. The distances between the aza 
analogue (7R,4S,5S)-84  and aromatic amino acids Y61, F81 and F147 are 3.4, 3.7 and 4.2 Å 
respectively. In order to accommodate the opposite enantiomer (7S,4R,5R)-84 the 
aromatic ring of Y61 rotates approximately 90° and so the edge of this ring rather than the 
face is oriented towards the active site cavity (Figure 2.31). The distances between the aza 
analogue (7S,4R,5R)-84 and aromatic amino acids Y61, F81 and F147 are 3.2, 3.5 and 4.01 Å 
respectively.  
Another interesting observation was that the C8 methylene group is oriented toward the 
PPi anion.140 This may imply that the PPi anion serves as a general base for the 
stereospecefic deprotonation of the H-8si atom in the cyclisation cascade. In addition, in 
each enzyme-inhibitor complex, the cationic amino group is oriented toward the PPi anion, 
so the binding orientation of each aza analogue appears to be governed by favourable 
electrostatic interactions. 
 
 
 
 
 
    99 
 
 
Figure 2.30: Active site of AT-AS complexed with Mg2+-PPi and tertiary amino cation  
(7R,4S,5S)-84. (a) Simulated annealing omit map of (7R,4S,5S)-84 bound to monomer A in 
the AT-AS-(7R,4S,5S)-84 complex. Analogue (7R,4S,5S)-84) is shown in gray, and Atoms are 
shown in the following colors: C = yellow (protein), O = red, N = blue, P = orange, S = yellow, 
Mg2+ ions = silver spheres, solvent molecules = red spheres. Water molecule "w" is trapped 
in the active site along with (7R,4S,5S)-84. (b) Superposition of the AT-AS-(7R,4S,5S)-84 
complex with the AT-AS-FSDP complex.140 This structure was solved by the group of Prof. 
David W. Christianson, University of Pennsylvania. 
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Figure 2.31: Active site of AT-AS complexed with Mg2+-PPi and tertiary amino cation 
(7S,4R,5R)-84. (a) Simulation of tertiary amino cation (7S,4R,5R)-84 bound to monomer A in 
the AT-AS-(7S,4R,5R)-84 complex. Analogue (7S,4R,5R)-84 is shown in gray, and Atoms are 
shown in the following colors: C = yellow (protein), O = red, N = blue, P = orange, S = yellow, 
Mg2+ ions = silver spheres, solvent molecules = red spheres. Water molecule "w" is trapped 
in the active site along with (7S,4R,5R)-84. (b) Superposition of the AT-AS-(7S,4R,5R)-84 
complex with the AT-AS-FSDP complex.140 This structure was solved by the group of Prof. 
David W. Christianson, University of Pennsylvania. 
 
 
 
    101 
 
 
 
 
 
 
CHAPTER THREE 
APPROACHES TOWARDS THE SYNTHESIS OF 
5-AZA-EUDESMANE CATION  
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3.1 Retrosynthetic analysis of 5-aza-eudesmane cation (83) 
For the synthesis of 83, iminium 262 salt (Figure 3.1) could be synthesised by kinetic 
deprotonation at the α-position of a cyclic imine 182, followed by double alkylation with 
(R)-1,3-dibromobutane (184). Cyclic imine 182 could be obtained via cyclisation of 
carbamate 186, which would be obtained via keto acid 211 through degradation of 
limonene oxide (187) and subsequent Curtius rearrangement of 211.  
 
 
Figure 3.1: Retrosynthetic analysis of 5-aza-edesmane cation (83) 
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3.2 Preparation of monocyclic imine 182 
The synthesis of ring A in 83 was constructed from (4S)-limonene (263) (Scheme 3.1). 
Epoxidation of limonene was carried out according to a literature procedure 77, 141 using m-
CPBA in the presence of NaHCO3 to provide a mixture of diastereoisomers of (4S)-limonene 
oxides (187) in 65% yield. Under these conditions, the double bond on the isopropylidine 
group was not oxidized by m-CPBA as it is less electron rich than the substituted double 
bond within the ring. The peroxide selectively attacks the top face of the ring opposite to 
the isopropenyl group on the bottom face. The m-CPBA reaction is a concerted 
electrophilic process via a ‘butterfly’ transition state where the oxygen is added and the 
proton shifted simultaneously (Scheme 3.1). As the reaction was performed without any 
stereochemical control the product was generated as a mixture of cis- and trans-isomers. 
The diastereoisomers are distinguishable by 1H NMR spectroscopy. The lack of signals 
above 5 ppm (olefinic region) indicate the loss of the double bond on the cyclohexene ring, 
whilst the appearance of a doublet at 3 ppm and a triplet at 3.06 ppm, both of which 
integrate for 1H and correspond to the proton of the trisubstituted epoxide. The multiplets 
at 4.67 and 4.72 ppm both integrate to 1H and correspond to the methylene group. The 
singlets at 1.67 and 1.69 ppm correspond to the protons on the methyl group adjacent to 
the exo double bond. The olefinic CH3 appeared downfield (1.67 and 1.69 ppm) when 
compared to the epoxide’s methyl group (1.31 and 1.32 ppm) because the α-double bond 
has a greater deshielding effect than the β-oxygen of the epoxide (Figure 3.2). 
 
Figure 3.2: Positions of α-double bond and β-oxygen with respect to the methyl group 
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Scheme 3.1: Epoxidation of (-)-limonene (263) to (-)-limonene oxide (187) 
Among the synthetic intermediates, the acyclic keto acid 211 is very important, since it is 
the precursor of the cyclic imine 182. The preparation of keto acid 211 was reported by 
Kido and co-workers and has been discussed in chapter two.114 (4S)-Limonene oxide (187) 
was converted to keto acid 211,114,142 as before (see chapter two) in four steps and 79% 
overall yield (Scheme 3.2).  
 
 
  Scheme 3.2: Conversion of (-)-limonene oxide (187) to keto acid 211 
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Alternatively, the keto acid could also be obtained by direct oxidation of diol 199 with 
Jones’ reagent (Scheme 3.3).115 Jones’ reagent is a solution of chromium trioxide in dilute 
sulfuric acid used for the general oxidation of primary and secondary alcohols to acids and 
ketones,  respectively.  
 
Scheme 3.3: Synthesis of keto acid 211 by oxidation of diol 199 with Jones’ reagent. 
The 1H-NMR spectrum of keto ester 198 displayed a characteristic singlet at 3.65 ppm 
ascribed to COOCH3. This signal was absent in the 
1H-NMR spectrum of keto acid 211. The 
13C-NMR spectrum of keto ester 198 showed a signal for COOCH3 at 173.6 ppm. This signal 
was shifted downfield to 178.5 ppm for COOH in the 13C-NMR spectrum of keto acid 211. 
The IR spectrum of keto ester 198 showed two characteristic bands at 1710 and 1725 cm-1 
assigned to the ketone C=O stretch and C=O ester, while the keto acid showed a very 
strong band at 3360 cm-1 owing to the OH stretch, and another two bands at 1738 and 
1715 cm-1 due to the C=O stretches of the acid and CO ketone groups, respectively. 
3.2.1 Curtius rearrangement 
With the keto acid 211 in hand, the next synthetic objective was to introduce the amine 
functionality regioselectively at the acid site, and then induce the cyclisation to form the 
advanced cyclic imine 182. The keto acid 211 was converted to isocyanate 265 under 
Curtius rearrangement conditions when treated with diphenyl phosphoryl azide and 
triethyl amine in refluxing toluene (Scheme 3.4). The unstable isocyanate was quenched in 
situ with p-methoxy benzyl alcohol and the mixture was heated under reflux for 24 h.143 
TLC analysis of the crude mixture showed three spots, the middle one was identified as p-
methoxy benzyl alcohol, and the UV active spot at the bottom was identified as the 
urethane 186 as determined by 1H-NMR spectroscopy after purification. The product was 
purified by chromatography on silica to give the desired compound 186 in 61% yield.  
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Scheme 3.4: Mechanism of the Curtius rearrangement of keto acid 211 
The Curtius degradation of acyl azide 264 (Scheme 3.4) consists of the thermolysis of the 
“inner” N=N double bond. This thermolysis expels a nitrogen molecule and at the same 
time leads to the [1,2]-rearrangement of the substituent attached to the carboxyl carbon. 
It is the simultaneous occurrence of these two events that prevents the formation of an 
energetically disfavoured acylnitrene intermediate. This one-pot procedure was 
convenient because there was no need to isolate the potentially explosive acyl azide 
    107 
 
264.118 The isocyanate 265 can be reacted with heteroatom-nucleophiles in situ. In this 
case, the nucleophile (p-methoxybenzyl alcohol) was added to the C=N double bond of the 
isocyanate 265 to afford carbamate 186.  
3.2.2 Cyclic imine-enamine ring formation  
Hydrolysis of urethane 186 with 10% mol of p-TsOH.H2O in benzene at reflux resulted in 
the formation of enamine compound 266 (Scheme 3.5). Treatment of 266 with 5 
equivalents of aqueous potassium hydroxide in DMSO gave cyclic imine 182 in 46% yield 
after purification by chromatography.144  
 
Scheme 3.5: Cyclisation of urethane 186 to imine 182 
 
To optimise the yield of cyclic imine, the Albericio145 method was used to remove the 
protecting group in 186. This involved deprotection with 10% trifluoroacetic acid in DCM at 
RT for 10 min followed by cyclisation during basic work up (aqueous KOH, 0 °C, 20 min) to 
produce cyclic imine 182 (Scheme 3.6) in 74% yield  and excellent purity (without further 
purification). The product was stored at -20 °C under N2. 
The 1H-NMR spectrum of cyclic imine 182 revealed signals at δ 3.10-3.25 of HaCHN, 3.65-
3.78 of HCHbN, 1.87 of CH3C=N and 2.15-2.25 of CH2C=N. These values were in good 
agreement with those previously reported for the 2-methyl-3,4,5,6-tetrahydropyridine 165 
(Figure 3.3).146  
 
    108 
 
 
Scheme 3.6: Intramolecular cyclisation of urethane 186 to cyclic imine 182 in 74% yield 
 
Figure 3.3: Structures of imines 165 and 182 
 
3.3 Attempted stereospecific synthesis of (R)-1,3-dibromobutane 
The synthesis of amine 267 would require the stereospecific synthesis of (R)-1,3-
dibromobutane (184). The general strategy to introduce ring B consisted of the 
deprotonation of the methyl group at the α-position of 3S-(prop-1-en-2-yl)-6-methyl-
2,3,4,5-tetrahydropyridine (182), followed by alkylation with (R)-1,3-dibromobutane (184) 
to generate a new chiral centre at C4 with an inverted configuration (Figure 3.4). 
 
Figure 3.4: General scheme for the stereospecific synthesis of amine 267 
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Paquette and Freemann have reported the synthesis of (R)-1,3-dibromobutane (184).147 
Following the same procedure, (S)-(+)-1,3-butanediol (188) [α]24D = +10.1 (c 10.17, CHCl3) 
was treated with 2 equivalents of  freshly distilled methanesulfonyl chloride in dry pyridine 
at -5 °C to afford (S)-1,3-butanediol bis-methanesulfonate (268) in 70% yield with optical 
rotation [α]22D = + 30.1 (c 12.5, CHCl3) and is consistent with that reported in the literature 
[α]22D = + 10.1 (c 10.17, CHCl3)
147 (Scheme 3.7). The 1H-NMR spectrum of dimesylate 268 
displayed similar values to those reported by Paquette and Freemann. 
Dimesylate 268 was treated with lithium bromide (5 equivalents) in dry THF at reflux to 
give racemic 1,3-dibromobutane instead of desired (R)-(-)-1,3-dibromobutane (184) in 75% 
yield. The optical rotation obtained for racemic 1,3-dibromobutane was [α] 24D = 0. 
Paquette and Freemann reported the optical rotation for (R)-(-)-1,3-dibromobutane as 
[α]24D = -29.9 (c 17.7, CHCl3) (Scheme 3.7).
147 However, attempts to prepare (R)-(-)-1,3-
dibromobutane from dimesylate 268 by changing the number of equivalents of lithium 
bromide, temperature and solvent were unsuccessful. It seemed that this reaction took 
place with anchimeric (neighbouring group participation) assistance from the primary 
bromine atom, forming the bromonium ion intermediate  (Scheme 3.8). This allows for the 
nucleophilic attack of a second Br– to the primary electrophilic centre, yielding the (S)-
enantiomer of 1,3-dibromobutane. Equilibration of the forward and backward reactions of 
this process racemise 1,3-dibromobutane from chiral diol 188. 
 
Scheme 3.7: Conversion of (S)-1,3-butanediol (188) to racemic 1,3-dibromobutane 
    110 
 
 
Scheme 3.8: Proposed mechanism for conversion of chiral diol 188 to racemic 1,3-
dibromobutane  
 
3.4 Synthesis of dehydroquinolizidinium salt 262 
 Kinetic deprotonation of 3S-(prop-1-en-2-yl)-6-methyl-2,3,4,5-tetrahydropyridine (182) 
was carried out at -35 °C with 1.5 equivalents of LDA in dry THF under argon for 30 min, 
followed by alkylation with 1,3-dibromobutane at -78 °C, the mixture was then allowed to 
warm to room temperature and stirred for 24 h.148,149 Work-up was carried out by pouring 
the mixture into a solution of 0.5 M aqueous sodium hydroxide. After extraction and 
purification by alumina column chromatography, compound 270 was obtained in 71% yield 
(Scheme 3.9). A more polar compound was also obtained and determined by 1H-NMR 
spectroscopy to be  bicyclic enamine 271 in 20% yield.  
In another experiment, cyclic imine 182 was treated with 1.1 equivalents of LDA at -35 °C 
for 30 min, followed by reaction with 1,3-dibromobutane at -78 °C. The reaction mixture 
was stirred at room temperature for 24 h and iminum salt 262 was obtained as a yellow-
orange salt in 74% yield without using 0.5 M aqueous sodium hydroxide (Scheme 3.9). The 
solvent was evaporated under reduced pressure and the final traces of solvent under high 
vacuum for 2-3 h. Because of the hygroscopic nature of iminum salt 262, it was difficult to 
measure the melting point. The purity of this salt was sufficient for use in the next step. 
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Scheme 3.9: Reaction of cyclic imine 182 with racemic 1,3-dibromobutane 
 
Apparently after alkylation, the small excess of LDA (~0.4 eq) led to dehydrohalogenation, 
thus generating compound 270 (Scheme 3.9). The alkylated compound 269 is a secondary 
alkyl bromide (Scheme 3.10), therefore the HBr elimination reaction could take place 
either via a concerted E2 mechanism or a stepwise E1 mechanism (Scheme 3.10). 
 
Scheme 3.10: Possible elimination reaction mechanisms of alkylated compound 269 
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3.5 Introduction of bridgehead methyl group to iminium salt 262 
Introduction of the bridgehead methyl group, and the formation of 10-methylquinolizidine 
was performed by treatment of dehydroquinolizidinium salt 262 with methylmagnesium 
bromide in dry refluxing THF for 24 h.99 TLC analysis on alumina of the crude mixture 
showed two spots corresponding to 108 and 109 (Scheme 3.11). The mixture of isomers 
was isolated by basic alumina-column chromatography. The two diastereomeric isomers 
were formed in the ratio 6:4 in 70% overall yield. 
 
Scheme 3.11: Conversion of iminium salt 262 to diastereoisomeric amines 108 and 109 
 
Four possibilities of 10-methyl quinolizidine in different configurations and conformations 
were predicted, due to the racemic form of iminium salt 262 (Scheme 3.12). The most 
stable isomers, amines 108 and 109 were characterised by nOe difference spectra and 
NOESY experiments and identified unambiguously by X-ray crystallography.  
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Scheme 3.12: The configuration and conformational possibilities of 4,10-dimethyl 
quinolizidines 272, 109, 108 and 267 
In the infrared spectrum, the typical Bohlmann bands appeared at 2791-2856 cm-1 for the 
isomer 108, thus, indicating that the bicyclic structure of this isomer was most likely trans-
fused. The streochemistry of isomer 108 was determined using nOe difference spectra and 
NOESY experiments. Irradiation of CH2=C at 4.65 ppm led to nOe enhancement on Hα 
(2.1%) of CH2N at 2.13 ppm and CHN (2.4%) on C4 at 2.87-2.90 ppm (Figure 3.5), nOe were 
also observed for the protons of CH3 (3.5%) on C4 at 0.96 ppm when Hβ of CH2N at 2.35 
ppm was irradiated. Irradiation of the protons of the C4 CH3 doublet at 0.96 ppm did not 
enhance the CH3 singlet on C10, also no nOe was observed for the CH3 singlet when the  
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CH3 doublet was irradiated, thus allowing the methyl group on C4 to be assigned as anti 
relative to CH3 at C10.   
 
 
Figure 3.5: Stereochemistry of amine 108 
The NOESY spectra of amine 108 showed a cross-peak between the signal at 4.65 ppm 
(CH2=C) in one-dimension and the signal at 2.35 ppm (CHN) in the other dimension. A 
cross-peak between CHN and CH3C also occurred. The absolute stereochemistry of isomer 
108 was determined unequivocally by X-ray crystallography (Figure 3.6), using the 
perchlorate salt 273 prepared by treating free amine 108 with perchloric acid in ethanol 
(Scheme 3.13). 
 
 
Scheme 3.13: Formation of perchlorate salt 273 (carried out by Dr. Juan. A. Faraldos) 
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Figure 3.6: Ball and stick representation of the X-ray crystal structure of the perchlorate salt 
273 (solved by Dr. Benson Kariuki) 
 
The IR spectrum of isomer 109 did not show Bohlmann bands at 2700-2870 cm-1 , 
indicating that the bicyclic structure of this isomer was most likely cis-fused. The 
stereochemistry of isomer 109 was determined by NOESY and nOe difference spectra 
experiments. Irradiation of the protons of CH2=C at 4.74 ppm led to enhancement of Hα of 
CH2N at 2.41 ppm (2%) and of the C4 CH3 doublet at 0.98 ppm (3.1%) (Figure 3.7). Another 
nOe was observed for Hβ of CH2N at 2.66 ppm (2.4%) when the C7 CH proton at 2.01 ppm 
was irradiated. There was no nOe between the CH3 singlet and CH3 doublet, thus allowing 
the methyl group on C10 to be assigned also as anti relative to the methyl at C4.  
 
Figure 3.7: Stereochemistry of amine 109 
The NOESY spectra of amine 109 displayed cross-peaks between the signal at 3.14 ppm 
(CHN) and the C10 CH3 signal at 1.13 ppm. A cross-peak between CH3 on C4 and Hβ of 
CH2N also occurred. The absolute stereochemistry of isomer 109 was unambiguously 
determined by X-ray crystallography (Figure 3.8), the perchlorate salt 274 prepared from 
109 as before (Scheme 3.14). 
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Scheme 3.14: Formation of perchlorate salt 274 (carried out by Dr. Juan. A. Faraldos) 
 
 
Figure 3.8: Ball and stick representation of the X-ray crystal structure of the perchlorate salt 
274 (solved by Dr. Benson Kariuki) 
All possible isomeric monomethylated quinolizidines have been subjected to a thorough 
investigation, and are known to exist predominantly in the trans-fused configuration, 
except for 4-methyl quinolizidine (Figure 3.9).93 Thus, all the compounds, with the 
exception of 4-methyl quinolizidine showed Bohlmann bands. However, another study150 
has shown that 4-methylquinolizidine exists in a predominantly trans-fused ring 
conformation at room temperature as indicated by an IR band at 2850 cm-1, which is 
probably a trans band. Therefore, the Bohlmann criterion must be used with caution when 
dealing with 4-substituted quinolizidines such as 108 and 109. 
 
Figure 3.9: Conformations of 1-, 2-, 3- and 4-methylquinolizidines 
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The chemical shift of the methyl doublet and the apparent coupling constant are an 
excellent indication of the equatorial or axial orientation of the methyl group in 
monomethyl quinolizidines. It is known that the axial methyl group resonates at lower 
field151 and shows a larger J coupling than its corresponding epimer.151 Thus, the chemical 
shift and coupling constant of the CH3CH doublet at C4 for isomer 109 are greater than the 
isomer 108 (Figure 3.10). Hence, the C4-methyl in amine 109 must be axial. The synthetic 
sequence leading to the bicyclic amines 108 and 109 is outlined in (Scheme 3.15). 
 
Figure 3.10: Comparison of coupling constant of CH3CH doublets between distereoisomers 
108 and 109  
    118 
 
 
Scheme 3.15: Stereoselective synthesis of trans-fused-quinolizidine 108 and cis-fused-
quinolizidine 109 
 
3.6 Crystal structure of AT-AS complexed with amino cation 275 
Tertiary amino cation 275 partially mimics the possible 5-eudesmane cation intermediate 
(69) (Figure 3.11) that would be formed in a stepwise mechanism, in which 4-eudesmane 
cation (69) undergoes a 1,2-hydride shift to form a tertiary carbocation at the ring-junction 
carbon. However, compound 275 is an imperfect mimic, due to incorrect stereochemistry 
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at the C5 atom (R instead of S), the protonated amino nitrogen is sp3-hybridized rather 
than sp2-hydridized and the analogue adopts a configuration identical to that of cis-decalin. 
In spite of these facts, the co-crystal structure of AT-AS-275 complex (solved by the group 
of Prof David W. Christianson, University of Pennsylvania, Figure 3.12 b)140 showed that the 
tertiary amino cation 275 binds at the active site of AT-AS. The simulated annealing omit 
map of the AT-AS-275 complex revealed that the isopropylidine group is nestled within the 
cavity formed by the side chains of Y61, F81, and W302. The distances between the aza 
analogue 275  and aromatic amino acids Y61, F81 and W302 are 3.2, 3.5 and 5.9 Å 
respectively.140 Although the conformations of surrounding residues are almost identical to 
those observed in previous structures (Figures 2.30 and 2.31), F81 moves slightly toward 
the bottom of the cleft to accommodate 275. In addition, the C8 methylene group is 
oriented toward the PPi anion.140 This suggests that the PPi anion could be acting as a 
general base for the stereospecific deprotonation of the H-8si atom in the cyclisation 
cascade leading to (+)-aristolochene formation as shown in Scheme 1.10. 
 
Figure 3.11: Stepwise mechanism in AT-AS biosynthesis 
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Figure 3.12: Active site of AT-AS complexed with Mg2+-PPi and tertiary amino cation 275. 
(a) Simulated annealing omit map of 275 bound to monomer A in the AT-AS-275 complex. 
Analogue 275 is shown in grey, and atoms are shown in the following colours: C = yellow 
(protein), O = red, N = blue, P = orange, S = yellow, Mg2+ ions = silver spheres, solvent 
molecules = red spheres. Water molecule "w" is trapped in the active site along with 275. 
(b) Superposition of the AT-AS-275 complex with the AT-AS-FSDP complex.140 This structure 
was solved by the group of Prof. David W. Christianson, University of Pennsylvania. 
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3.7 Polonovski-Potier reaction of isomers 108 and 109 
Treatment of a tertiary N-oxide 276 with an activating agent such as acetic anhydride, 
results in rearrangement where an N,N-disubstituted acetamide 277 and an aldehyde 278 
are generated (Scheme 3.16). The central features of the Polonovski reaction are the 
transformation of an N-oxide to an iminum ion intermediate 279. The reaction will either 
stop at this stage and the iminium ion becomes the Polonovski product, or HOAc 
elimination proceeds to afford an enamine.152  
 
Scheme 3.16: General scheme of Polonovski reaction of N-oxide 276 
In the first step of the Polonovski reaction, a tertiary amine is oxidized through the 
interaction of the pair of electrons on nitrogen with electrophile X, followed by elimination 
of HX to generate an iminium ion. Considering the rich chemistry and versatility of iminium 
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ions, many uses of this ion have been applied especially in the stereoselective synthesis of 
quionolizidines alkaloids. 
The Polonovski-Potier reaction was applied to both diastereomeric isomers 108 and 109, as 
a plausible means for the stereoselective synthesis of desired amine 266 (Figure 3.13).  
 
 
Figure 3.13: Polonovski-Potier inversion of isomer 109 
 
3.7.1 Anti Polonovski-Potier inversion of bicyclic trans-fused 
quinolizidine 108 
The trans-quinolizidine-N-oxide 282 was easily obtained by treating quinolizidine 108 with 
m-CPBA and K2CO3 in DCM at 0 °C for 2h (Scheme 3.17). The crude product was purified by 
basic alumina-column chromatography to give N-oxide 282 in 76% yield.92,153  
 
Scheme 3.17: Synthesis of trans-fused-quinolizidine-N-oxide 282 
1H-NMR, 13C-NMR, DEPT and HSQC spectroscopic analyses of 282 were used to determine 
the structure of this compound. The signals of the 1H- and 13C-NMR spectra were shifted 
downfield when compared to those of the free amine, due to the deshielding effect of the 
N-O group. The IR spectrum of the N-oxide displayed characteristic Bohlmann bands at 
2735-2822 cm-1.  
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The 1H-NMR spectrum of amine-N-oxide 282 revealed signals at δ 3.77 of CHN-O, 3.41 
owing to HCHN, 3.18 of HCHN, 1.19 of CH3CHN, these values were in a good agreement 
with those previously reported for cermizine C N-oxide (283) (Figure 3.14) at δ 3.63, 3.36, 
3.07 and 1.24 arising from CHN-O, HCHN, HCHN and CH3CHN, respectively.
92 
 
Figure 3.14: Structures of trans-quinolizidine-N-oxide 282 and cermizine C N-oxide (283) 
The relative stereochemistry of isomer 282 was determined by NOESY experiments. The 
NOESY spectrum of amine-N-oxide 282 showed cross-peaks between the CH3 singlet at 
1.42 ppm in one-dimension and the axial proton of CH2N at 2.82 ppm in the other 
dimension (Figure 3.15). A cross-peak between the CH3 singlet and CHN also occurred and 
another correlation was observed between the CH3 doublet at 1.19 ppm and both CH on 
C7 and the equatorial proton of CH2N at 3.18 ppm. 
 
Figure 3.15: Stereochemistry of amine N-oxide 282 
The next step in this inversion protocol was the generation of an iminium ion. Amine-N-
oxide 282 was treated with trifluoroacetic anhydride (TFAA) in DCM at 0 °C for 4h followed 
by room temperature for 24 h to give iminium ion 112 in 90% yield (Scheme 3.18).92,153,154 
The purity of this compound 112 was sufficiently high to use in the next step without 
purification. It is worth mentioning that the same result was obtained when freshly 
distilled acetic anhydride was used instead of TFAA. 
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Scheme 3.18: Synthesis of iminium ion 112 
 
The 1H-NMR spectrum of iminium ion 112 displayed signals at δ 4.17 (HCHN+), 3.51 
(HCHN+) and 2.44 ppm (CH3C=N
+), these chemical shifts were in a good agreement with 
those previously reported for natural (-)-senepodine G (114) (Scheme 3.19) at δ 3.96, 3.53 
and 2.45 ppm corresponding to HCHN+, HCHN+ and CH3C=N
+ respectively.92 
 
 
Scheme 3.19: Synthesis of iminium ion 112 and comparison with (-)-senepodine G (114) 
Reduction of iminium ion 112 with NaBH4 in MeOH at 25 °C for 10 min gave back the free 
amine 108. Thus, hydride addition to iminum ion 112 took place stereospecifically by axial 
attack from the bottom face (Scheme 3.20).155 The axial attack prevents the formation of 
the high energy isomer 284.  
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Scheme 3.20: Reduction of iminium ion 112 with NaBH4 
Hydride reductions of (-)-senepodine G (114) and epi-senepodine G (156) (Scheme 3.21) 
have been previously reported by Snider and Grabowski.155 The reduction of 114 with 
NaBH4 afforded (+)-cermizine C (113), thus, hydride addition to (-)-senepodine G also 
occurred by axial attack from the bottom face. Likewise, the reduction of epi-senepodine G 
(156) with NaBH4 took place stereospecifically by axial attack from less hindered top face 
to give (±)-5-epi-cermizine C (151).  
 
Scheme 3.21: Stereospecifically addition of hydride to (-)-senepodine G (114) and (±)-epi-
senepodine G (156) 
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3.7.2 Anti Polonovski-Potier inversion of quinolizidine 109 
cis-Quinolizidines have been reported to react with air to give N-oxide more readily than 
trans-quinolizidines.156 Therefore, the cis-quinolizidne reacted with mCPBA and K2CO3 in 
DCM at 0 °C for 30 min to give cis-quinolizidine-N-oxide 280. The crude mixture was 
purified on basic alumina-column to give pure N-oxide in 85% yield (Scheme 2.22).92 
 
 
Scheme 3.22: Synthesis of amine-N-oxide 280 
Generation of the iminium ion from N-oxide 280 was carried out following the same 
procedure as described for trans-quinolizidine-N-oxide 282.92 Reaction of cis-N-oxide 280 
with TFAA in DCM at 0 °C and then stirring at room temperature for 24 h provided iminium 
ion 285 instead of iminum ion 281 (Scheme 2.23). The reason for elimination of the proton 
from C 6 in ring A instead of C 4, as expected was that the only proton situated in an anti-
position to the N-O bond in N-oxide derivative 280 was on C 6. Iminium ion 285 isomerised 
to the unexpected conjugated iminum ion 286 when left with TFAA for another 24 h. 
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Scheme 3.23: Conversion of cis-N-oxide 280 to iminum ion 285 and isomerization to 
unexpected conjugated iminum ion 286 
The 1H-NMR spectrum of iminum ion 285 revealed characteristic a signal in the downfield 
region at 8.43 ppm owing to proton of CH=N+. The two vinylic protons of CH2=C of the 
isopropylidene unit were not observed in the proton NMR spectrum of conjugated iminum 
ion 286,  showing instead another two signals at 1.45 and 1.46 ppm arising from the two 
methyl groups attached to the  exo-methylene double bond [(CH3)2C=C]. 
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3.8 Stereoselective synthesis of (-)-5-aza-eudesemane cation  
epi-Aristolochene synthase from tobacco (TEAS) catalyses conversion of farnesyl 
diphosphate FDP 5 to 5-epi-aristolochene (287) (Scheme 2.24). The complex reaction 
mechanism has been studied by site directed mutagenesis, providing evidence for 
intermediacy of the neutral hydrocarbon (+)-germacrene A (288) and the highly reactive 
bicyclic (-)-5-aza-eudesmane cation (290).157  
 
Scheme 3.24: Biosynthesis of 5-epi-aristolochene (287) 
In order to explore the intermediacy of carbocation intermediate 290, (-)-5-aza-eudesmane 
cation (292) was designed to mimic the electrostatic and geometric of putative carbocation 
290 (Figure 3.16). 
 
Figure 3.16: Structures of (-)-5- eudesmane cation (290) and its ananlogue (-)-5-aza-
eudesmane cation (292) 
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(-)-5-Aza-eudesmane cation (292) was synthesized in eight steps following the same 
sequence of steps used to prepare the isomers 108 and 109, starting from (R)-limonene 
(293). Epoxidation of limonene (293) was achieved by reaction of limonene with mCPBA 
and K2CO3 in DCM at 0 °C to produce limonene oxide (248) in 63% yield (Scheme 2.25). 
Hydrolysis of (R)-limonene oxide (248) with KOH and H2O in DMSO for 24 h gave 
diastereomeric diaxial diol 249 in 72% yield. Jones oxidation of diol 249 in acetone at 0 °C 
afforded keto acid in 69% yield 294. Treatment of keto acid 294 with diphenylphosphoryl 
azide and triethylamine in toluene yielded keto acyl azide 295, that underwent Curtius 
rearrangement to produce keto isocyanate 296, followed by addition of p-methoxybenzyl 
alcohol to give urethane 297 in 60% yield. Deprotection of urethane 297 was carried out by 
using 10% TFA, and then cyclisation was induced by use of an aqueous solution of KOH to 
produce cyclic imine 298 in 72% yield.  
 Kinetic deprotonation of 3R-(prop-1-en-2-yl)-6-methyl-2,3,4,5-tetrahydropyridine (298) 
was carried  out at -35 °C with LDA, followed by subsequent alkylation with 1,3-
dibromobutane to yield iminum ion salt 299 in 57% yield. Introduction of the angular 
methyl group was achieved by treating iminum ion 304 with methyl magnesium bromide 
to afford diastereomeric isomers 110 and 111 in 6:4 ratios in 52% as total yield. The 
synthetic sequence leading to the bicyclic amines 110 and 111 is outlined in (Scheme 3.25). 
trans-Quinolizidine isomer 110 and cis-quinolizidine 111 were treated with TFA to produce  
(-)-5-aza-eudesmane cation 292 in 82% yield and cis-quinolizidinum salt 300 in 84% yield 
respectively (Scheme 3.26).  
Although four quinolizidines (108-111) were prepared in good yields, attempts to 
synthesise 5-aza-eudesmane cation (83) were unsuccessful. Annualation of cyclic imine 182 
with 1,3-dibromobutane led to the formation of compounds 108 and 109. Attempts at the 
stereospecific synthesis of (R)-1,3-dibromobutane were fruitless. Polonovski-Potier 
inversion of 109 caused loss of the isopropylidene group. Therefore, other methodologies 
are needed to complete the synthesis of the target compound 83.  
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Scheme 3.25: Stereoselective synthesis of trans-quinolizidine 110 and cis-quinolizidine 111 
 
 
Scheme 3.26: Preparation of 5-aza-eudesmane cation (292) and cis-quinolizidinium 
salt 300 (carried out by Dr. Juan. A. Faraldos) 
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3.9 Another approach to the stereoselective synthesis of 5-aza-
eudesmane cation 83 
A new synthetic methodology was designed to synthesise 5-aza-eudesmane cation (83) 
with the correct stereochemistry regarding the two methyl groups. Since the introduction 
of the angular methyl group at C10 into the bicyclic iminium ion 262 in the first strategy 
was directed by the methyl group at C4, the methyl group at C10 needed to be introduced 
first, using the monocyclic compound 302 prior to cyclisation to the iminium ion 281 
(Scheme 3.27).  
This route also started with the kinetic deprotonation of cyclic imine 182, followed by 
alkylation with bromo acetal 301 to afford imine acetal 302. The introduction of a methyl 
group could potentially require activation of the imine acetal 302. Cyclisation of secondary 
amine acetal 303 to Schiff base 281 should be induced with aqueous acid. Reduction of 
iminium ion 281 with NaBH4 would then generate the desired compound 267. 
 
Scheme 3.27: An alternative approach to the synthesis of bicyclic amine 266 
 
The kinetic deprotonation of cyclic imine 182 was carried out with LDA at -35 °C for 30 min, 
followed by alkylation with acetal bromide 301 at -78 °C and stirring at room temperature 
for 24 h to produce imine acetal 302 in 70% yield after purification of crude mixture on 
basic alumina-column chromatography (Scheme 3.28).148  
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Attempts to introduce a methyl group without activating imine acetal 302 were 
unsuccessful. The reaction of imine acetal 302 with methyl magnesium bromide in dry THF, 
did not give the desired compound 303, even when the reaction mixture was heated under 
reflux for 24 h. Imine acetal was activated with anhydrous TFA at room temperature to 
afford iminum salt 304 (Scheme 3.28).148 Reaction of iminum salt 304 with methyl 
magnesium bromide yielded the starting material, due to the reaction of methyl 
magnesium bromide with C=N+H to produce CH4 and imine acetal 302.  
 
 
Scheme 3.28: Synthesis of imine acetal 302 and attempts to introduce methyl group to 302 
 
A second attempt to activate imine acetal 302 towards the nucleophilic addition with 
methyl magnesium bromide was developed by oxidation to the nitrone 305 (Scheme 3.29). 
Nitrone 305 can then undergo reaction with nucleophiles like methyl magnesium bromide 
to produce α-methyl hydroxylamine 306. This hydroxylamine 306 can then be converted to 
the corresponding secondary amine 303 upon treatment with a Lewis acid such as TiCl4 in 
mixture of water and methanol. 
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Scheme 3.29: General strategy to activate imine acetal 302 as nitrone 305 towards 
addition of methyl magnesium bromide 
Thus, following a published protocol,158  302 was treated with a mixture of oxidizing agents, 
UHP (urea hydrogen peroxide) and a catalytic amount of MTO (methyltrioxorhenium)158 in 
dry methanol at room temperature to give a mixture of compounds 307 and 308 instead of 
the expected nitrone 305 (Scheme 3.30). Although quite a few modifications were tried in 
efforts to get this reaction to work; such as variation the reaction time and temperature or 
the use of lower amounts of oxidizing agent, no significant difference in the outcome was 
observed. The signals of the two protons of the vinylic group in the isopropylidene unit in 
the proton NMR spectra of two epoxide compounds 307 and 308 disappeared, and two 
new signals appeared at 1.24 and 2.43 ppm. corresponding to the CH3CO and CH2O groups 
respectively. 
 
 
Scheme 3.30: Epoxidation of vinylic group of imine acetal 302 to epoxides 307 and 308 
 
    134 
 
3.10 Summary and future work 
A variety of quinolizidines analogues were prepared using both published protocols and 
novel methodologies. The synthesis of tertiary amines 108 and 109 were accomplished in 6 
steps, starting from the known keto ester 198. The syntheses of amine 106 and its mirror 
image 107 were accomplished in 8 steps, starting also from the keto ester 198 and its 
mirror image. The two enantiomers of 198 were obtained through degradation of (-)-
limonene (263) and its mirror image.77,114,139 The synthesis of 108 and 109 featured a 
modified Curtius rearrangement141 that, after acid-promoted cyclisation, gave rise to a 3-
alkylated cyclic amine 182.143 Cyclic imine 182 was easily converted to the final 3,7,10-alkyl 
substituted quinolizidines 108 and 109, essentially as described by De Kimpe.147 An 
identical synthetic protocol was repeated from (+)-limonene to give amines 110 and 111.  
Starting from keto ester 198, the synthesis of 106 was carried out using a Beckmann 
rearrangement117 that provided, after cyclisation, the enantiopure lactam 183. The latter 
was then converted to the final quinolizidine 106 via a tandem aza-Robinson 
annulations/Michael alkylation/Wolff-Kishner reduction that installed the syn vicinal 
methyl groups of 106 with excellent stereospecficity.123,137,138 An identical synthetic 
protocol was repeated from (+)-limonene to give amine 107, the enantiomer of 
quinolizidine 106. The absolute configuration of amines 106-109 was determined using a 
combination of 1D and 2D NMR experiments and confirmed by X-ray crystal structure 
determinations of the perchlorate salts of 108, 109, 110 and 111.  
In order to probe the transformation of eudesmane cation 68 to (+)-aristolochene (24), the 
three novel aza-analogues, 178, (7R,4S,5S)-84 and its mirror image (7S,4R,5R)-84 were 
evaluated with aristolochene synthase. The kinetic results revealed that the tertiary amino 
cation (7R,4S,5S)-84 acted as a moderate competitive inhibitor (Ki = 38 µM) while the 
compound (7S,4R,5R)-84, which has incorrect stereochemistry, did not act as inhibitor of 
PR-AS (Ki = 1.03 mM). The data obtained for this compound highlights the chiral 
environment of the active site of PR-AS. Interestingly, more recent studies have reported 
X-ray crystal structures of aristolochene synthase from Aspergillus terreus (AT-AS) 
complexed with three Mg2+ ions, inorganic diphosphate (PPi), and amino and imino 
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 analogues (7R,4S,5S)-84, (7S,4R,5R)-84 and an analogue 275 of bicyclic carbocation 
intermediates 69 and 70 proposed in the cyclisation cascade.140 Surprisingly, the active site 
of AT-AS was sufficiently flexible to accommodate analogues (7R,4S,5S)-84, (7S,4R,5R)-84 
and analogue 275 with partially or completely incorrect stereochemistry. In addition, in 
each enzyme-inhibitor complex, the cationic amino group is oriented toward the PPi anion, 
so the binding orientation of each aza analogue appears to be governed by favourable 
electrostatic interactions. 
Chapter three was focused on the design, and progress toward the stereoselective 
synthesis of 5-aza-eudesmane cation (83). This teriary amine 83 is a structural mimic of the 
5-eudesmyl carbocation (69), a key intermediate in the biosynthesis of AS. However, this 
tertiary amine was not obtained with desired stereochemistry, namely cis-1,3-dimethyl 
quinolizidine. Instead, two different diastereoisomers were gained. Although four 
quinolizidines (108-111) were prepared in good yields, attempts to synthesise the 5-aza-
eudesmane cation (83) with the required stereocenters were unsuccessful. Since the 5-
eudesmane cation is an important analogue, efforts are still underway to synthesise this 
compound by other methodologies. 
In the near future, work is underway to employ the efficient synthetic methodology 
described here to prepare libraries of novel multi-substituted quinolizidines and indolizines 
alkaloids. These will be used as mechanistic probes and protein crystallization aids of 
sesquiterpene synthases. The results gathered from this demanding approach, in 
combination with those obtained from site-directed mutagenesis and substrate analogues, 
will expand our current understanding of the complex chemistry exhibited by terpene 
synthase and will help in the major goal of designing and preparing terpene synthases of 
specific artificial activity. Ultimately, this knowledge may be applied to engineering yeast or 
bacterial organisms for the production of natural and non-natural valuable 
(sesqui)terpenes.  
In addition, the synthetic efforts successfully applied here in the synthesis of aza-analogs 
(108-111) from commercial available chiral pools (eg. (S)- and (R)-limonene), could also be 
applied in the total synthesis of important natural alkaloids (Lycopodium alkaloids) of 
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commercial, pharmaceutical or medicinal value. At the same time, the future library of 
unnatural quinolizidine and indolizines alkaloids could be tested for biological activity using 
different cancer cell lines, or other biomedicinal targets.  
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CHAPTER FOUR 
EXPERIMENTAL 
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4.1 General experimental 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Tetrahydrofuran 
(THF) was distilled from sodium/benzophenone ketyl under nitrogen; diethyl ether was 
distilled from sodium under nitrogen. Triethylamine, DCM and toluene were distilled from 
calcium hydride under nitrogen. DBU, Me2SO4 and TFAA were distilled under reduced 
pressure and a nitrogen atmosphere. Acetic anhydride was distilled from quinoline under 
reduced pressure and nitrogen atmosphere.  
1H-NMR spectra were measured on a Bruker Avance 500 MHz spectrometer or or a Bruker 
Avance DPX 400 NMR spectrometer and are reported as chemical shifts in parts per million 
(δ scale) downfield from tetramethylsilane (TMS). The following solvents and reference 
values in ppm were used in obtaining the NMR data: CDCl3 (
1H, 7.26, 13C 77.0), D2O (
1H, 
4.79), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling 
constant (to the nearest 0.5 Hz) and assignment respectively. The abbreviation “app” 
(apparent) in NMR data means that interpretation was based on first-order analysis of the 
multiplet in question and the data gives the appearance, positions, and spacing of the 
signals. 13C-NMR spectra were measured on a Bruker Avance 500 MHz spectrometer and 
are reported as chemical shift downfield from tetramethylsilane, coupling constant where 
appropriate and assignment. The assignments are made to the limitations of COSY, DEPT 
90/135, and gradient HSQC and gradient HMBC spectra. IR spectra were recorded on 
Perkin ELMER 1600 series FTIR spectrometer, and samples were prepared as thin films of 
neat liquid on NaCl discs for oils and as KBr disks for solids. EI+ mass spectra were 
measured on a Micromass LCT premiere XE mass spectrometer, ES- mass spectra were 
provided by the UK EPSRC mass spectrometry service. The purity of purified compounds 
was judged to be > 95% by TLC and/or GC analyses and NMR spectroscopic analyses. TLC 
analyses were performed on plates pre-coated with 250 µM layers of either silica gel 60 
F254 or alumina 60 F254. All retention factors (Rf) are on silica gel and alumina TLC plates. 
TLC visualisations were performed with 5% phosphomolybdic acid, CAM (ceric-ammonium-
molybdate), KMnO4, I2 vapour, or UV light. Optical rotations were measured on a JASCO 
DIP-370 Digital Polarimeter at rt. Melting points were recorded with a melting apparatus 
and are quoted uncorrected. 
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4.2 Experimental  
(1S,8S,9aR)-1,9a-Dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium2,2,2-
trifluoroacetate (84)  
 
To a solution of the free amine 106 (20 mg, 0.09 mmol) in dry DCM (2 mL) was added TFA 
(8 µL, 0.09 mmol). After 15 min, the solvent was evaporated under reduced pressure, and 
the residue was purified by column chromatography on alumina (ethyl acetate-methanol, 
15%, Rf 0.15) to give pure TFA salt 84 as yellow oil (28 mg, 90%): IR (thin film) cm
-1 3050 
(m) (CH, stretch), 2670-2795 (s) (CH, stretch), 1660 (m) (C=C, stretch); 1H-NMR (500 MHz, 
CDCl3) δH 0.85-.86 (3H, d, J = 6.5 Hz, CH3CH), 1.19 (3H, s, CH3C), 1.18-1.29 (2H, m, CH2), 
1.36-1.41 (1H, m, CHCH3), 1.52-1.63 (2H, m, CH2CCH3), 1.50-1.74 (4H, m, CH2CH2N, 
CH2CH2N), 1.65 (3H, s, CH3C=C), 2.02-2.15 (1H, m, CH), 2.71-2.86 (2H, ddd, J = 7.5, 6.0, 5.5 
Hz, CH2N), 3.20-3.36 (2H, m, CH2N), 4.69 (1H, s, CHaH=C), 4.73 (1H, s, CHHb=C), 9.28 (1H, 
broad s, NH); 13C-NMR (125 MHz, CDCl3) δC 9.8 (CH3C), 15.6 (CH3CH), 20.0 (CH3C=C), 22.4 
(CH2CCH3), 26.6 (CH2CCH3), 27.8 (CH2CH2N), 36.9 (CH2CH2N), 39.3 (CH), 39.4 (CHCH3), 49.6 
(CH2N), 49.7 (CH2N), 64.8 (CCH3), 111.0 (CH2=C), 114.8-117.1 (q, J = 285 Hz, CF3), 146.2 
(CH2=C), 161.0-161.3 (q, J = 39.0 HZ, COO); HRMS(EI
+) found 208.2065, C14H26N requires 
208.2065.  
(1S,9aR)-1,9a-Dimethyloctahydro-1H-quinolizine (105) 
 
A stream of nitrogen was bubbled through a solution of amino ketone 223 (100 mg, 0.55 
mmol), potassium hydroxide (129 mg, 1.7 mmol), diethylene glycol (1 mL), 85% hydrazine 
hydrate (0.2 mL, 1.7 mmol) and absolute ethanol (3 mL). The mixture was heated under 
reflux at (160-165 °C) for 3 h. The temperature was increased to 180 °C to distill off water 
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and excess hydrazine hydrate, and the residue was then heated under reflux for 4 hrs. 
After cooling, the mixture was poured into water (20 mL) and extracted with Et2O (3 x 5 
mL). The resulting ethereal layers were washed with 10% HCl (5 mL). The separated 
aqueous layer was adjusted to pH 12 with NaOH (pellets), and extracted with Et2O (3× 10 
mL). The combined ethereal layers were dried (K2CO3) and filtered, and the solvent was 
removed under reduced pressure. The residue was purified by column chromatography on 
alumina (hexane-ethyl acetate, 1:1, Rf 0.15) to give free amine 105 as pale yellow (68 mg, 
74%): IR (NaCl) cm-1 3050 (m) (CH, stretch), 2790-2927 (s) (stretch C-H), 1260 (m) (CN, 
stretch); 1H-NMR (400 MHz, CDCl3) δH 0.72-0.73 (3H, d, J= 7.0 Hz, CH3CH), 0.76 (3H, s, 
CH3C), 1.32-1.43 [1H, m, CH(CH3)], 1.18-1.67 [10H, m, (CH2)5], 2.34-2.43 [4H, m, (CH2)2N]; 
13C-NMR (100 MHz, CDCl3) δC 4.3 (CH3C), 15.1 (CH3CH), 19.4 [CH2C(CH3)], 24.8 
[(CH2CH2C(CH3)], 25.3 [CH2CH(CH3)], 28.3 (CH2CH2N), 36.7 (CH2CH2N), 41.1 (CH3CH), 48.9 
(CH2N), 49.1 (CH2N), 55.6 (CH3C); HRMS(EI
+) found 167.1672, C11H21N requires 167.1674.  
(1S,8S,9aR)-1,9a-Dimethyl-8-(prop-1-en-2-yl)octahydro-1H-quinolizine (106) 
 
A stream of nitrogen was bubbled through a solution of amino ketone 197 (100 mg, o.45 
mmol), potassium hydroxide (129 mg, 1.35 mmol), diethylene glycol (1 mL), 85% hydrazine 
hydrate (0.2 mL, 1.35 mmol) and absolute ethanol (3 mL). The mixture was heated under 
reflux at (160-165 °C) for 3 h. The temperature was increased to 180 °C to distill off the 
water and excess hydrazine hydrate, and the residue was heated under reflux for another 
3h. After cooling, the mixture was poured into water (20 mL) and extracted with Et2O (3 x 
10 mL). To the pooled ethereal layers was added 10% HCl (5 mL) and the two phases were 
separated. The aqueous phase was adjusted to pH 12 with NaOH (pellets) and extracted 
with Et2O (5 x 10 mL). The combined ethereal layers were dried (K2CO3) then filtered and 
the solvent was removed under reduced pressure. The crude was purified by 
chromatography on basic alumina (hexane-diethyl ether, 10%, Rf 0.22) to afford the final 
free amine 106 as colourless oil (65 mg, 74%): IR(thin film) (NaCl) cm-1 3040 (m) (CH, 
stretch), 2700-2825 (s) (CH, stretch), 1640 (m) (C=C, stretch); 1H-NMR (500 MHz, CDCl3) δH 
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0.73 (3H, d, J = 6.5 Hz, CH3CH), 0.77 (3H, s, CH3C), 1.18-1.29 (2H, m, CH2CHCH3), 1.36-1.41 
(1H, m, CHCH3), 1.51-1.62 (2H, CH2CCH3), 1.50-1.74 (4H, m, CH2CH2N, CH2CH2N), 1.65 (3H, 
s, CH3C=C), 2.02-2.15 (1H, CH), 2.31-2.40 (2H, ddd, J = 7.5, 6.5, 5.0 Hz, CH2N), 2.52-2.55 (2H, 
m, CH2N), 4.60 (1H, s, CHaH=C), 4.65 (1H, s, CHHb=C); 
13C-NMR (125 MHz, CDCl3) δC 5.7 
(CH3C), 16.1 (CH3CH), 20.6 (CH3C=C), 22.3 (CH2CH2CH2N), 25.8 (CH2CHCH3), 29.0 (CH2CH2N), 
31.2 (CH2CH2N), 39.0 (CH), 42.9 (CHCH3), 49.7 (CH2N), 49.9 (CH2N), 55.6 (CCH3), 108.6 
(CH2=C), 150.0 (CH2=C); HRMS(EI
+) found 208.2065, C14H25N requires 208.2066.  
(1R,8R,9aS)-1,9a-Dimethyl-8-(prop-1-en-2-yl)octahydro-1H-quinolizine (107) 
 
A stream of nitrogen was bubbled through a stirred mixture of amino ketone 259 (100 mg, 
o.45 mmol), potassium hydroxide (0.129 g, 1.35 mmol), diethylene glycol (1 mL), 85% 
hydrazine hydrate (0.2 mL, 1.35 mmol) and absolute ethanol (3 mL) . The mixture was 
heated under reflux at 160-165 °C for 3 h. The temperature was then increased to 180 °C 
to distill off the water and excess hydrazine hydrate, and the residue was heated under 
reflux for another 3h. After cooling, the mixture was poured into water and the resulting 
mixture was extracted with Et2O (3 x 10 mL). To the pooled ethereal extracts was added 
10% HCl (5 mL) and extracted and the two phases were separated. The aqueous phase was 
adjusted to pH 12 with NaOH (pellets) and extracted with Et2O (5 x 10 mL). The combined 
ethereal extracts were dried (K2CO3) then filtered and the solvent was removed under 
reduced pressure. The crude product was purified by chromatography on basic alumina 
(Hexane-diethyl ether, 10%, Rf 0.22) to afford the final free amine 107 as colourless oil (50 
mg, 54%); IR(thin film) (NaCl) cm-1 3060 (m) (CH, stretch), 2667-2825 (s) (CH, stretch), 1640 
(m) (C=C, stretch); 1H-NMR (500 MHz, CDCl3) δH 0.73 (3H, d, J = 6.5 Hz, CH3CH), 0.77 (3H, s, 
CH3C), 1.18-1.29 (2H, m, CH2CHCH3), 1.36-1.41 (1H, m, CHCH3), 1.51-1.62 (2H, CH2CCH3), 
1.50-1.74 (4H, m, CH2CH2N, CH2CH2N), 1.65 (3H, s, CH3C=C), 2.02-2.15 (1H, CH), 2.31-2.40 
(2H, ddd, J = 7.5, 6.5, 5.0 Hz, CH2N), 2.52-2.55 (2H, m, CH2N), 4.60 (1H, s, CHaH=C), 4.65 
(1H, s, CHHb=C); 
13C-NMR (125 MHz, CDCl3) δC 5.7 (CH3C), 16.1 (CH3CH), 20.6 (CH3C=C), 22.3 
(CH2CH2CH2N), 25.8 (CH2CHCH3), 29.0 (CH2CH2N), 31.2 (CH2CH2N), 39.0 (CH), 42.9 (CHCH3), 
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49.7 (CH2N), 49.9 (CH2N), 55.6 (CCH3), 108.6 (CH2=C), 150.0 (CH2=C); HRMS(EI
+) found 
208.2065, C14H25N requires 208.2066.  
(3R,6S,9aS)-6,9a-Dimethyl-3-(prop-1-en-2-yl)octahydro-1H-quinolizine (108) and 
(3R,6R,9aR)-6,9a-Dimethyl-3-(prop-1-en-2-yl)octahydro-1H-quinolizine (109) 
 
To a stirred solution of dehydroquinolizidinium bromide 262 (450 mg, 2.34 mmol) in dry 
THF (10 mL) at room temperature under argon was slowly added methylmagnesium 
bromide (2.5 M in diethyl ether, 2.8 mL, 7.03 mmol). The mixture was then heated under 
reflux for 24 h and after cooling, a saturated ammonium chloride (10 mL) and 10% NH4OH 
(10 mL) were added and extracted with diethyl ether (4 x 10 mL). The combined ethereal 
extracts were dried over K2CO3 then filtered and concentrated under reduced pressure. 
The residue was purified by column chromatography on alumina (hexane-ethyl acetate, 
10%, Rf 0.30) to give trans-fused-dimethylquinolizidine 108 as colourless oil (200 mg, 42%); 
IR (NaCl) cm-1 3010 (m) (CH, stretch), 2750-2876 (m) (CH, stretch), 1660 (m) (C=C, stretch), 
1346 (m) and 1241 (m) (C-N stretch); 1H-NMR (400 MHz, CDCl3) δH 0.89 (3H, s, CH3), 0.96-
0.97 (3H, d, J = 6.5 Hz, CH3), 1.35-1.55 (10H, m, 5 x CH2), 1.66 (3H, s, CH3), 1.91-1.93 (1H, t, J 
= 6.0 Hz, CH), 2.13-2.14 (1H, m, HCHN), 2.35-2.36 (1H, m, HCHN), 2.87-2.90 (1H, dd, J = 6.5, 
5.5 Hz, CHN), 4.64 (1H, s, CHaH=C), 4.66 (1H, s, CHHb=C);
 13C-NMR (100MHz, CDCl3) δ 11.0 
(CH3C), 18.2 (CH3CH), 20.1 (CH2), 21.3 (CH2), 25.2 (CH3C=C), 35.9 (CH2), 40.4 (CH2), 40.7 
(CH2) 48.4 (CH), 51.0 (CH2N), 51.3 (CHN), 53.3 (CN), 109.1 (CH2=C), 148.6 (CH2=C); 
HRMS(EI+) found 207.1283, C14H25N requires 207.1280; [α]
22
D = + 26.6 (c = 10, CHCl3).  
A second elution with (hexane-ethyl acetate, 20%, Rf 0.23) gave cis-fused- 
dimethylquinolizidine 109 as colourless oil (134 mg, 27%): IR (thin film) cm-1 3080 (m) (CH, 
stretch), 2925 (m) (CH, stretch), 1660 (m) (C=C, stretch), 1346 (m) and 1241 (m) (C-N, 
stretch)1H-NMR (400 MHz, CDCl3) δH 0.98-1.00 (3H, d, J = 7.0 Hz, CH3CH), 1.13 (3H, s, CH3C), 
1.35-1.54 (10H, m, 5 x CH2), 1.68 (3H, s, CH3), 2.01-2.05 (1H, m, CH), 2.41-2.45 (1H, t, J = 6.5 
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Hz, HCHN), 2.60-2.66 (1H, dd, J = 6.0, 5.5 Hz, HCHN), 3.13-3.14 (1H, m, CHN), 4.70 (1H, s, 
CHaH=C), 4.74 (1H, s, CHHb=C);
 13C-NMR (100MHz, CDCl3) δC 21.3 (CH3CH), 21.4 (CH3C=C), 
21.8 (CH2) 23.6 (CH2), 25.2 (CH3C), 26.0 (CH2), 26.8 (CH2), 40.8 (CH), 44.0 (CH2N), 44.7 
(CH2N), 50.9 (CHN), 53.4 (CN), 109.5 (CH2=C), 148.5 (CH2=C); HRMS(EI
+) found 207.1283, 
C14H25N requires 207.1280; [α]
22
D = + 16.6 (c = 5, CHCl3). 
(3S,6R,9aR)-6,9a-Dimethyl-3-(prop-1-en-2-yl)octahydro-1H-quinolizine (110) and 
(3S,6S,9aS)-6,9a-Dimethyl-3-(prop-1-en-2-yl)octahydro-1H-quinolizine (111) 
 
To a stirred solution of quinolizidinium bromide 299 (900 mg, 2.34 mmol) in dry THF (10 
ml) at  room temperature under argon was slowly added methylmagnesium bromide (2.5 
M in diethyl ether, 2.8 mL, 7.03 mmol). The mixture was then heated under reflux for 24 h 
and after cooling, a saturated ammonium chloride (30 mL) and 10% NH4OH (30 mL) were 
added and the mixture was extracted with DCM (4 x 10 mL). The combined DCM extracts 
were dried over K2CO3 then filtered and concentrated under reduced temperature. The 
residue was purified by column chromatography on alumina (hexane-ethyl acetate, 10%, Rf 
0.30) to give trans-fused-dimethylquinolizidine 110 as colourless oil (485 mg, 52% yield); IR 
(NaCl) cm-1 3010 (m) (CH, stretch), 2750-2876 (m) (CH, stretch), 1667 (m) (C=C, stretch); 1H-
NMR (400 MHz, CDCl3) δH 0.89 (3H, s, CH3), 0.96-0.97 (3H, d, J = 6.5 Hz, CH3), 1.35-1.55 
(10H, m, 5CH2), 1.66 (3H, s, CH3), 1.91-1.93 (1H, t, J = 6.0 Hz, CH), 2.13-2.14 (1H, m, HCHN), 
2.35-2.36 (1H, m, HCHN), 2.87-2.90 (1H, dd, J = 6.5, 5.5 Hz, CHN), 4.64 (1H, s, CHaH=C), 4.66 
(1H, s, CHHb=C);
 13C-NMR (100MHz, CDCl3) δ 11.0 (CH3C), 18.2 (CH3CH), 20.1 (CH2), 21.3 
(CH2), 25.2 (CH3C=C), 35.9 (CH2), 40.4 (CH2), 40.7 (CH2) 48.4 (CH), 51.0 (CH2N), 51.3 (CHN), 
53.3 (CN), 109.1 (CH2=C), 148.6 (CH2=C); HRMS(EI
+) found 207.1283 C14H25N requires 
207.1280; 
A second elution with (hexane-ethyl acetate, 20%, Rf 0.23) to give cis-fused- 
dimethylquinolizidine 111 as colourless oil (185 mg, 38%): IR (NaCl) cm-1 3030 (m) (CH, 
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stretch), 2740-2856 (m) (CH, stretch), 1667 (m) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 
0.98-1.00 (3H, d, J = 7.0 Hz, CH3CH), 1.13 (3H, s, CH3C), 1.35-1.54 (10H, m, 5CH2), 1.68 (3H, 
s, CH3), 2.01-2.05 (1H, m, CH), 2.41-2.45 (1H, t, J = 6.5 Hz, HCHN), 2.60-2.66 (1H, dd, J = 6.0, 
5.5 Hz, HCHN), 3.13-3.14 (1H, m, CHN), 4.70 (1H, s, CHaH=C), 4.74 (1H, s, CHHb=C);
 13C-NMR 
(100MHz, CDCl3) δC 21.3 (CH3CH), 21.4 (CH3C=C), 21.8 (CH2) 23.6 (CH2), 25.2 (CH3C), 26.0 
(CH2), 26.8 (CH2), 40.8 (CH), 44.0 (CH2N), 44.7 (CH2N), 50.9 (CHN), 53.4 (CN), 109.5 (CH2=C), 
148.5 (CH2=C); HRMS(EI
+) found 207.1283 C14H25N requires 207.1280; [α]
22
D = -6.6 (c = 5, 
CHCl3).  
(1S,9aR)-1,9a-Dimethyldecahydroquinolizin-5-ium 2,2,2-trifluoroacetate (178) 
 
To a solution of free amine 105 (68 mg, 0.4 mmol) in anhydrous DCM (2 mL) was added 
trifluoroacetic acid (22 µL, 0.4 mmol) at room temperature. After 5 min, solvent was 
removed under reduced pressure, and the residue was purified by column 
chromatography on alumina (diethyl ether-methanol, 15%, Rf 0.12) to afford the TFA salt 
178 as yellow-orange oil (80 mg, 70%); IR (NaCl) cm-1 3060 (m) (CH, stretch), 2785-2935 (s) 
(CH, stretch), 1225 (m) (CN, stretch); 1H-NMR (400 MHz, CDCl3) δH 0.80-0.81 (3H, d, J = 6.5 
Hz, CH3CH), 1.07 (3H, s, CH3C), 1.33-1.98 (11H, m, (CH2)5CH, CH(CH3) ), 2.67-2.74 (2H, m, 
CH2N), 2.94-3.05 (2H, m, CH2N), 9.28 (1H, broad s, NH); 
13C-NMR (100 MHz, CDCl3) δC 15.6 
(CH3C), 18.7 (CH3CH), 23.0 [CH2C(CH3)], 23.5 [(CH2CHC(CH3)], 27.0 [CH2CH(CH3)], 27.4 
(CH2CH2N), 34.8 (CH2CH2N), 39.0 (CH3CH), 48.9 (CH2N), 49.12 (CH2N), 55.6 (CH3C), 115.7-
118.0 (q, 2JCF = 285 HZ, CF3), 162.0-162.3 (q, 
3JCF = 38.0 HZ, COO); HRMS(EI
+) found 
168.1753, C11H22N requires 168.1752.  
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(R)-6-Methyl-3-(prop-1-en-2-yl)-2,3,4,5-tetrahydropyridine (182) 
 
Method 1  
To a solution of urethane 186 (200 mg, 0.62 mmol) in benzene (5 mL) was added p-
toluenesulfonic acid (45 mg, 0.50 mmol), and the reaction mixture was stirred at 65 °C 
under Dean-Stark condition for 1.5 h. The reaction temperature was cooled to 45 °C and 
dimethyl sulfoxide (10 mL) was added followed by aqueous 3M NaOH solution (9 mL, 27 
mmol). The red reaction mixture was then stirred for 3 h before being cooled to room 
temperature and diluted with a saturated aqueous solution of ammonium chloride (10 
mL). The mixture was extracted with Et2O (5 x 5 mL). The combined organic layers were 
washed with brine (4 x10 mL), dried over K2CO3 then filtered and concentrated under 
reduced pressure. The residue was purified on basic alumina column (1: 1 hexane: ether, Rf 
0.2) to give cyclic imine 182 as yellow oil (40 mg, 47%). 
Method 2: 
To a stirred solution of urethane 186 (1.0 g, 3.1 mmol) in DCM (40 mL) was added, 
dropwise, a solution of TFA (8 mL) in DCM (40 mL) to give a bright orange solution. After 10 
min, triisopropylsilane (1.2 mL) was added and stirring was continued for 5 min before ice-
water (100 mL) was added. The aqueous phase was washed with DCM (2 x 20 mL) and then 
adjusted to pH 12 with KOH pellets. The aqueous layer was extracted with DCM (4 x 20 
mL). The combined DCM extracts were dried over K2CO3 and concentrated under reduced 
pressure. The crude product was purified by chromatography on basic alumina (hexane-
Et2O, 50%, Rf 0.35) to give cyclic imine 182 as yellow oil (316 mg, 74%); IR (NaCl) cm
-1 3060 
(m) (CH, stretch), 2975 (s) (CH, stretch), 1616 (m) (C=C, stetch), 1660 (m) (C=C, stretch); 1H-
NMR (400 MHz, CDCl3) δH 1.42-1.60 (1H, m, HCHCH2C=N), 1.65 (3H, s, CH3C=C), 1.70-1.81 
(1H, m, HCHCH2C=N), 1.87 (3H, s, CH3C=N), 2.01-2.11 (1H, m, CH), 2.15-2.25 (2H, m, 
    146 
 
CH2C=N), 3.10-3.25 (1H, m, HCHN), 3.65-3.78 (1H, m, HCHN), 4.67 (1H, s, CHaH=C), 4.78 
(1H, s, CHHb=C); 
13C-NMR (100MHz, CDCl3) δC 20.0 (CH3C=C), 24.4 (CH3C=N), 27.0 
(CH2CH2C=N), 30.3 (CH2C=N), 39.7 (CHCH2), 54.1 (CH2N), 110.0 (CH2=C), 147.2 (CH2=C), 
167.5 (C=N); HRMS(EI+) found 138.1283, C9H15N requires 138.1280. 
(S)-4-(Prop-1-en-2-yl)piperidin-2-one (183) 
 
A stirred mixture of acetamide 189 (267 mg, 1.3 mmol) and 3 M sodium hydroxide solution 
(30 mL, 90 mmol) was heated under reflux for 3 h. After cooling the solution was adjusted 
to pH 6 with 1M HCl. The resulting mixture was evaporated under reduced pressure to 
dryness and the residue was heated at 130 °C for 3 h, the solid was extracted with 
petroleum ether (12 × 25 mL). The combined organic extracts were concentrated under 
reduced pressure and the residue was purified by chromatography on silica gel (diethyl 
ether, Rf 0.35) to give the lactam 183 as a white crystalline solid (140 mg, 77%); mp 53-
55˚C; IR (NaCl) cm-1 3212 (s) (NH, stretch), 3083 (m) (CH, stretch), 2923 (m) (CH, stretch), 
1668 (s) (lactam C=O, stretch), 1645 (s) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.69 
(3H, s, CCH3), 1.18-1.88 (1H, m, CH), 2.15-2.23 (2H, q, J = 6.0, 5.5 Hz, CHCH2CH2), 2.37-2.46 
(2H, m, CHCH2CO), 3.27-3.28 (2H, m, CH2N), 4.68 (1H, s, CHaH=C), 4.76 (1H, s, CHHb=C) and 
6.38 (1H, br s, NH); 13C-NMR (100 MHz, CDCl3) δC 21.0 (CH3C), 27.2 (CH2CHCH2), 36.8 
(CH2CHCH2), 39.6 (CH2CO), 41.5 (CH2NH), 110.6 (C=CH2), 146.8 (C=CH2) and 173.0 (C=O 
lactam); HRMS(EI+) found 139.0996, C8H13NO requires 139.0997; [α]
22
D  = -6.8 (c 3.22, 
CHCl3). 
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(R)-4-Methoxybenzyl (5-oxo-2-(prop-1-en-2-yl)hexyl)carbamate (186) 
 
To a stirred solution of keto acid 211 (700 mg, 3.8 mmol) in dry toluene (10 mL) was added  
Et3N (1.1 mL, 7.98 mmol) followed by diphenylphosphoryl azide (2.55 mL, 11. 8 mmol), 
with stirring under nitrogen. After stirring for 15 min at room temperature, the solution 
was heated at reflux for 2.5 h, after which time, the starting material was converted 
completely to the isocyanate as judged by TLC (eluent hexane-ethyl acetate, 25%, Rf 0.37). 
p-Methoxybenzyl alcohol (0.94 mL, 7.6 mmol) was then added and the resulting mixture 
was heated under reflux for 24 h. The solvent was evaporated under reduced pressure to 
give a black oil that was purified by flash chromatography on silica-gel (hexane-ethyl 
acetate, 25%, Rf 0.28) to give the urethane 186 as a yellow oil (730 mg, 61%); IR (NaCl) cm-1 
3120 (m) (NH, urethane, stretch), 2975 (m) (CH, stretch), 1716 (C=O, stretch), 1665 (m) 
(C=C stretch); 1H-NMR (400 MHz, CDCl3) δH 1.52 (3H, s, CH3C=C), 2.14 (3H, s, CH3C=O), 1.80-
2.72 [5H, m, (CH2)2CH], 2.91-3.10 (1H, m, CHNH), 3.20-3.31 (1H, m, HCNH), 3.75 (3H, s, 
OCH3), 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C), 5.25 (2H, s, OCH2), 6.85 (2H, d, J = 8.5 
Hz), 7.27 (2H, d, J = 8.5 Hz); 13C-NMR (100 MHz, CDCl3) δC 18.2 (CH3C=C), 23.9 (CH3CO), 30.0 
(CH2CH), 40.9 (CH2CO), 43.1 (CH), 46.6 (CH2N), 55.2 (OCH3), 66.4 (OCH2), 113.9 (CH2=C), 
114.2 (ArCH, ArCH), 128.7 (ArCCH2O), 129.9 (ArCH, ArCH), 144.3 (CH2=C), 156.3 (COO), 
159.6 (ArCOCH3), 208.3 (C=O);HRMS(EI
+) found 319.1812, C18H25NO4 requires 319.1811. 
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(4S)-Limonene oxide [(4S)-4-isopropyl-1-methyl-7-oxabicyclo[4.1.0]heptane] (187) 
 
A mixture of (20.5 g, 150 mmol) of (-)-(S)-limonene 263 and (25.2 g, 300 mmol) of NaHCO3 
in DCM (150 mL) was stirred at 0-5 °C, as a solution of 75% m-CPBA (47.0 g, 150 mmol) in 
DCM (250 mL) was added over 50 min. The mixture was stirred at 0 °C for 30 min and then 
a solution of Na2SO3 (10 g) in water (100 mL) was added. The mixture was stirred for 30 
min at room temperature and diluted with water (100 mL) before separating the organic 
fraction. The aqueous layer was extracted with DCM (3 x 100 mL) and the combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure. The residue 
was purified by  chromatography on silica gel (hexane-ethyl acetate, 5%, Rf 0.40) to give 
limonene oxide 187 as a colourless oil which was a 60: 40 mixture of two isomers (14.42 g, 
63%); IR (thin film) cm-1 3070 (m) (CH, stretch), 2918 (m) (CH, stretch), 1655 (m) (C=C, 
stretch); 1H-NMR (500 MHz, CDCl3) δH 1.23 and 1.25 (3H, s, CH3CO), 1.60  and 1.64 (3H, s, 
CH3C=C), 1.43-2.18 (7H, m, 3CH2, CH), 3.00 and 3.02 (1H, dd, J = 6.5 Hz, CHO), 4.68 (1H, s, 
CHaH=C), 4.74 (1H, s, CHHb=C); 
13C-NMR (125 MHz, CDCl3) δC 17.1 (CH3CO), 21.3 (CH3C=C), 
23.8 (CH2CHO), 27.9 (CH2CCH3), 28.6 (CH2CH), 39.3 (CH), 60.3 (CH3CO), 63.7 (CHO), 110.4 
(CH2=C), 147.8 (CH2=C); HRMS(EI
+) found 152.2303, C10H16O requires 152.2301  
(S)-Methyl 3-(2-acetamidoethyl)-4-methylpent-4-enoate (189) 
 
p-Toluene sulfonyl chloride (231 mg, 1.21 mmol) was added in one portion to a solution of 
freshly prepared oxime 204 (130 mg, 0.61 mmol) in dry benzene (4 mL) and pyridine (2 
mL). The mixture was stirred at room temperature in the dark for 7 days. The solvent was 
removed under reduced pressure and the residue was dissolved in ethyl acetate (50 mL) 
and washed with 10% hydrochloric acid (10 mL). The organic layer was dried over 
anhydrous Na2SO4 then filtered and the solvent was removed under reduced pressure. The 
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residue was purified by chromatography on silica gel (ethyl acetate, Rf 0.18) to give 
acetamide 189 as a colourless oil (116 mg, 90%); IR (thin film) cm-1 3296 (s) (NH, stretch), 
3078 (m) (CH, stretch), 2950 (m) (CH, stretch), 1739 (s) (ester C=O, stretch), 1647 (s) 
(amide, C=O, stretch), 1558 (s) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.65 (3H, s, 
CCH3), 1.99 (3H, s, COCH3), 2.35-2.65 (3H, m, CH2, CH), 3.01-3.25 (2H, m, CH2NH ), 3.65 (3H, 
s, OCH3), 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C) and 5.56 (1H, br s, NH); 
13C-NMR (100 
MHz, CDCl3) δC 18.6 (CH3C), 23.4 (COCH3), 38.4 (CH), 39.2 (CH2COO), 41.8 (CH2NH), 52.1 
(OCH3), 113.3 (C=CH2), 145.7 (C=CH2), 170.7 (C=O amide) and 173.7 (CO ester); HRMS(EI
+) 
found 214.1446, C10H20NO3 requires 214.1443; [α]
22
D  = -6.3 (c 2.07, CHCl3). 
9-Methyl-3,4,6,7-tetrahydro-1H-quinolizin-8(2H)-one (193) 
 
Oxo-thione 222 (2.5 g, 12.6 mmol) was suspended under nitrogen atmosphere in 
anhydrous toluene (80 mL), and then Me2SO4 (2.1 mL, 21.4 mmol) was added dropwise by 
a syringe at room temperature and under stirring. After the addition was complete, the 
flask was placed into an oil bath at 140-150 °C. After refluxing for 15 min, 1,8-diazabicyclo 
[5.4.0] undec-7ene (DBU) (3.1 mL, 21.4 mmol) was added dropwise by syringe and the 
resulting solution heated under reflux for a further 20 min. After cooling to room 
temperature, the solution was diluted with CH2Cl2 (100 mL), and washed with water (100 
mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under 
reduced pressure. The resulting crude oil was purified by flash chromatography on basic 
alumina (hexane: diethyl ether, 10%, Rf 0.27) to give the enaminone 193 as a yellow oil (1.8 
g, 78%); IR (NaCl) cm-1 3060 (m) (CH, stretch), 2946 (s) (CH, stretch), 1711 (s) (ketone C=O, 
stretch), 1657 (s) (C=C, stretch), 1326 (m) and 1252 (s) (CN, stretch); 1H-NMR (400 MHz, 
CDCl3) δH 1.61 (2H, m, CH2CH2CH2N), 1.62 (3H, s, C=C-CH3), 1.70 (2H, m, CH2), 2.37 (4H, m, 
CH2CO, CH2C=C), 3.12 (2H, t, J = 5.0 Hz, O=CCH2CH2N) and 3.25 (2H, t, J = 7.0 Hz, CH2CH2N); 
13C-NMR (100 MHz, CDCl3) δC 9.4 (C=C-CH3), 19.6 (CH2CH2CH2N), 22.7 (CH2CH2CH2), 26.9 
(CH2CO), 35.1 (CH2C=C), 50.3 (COCH2CH2N), 50.7 (CH2CH2N), 103.1 (C=C-CH3), 160.3 (CC=C-
CH3) and 188.7 (C=O); HRMS(EI
+) found 166.1238, C10H15NO requires 166.1232.  
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(S)-9-Methyl-2-(prop-1-en-2-yl)-3,4,6,7-tetrahydro-1H-quinolizin-8(2H)-one (194) 
 
To a stirred suspension of oxo-piperidine-2-thione 244 (500 mg, 2.09 mmol) in anhydrous 
benzene (10 mL) under nitrogen was added freshly distilled Me2SO4 (0.33 mL, 3.55 mmol) 
drop wise. The mixture was heated under reflux for 30 min, and then 1, 8-diazabicyclo 
[5.4.0] undec-7-ene (DBU) (0.53 mL, 3.55 mmol) was added drop wise. The resulting 
solution was heated under reflux for a further 1 h. After cooling to room temperature, the 
solution was diluted with DCM (100 mL), and washed with water (100 mL). The organic 
layer was dried over K2CO3, filtered and concentrated under reduced pressure. The residue 
was dissolved in Et2O (10 mL) and then adjusted to pH 2 with 10% HCl (5 mL) and extracted 
with Et2O (3× 10 mL). The aqueous phase was adjusted to pH 12 with NaOH (pellets) and 
extracted with Et2O (5 x 10 mL). The combined ethereal layers were dried (K2CO3) and 
filtered, and the solvent was removed under reduced pressure. The crude was purified by 
chromatography on alumina (hexane: diethyl ether, 10%, Rf 0.35). The by-product 245 
eluted first and was isolated as a yellow oil (185 mg, 41%). Further elution (hexane-diethyl 
ether, 30%, Rf 0.27) gave the bicyclic enone 194 as a colourless oil (221 mg, 54%); IR (thin 
film) cm-1 3080 (m) (CH, stretch), 2925 (m) (CH, stretch), 1660 (m) (C=C, stretch), 1643 (m) 
(ketone C=O, stretch), 1346 (m) and 1241 (m) (C-N stretch); 1H-NMR (400 MHz, CDCl3) δH 
1.52 [3H, s, C=C(CH3)CO], 1.55 (3H, s, C=CCH3), 1.81 (1H, m, CH), 2.08 (2H, d, J = 3.5 Hz, 
CHCH2C), 2.252 (2H, q, J = 6.0, 5.5 Hz, CHCH2CH2), 2.52 (2H, m, CH2CO), 3.02-3.14 (4H, m, 
CH2CH2NCH2), 4.63 (1H, s, CHaH=C), 4.73 (1H, s, CHHb=C); 
13C-NMR (100MHz, CDCl3) δC 9.6 
(CH2=CCH3), 20.6 [C=C(CH3)CO], 27.4 (CH2CHCH2), 32.2 (CHCH2CH2N), 35.1 (CHCH2C), 38.1 
(COCH2CH2), 50.2 (COCH2CH2N), 50.6 (CH2CH2N), 103.0 (CH2=CCH3), 110.5 [C=C(CH3)CO], 
146.9 (C=CCH3), 160.3 [C=C(CH3)CO] and 189.0 (CO ketone); HRMS(EI
+) found, 206.1540 
C13H19NO requires 206.1545; [α]
22
D = -9.1 (c 4.6, CHCl3). 
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Piperidone-2-thione (195) 
 
A mixture of 2-piperidone (216) (4 g, 40.3 mmol) and Lawesson’s reagent (8.1 g, 20.1 
mmol) was suspended in anhydrous toluene (200 mL), then heated under reflux under 
nitrogen atmosphere for 30 min. The solution was then cooled to room temperature and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica gel (eluent DCM-light petroleum ether, 10%, Rf 0.34) providing compound 195 as a 
pale yellow solid. After recrystillasation with isopropanol, 195 was isolated as white 
crystals (3.5 g, 88%); mp 110-113 °C; IR (NaCl) cm-1 3186 (s) (NH, stretch), 2948 (m) (CH, 
stretch), 1265 (s) and 1167 (s) (C=S, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.74-1.77 (2H, 
m, CCH2CC=S), 1.79-1.84 (2H, m, NCCH2C), 2.89 (2H, t, J = 6.0 Hz, CH2C=S), 3.35 (2H, dt, J = 
6.0 Hz, CH2N) and 8.90 (1H, br s, NH); 
13C-NMR (100 MHz, CDCl3) δC 20.3 (CH2CH2C=S), 20.9 
(CCH2N), 39.2 (CH2C=S), 44.2 (CN) and 202.9 (C=S). HRMS(EI
+) found 116.0531, C5H9NS 
requires 116.0534.  
(S)-4-(Prop-1-en-2-yl)piperidine-2-thione (196) 
 
A mixture of lactam 183 (200 mg, 1.43 mmol) and Lawesson’s reagent (250 mg, 0.72 mmol) 
was suspended in anhydrous toluene (10 mL), and heated under reflux for 1 h under 
nitrogen. The resulting mixture was cooled to room temp, and then solvent was removed 
under reduced pressure. The residue was purified by chromatography on slica-gel (DCM: 
petroleum ether, 2:1, Rf 0.33) to give a yellow powder. Recrystallisation from i-PrOH 
produced analytically pure white needles of thiolactam 196 (170 mg, 77%); mp 93-95 ˚C; IR 
(NaCl) cm-1 3169 (s) (NH, stretch), 3086 (m) (CH, stretch), 2952 (m) (CH, stretch), 1645 (s) 
(C=C, stretch), (m) (C=C, stretch), 1258 (m) and 1119 (s) (C=S); 1H-NMR (400 MHz, CDCl3) δH 
1.65 (3H, s, CH3C=C), 1.70-1.89 (1H, m, CH), 2.32 (2H, m, CH2), 2.69 (1H, dd, J = 4.0, 8.0 Hz, 
HCHC=S), 3.06 (1H, dd, J = 4.5, 8.0 Hz, HCHC=S), 3.27-3.40 (m, 2H, CH2N), 4.85 (1H, s, 
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CHaH=C), 4.94 (1H, s, CHHb=C) and 8.85 (1H, br s, NH); 
13C-NMR (100 MHz, CDCl3) δC 20.2 
(CH3C), 26.3 (CH2CHCH2), 38.7 (CHCH2CH2), 41.2 (CH2NH), 45.7 (CH2C=S), 112.8 (C=CH2), 
145.7 (C=CH2) and 206.9 (C=S); HRMS(EI
+) found 156.0847, C8H13NS requires 156.0847; 
[α]22D  = -3.4 (c 0.62, CHCl3).  
(1R,8S,9aR)-1,9a-Dimethyl-8-(prop-1-en-2-yl)hexahydro-1H-quinolizin-2(6H)-one (197) 
 
To a solution of the freshly prepared TFA salt 246 (350 mg, 1.09 mmol) in dry THF (5 mL) 
was added methylmagnesium bromide (3M in diethyl ether, 1.8 mL, 5.45 mmol) at room 
temperature under argon. The resulting mixture was heated under reflux for 24 h, and 
then a solution of NH4Cl (10 mL) and 10% NH4OH (10 mL) were added and extracted with 
Et2O (8 x 10 mL). The resulting residue was dissolved in Et2O (10 mL) and then adjusted to 
pH 2 with 10% HCl (5 mL) and extracted with Et2O (3 x 10 mL). The aqueous phase was 
adjusted to pH 12 with NaOH (pellets) and extracted with Et2O (5 x 10 mL). The combined 
ethereal layers were dried (K2CO3) then filtered and the solvent was removed under 
reduced pressure. The crude product was purified by chromatography on alumina (hexane-
ethyl acetate; 20%, Rf 0.26) to give amino ketone 197 as pale yellow oil (156 mg, 64%); IR 
(thin film) cm-1 3050 (m) CH, stretch), (2790-2966 (s) (CH, stretch), 1718 (s) (C=O, stretch), 
1600 (m) (C=C, stretch), 1326 (m) and 1252 (s) (CN, stretch); 1H-NMR (500 MHz, CDCl3) δH 
0.71 (3H, s, CCH3), 0.90 (3H, d, J = 7.0 Hz, CH3CH), 1.12-1.15 [2H, m, C(CH3)CH2CH], 1.17-
1.25 (2H, m, CH2CH), 1.50-1.55 (2H, ddd, J = 7.0, 6.5, 5.0 Hz, CH2CO), 1.63 (3H, s, CH3C=C), 
1.95-2.01 (1H, m, CH2CHCH2), 2.41-2.50 (1H, dddd, J = 8.0, 7.5, 6.0 Hz, CHCH3), 2.62-2.69 
(2H, m, CH2N), 2.80-2.86 (2H, m, CH2N), 4.65 (1H, s, CHaH=C), 4.69 (1H, s, CHHb=C); 
13C-
NMR (125 MHz, CDCl3) δC 14.0 (CH3C), 15.2 (CH3CH), 20.6 (CH3C=C), 31.9 (CH2CH2N), 37.6 
(CH2CCH3), 41.2 (CH2CO), 43.3 (CH2CHCH2), 49.7 (CH2N), 50.0 (CH2N), 56.5 (CHCH3), 60.0 
(CCH3), 109.1 (CH2=C), 149.1 (CH2=C), 210.6 (C=O); HRMS(EI
+) found 221.1783, C14H23NO 
requires 221.1781; [α]22D = -1.6. (c 0.12, CHCl3). 
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(S)-Methyl-6-oxo-3-(prop-1-en-2-yl)-heptanoate (198) 
 
To a stirred solution of hydroxy ketone 202 (5 g, 25 mmol) in methanol (40 mL) was slowly 
added lead tetraacetate (15 g, 33 mmol) at -5 °C over 30 min. The reaction mixture was 
stirred at 0 °C for an additional 1 h and then diluted with water (40 mL) and brine (20 mL). 
The product was extracted with Et2O (4 × 20 mL) and the combined ethereal extracts were 
dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was 
purified by silica gel column chromatography (hexane- ethyl acetate; 10%, Rf 0.26) to give 
methyl ester 198 as a colourless oil (3.7 g, 74%); IR (thin film) cm-1 3067 (m) (CH, stretch), 
1738 (s) (ester C=O, stretch), 1716 (s) (ketone C=O, stretch), 1646 (m) (C=C,  stretch); 1H-
NMR (400 MHz, CDCl3) δH 1.66 (3H, s, CH3C=C), 2.15 (3H, s, CH3CO), 1.85-2.75 [7H, m, 3 x 
CH2, CH), 3.65 (3H, s, OCH3) and 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C); 
13C-NMR (100 
MHz, CDCl3) δC 18.7 (CH3C=CH2), 26.6 (CH3CO), 30.4 (CH2CHCH2), 39.3 (CH2CHCH2), 41.5 
(CH2COO), 43.4 (CH2CO), 51.9 (OCH3), 113.3 (C=CH2), 145.7 (CH2=C), 173.1(CO ester) and 
208.8 (CO ketone); HRMS(EI+) found 199.1328, C11H18O3requires 199.1334. 
(4S)-1-Methyl-4-(prop-1-en-2-yl)-cyclohexane-1, 2-diol (199) 
 
A mixture of (-)-limonene oxide 187 (25 g, 0.16 mol), KOH (54.5 g, 1.36 mol), DMSO (82 mL) 
and water (75 mL) was heated at 110 °C for 24 h. The mixture was cooled to room 
temperature and cooled in an ice-bath to precipitate the diol as white crystals. Crystals 
were collected by filtration under reduced pressure. The filtrate was extracted with Et2O (6 
x 100 mL) and the combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The extracted diol, in addition to the first batch of 
crystals gave the diol 199 in a combined yield of 20 g (hexane:ethyl acetate, 20%, Rf 0.25, 
70%); mp 70-74 °C; IR (thin film) cm-1 3350 (s) (br), (OH, stretch), 3080 (m) (CH, stretch), 
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2924 (m) (CH, stretch), 1653 (m) (C=C, stretch), 1375 (m) and 1265 (m); 1H-NMR (400 MHz, 
CDCl3) δH 1.25 [3H, s, C(OH)CH3], 1.72 [3H, s, CH3C=C], 1.42-2.85 [9H, m, 3 x CH2, CH, 2 x 
OH], 3.62 [1H, s, CH(OH)] and 4.74 (2H, br s, CH2=C); 
13C-NMR (100 MHz, CDCl3) δC 21.1 
[C(OH)CH3], 26.2 (CH3C=CH2), 26.7 (CHCH2CH2), 33.6 (CH2CHCH2), 34.0 [C(OH)CH2CH], 37.4 
[C(OH)CH3CH2], 71.3 [C(OH)CH3], 73.9 [C(OH)], 109.0 (CH2=C) and 149.3 (CH2=C); HRMS(EI
+) 
found 170.1308, C10H18O2 requires 170.1307. 
(5S)-2-Hydroxy-2-methyl-5-(prop-1-en-2-yl)-cyclohexanone (202) 
 
To a stirred suspension of PCC (45 g, 0.2 mol) in CH2Cl2 (250 mL) was added dropwise at 
room temperature a solution of freshly prepared diol 199 (13 g, 0.07 mol) in DCM (250 
mL). After stirring for 2 h, the reaction mixture was filtered through a short silica-gel 
column using DCM. The filtrate was concentrated under reduced pressure. Purification of 
the residue by flash-column chromatography on silica gel (hexane-ethyl acetate, 20%, Rf 
0.30) gave the hydroxyl ketone 202 as a colourless oil (10 g, 75%); IR (thin film) cm-1 3423 
(s) (OH, stretch), 3083 (m) (CH, stretch), 2973 (m) (CH, stretch), 1717 (s) (C=O, stretch), 
1645 (m) (C=C, stretch) and 1375 (m); 1H-NMR (400 MHz, CDCl3) δH 1.37 [3H, s, C(OH)CH3], 
1.75 (3H, s, CH3C=C), 1.65-2.95 [7H, m, 3 x CH2, CH], 3.62 (1H, s, OH), 4.70 (1H, s, CHaH=C), 
4.86 (1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 21.5 (CH3C=CH2), 24.9 [C(OH)CH3], 25.2 
(CH2CHCH2), 40.7 (CH2CHCH2), 44.1 [C(OH)CH3CH2], 46.2 (CH2CO), 75.6 [C(OH)CH3], 110.6 
(CH2=C), 146.13 (CH2=C) and 209.64 (C=O); HRMS(EI
+) found 168.1152, C10H16O2 requires 
168.1150.  
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(S)-Methyl-6-(hydroxyimino)-3-(prop-1-en-2-yl)-heptanoate (204) 
 
Hydroxylamine hydrochloride (232 mg, 3.3 mmol) was added in one portion to a stirred 
solution of methyl ester 198 (444 mg, 2.2 mmol) in pyridine (1.5 mL) and ethanol (1 mL). 
The resulting mixture was stirred for 6 h and then diluted with water (5 mL) and extracted 
with ethyl acetate (6 x 5 mL). The combined organic extracts were washed with aqueous 
hydrochloric acid (10%, 5 mL), saturated sodium hydrogen carbonate (2 mL) and brine (5 
mL). The organic layer was dried (Na2SO4), filtered and concentrated under reduced 
pressure. The residue was purified by silica-gel column chromatography (hexane-ethyl 
acetate; 10%, Rf 0.30) to give a mixture of E/Z oximes 204 as a colourless oil (197 mg, 80%); 
IR (thin film) cm-1 3377 (s) (OH, stretch), 3086 (m) (CH, stretch), 2931 (m) (CH, stretch), 
1716 (s) (ester C=O, stretch), 1645 (s) (C=N, stretch), 1656 (m) (C=C, stretch); 1H-NMR (400 
MHz, CDCl3) δH 1.56 and 1.57 (3H minor and major isomers, 2 x s, CH3C=C), 1.75 and 1.76 
(3H, minor and major isomers, 2 x s, N=CCH3), 1.80-2.72 (7H, minor and major isomers, m, 
3 x CH2, CH ), 3.64 and 3.65 (3H, minor and major isomers, 2 x s, OCH3), 4.70, 4.74 and 4.75 
(2H, br s, minor and major isomers, CH2=C);
 13C-NMR (100 MHz, CDCl3) δC 14.0 (CH3C), 18.9 
and 18.8 (major and minor isomer, CH3CN), 29.4 and 28.6 (major and minor isomer, 
CHCH2CH2), 33.9 (CHCH2CH2), 39.9 and 39.4 (CH2CHCH2), 43.6 and 44.2 (major and minor 
isomer, CH2COOCH3), 51.2 (OCH3), 113.2 and 113.1 (C=CH2), 145.7 (C=CH2), 158.9 and 
158.5 (major and minor isomer, C=N) and 173.3 (CO ester); HRMS(EI+) found 213.1360, 
C11H19NO3 requires 213.1365. 
(S)-6-Oxo-3-(prop-1-en-2-yl)heptanoic acid (211) 
 
To a solution of methyl ester 198 (1.03 g, 5.0 mmol) in methanol (6 mL) was added a 
solution of 6 M LiOH (6 mL) with stirring. After stirring for 3 h, methanol was removed 
under reduced pressure and a solution of 1 M HCl (10 mL) was added. The mixture was 
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extracted with ethyl acetate (3 x 10 mL) and the combined organic extracts were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified 
by silica-gel column chromatography (hexane-ethyl acetate; 15%, Rf 0.21) to give keto acid 
221 as a colourless oil (0.74 g, 80%); IR (thin film) cm-1 3300 (vs) (OH, stretch), 2845 (m) 
(CH, stretch), 1738 (s) (acid C=O, stretch), 1715 (s) (ketone C=O, stretch), 1660 (m) (C=C, 
stretch); 1H-NMR (400 MHz, CDCl3) δH 1.56 (3H, s, CCH3), 1.8-2.7 (7H, m, 3 x CH2, CH), 2.15 
(3H, s, COCH3) and 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 
18.8 (CH3C), 26.6 (CH3CO), 30.4 (CH2CH2CO), 39.2 (CH2CHCH2), 41.5 (CH2COO), 43.1 
(CH2CO), 113.5 (C=CH2), 145.4 (CH2=C), 178.5 (CO acid), 209.3 (CO ketone); HRMS(EI
+) 
found 185.1178, C10H16O3 requires 185.1178. 
Jones oxidation of diol 199 to (S)-6-oxo-3-(prop-1-en-2-yl)heptanoic acid (211) 
 
Jones reagent: 25 g of CrO3 was dissolved in concentrated H2SO4 (25 mL). This solution was 
added very slowly to H2O (75 mL) that had been cooled to 0 °C with stirring. 
To a stirred solution of diol 199 (22.3 g, 0.13 mol) in acetone (200 mL) was slowly added 
Jones reagent (~50 mL) at 0 °C for 20 min. The addition was continued until the 
characteristic orange colour of Jones reagent persisted for about 20 min; the reaction was 
monitored by TLC (hexane-ethyl acetate; 15%, Rf 0.21). A solution of NaHCO3 (1N, 100 mL) 
was added, and the suspension was stirred vigorously until the pH of reaction mixture 
tested neutral. The suspension was filtered and the residue was washed with acetone (100 
mL). H2O (150 mL) was added to the filtrate and the solution was then extracted with DCM 
(5 x 100 mL). The organic layers were dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by chromatography 
on silica gel (hexane-ethyl acetate, 15%) to give pure keto acid as colourless oil (18.8 g, 
78%); IR (thin film) cm-1 3300 (vs) (stretch OH), 2845 (m) (C-H stretch), 1738 (s) (acid C=O, 
stretch), 1715 (s) (ketone C=O stretch), 1660 (m) (C=C stretch); 1H-NMR (400 MHz, CDCl3) 
δH 1.56 (3H, s, CCH3), 1.8-2.7 (7H, m, 3 x CH2, CH), 2.15 (3H, s, COCH3) and 4.74 (1H, s, 
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CHaH=C), 4.80 (1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 18.8 (CH3C), 26.6 (CH3CO), 
30.4 (CH2CH2CO), 39.2 (CH2CHCH2), 41.5 (CH2COO), 43.1 (CH2CO), 113.5 (C=CH2), 145.4 
(CH2=C), 178.5 (CO acid), 209.3 (CO ketone); HRMS(EI
+) found 185.1178, C10H16O3 requires 
185.1178. 
1-(3-Oxopentyl) piperidine-2-thione (222) 
 
Piperidine-2-thione (195) (2 g, 17.4 mmol), anhydrous K2CO3 (5.2 g, 38.2 mmol) (kept at 
140 °C for 12 h before use), and 18-crown-6 (0.58 g, 2.20 mmol) were suspended in 
anhydrous THF (100 mL) under N2. After cooling to 0 °C, a first portion of ethyl vinyl ketone 
(2.3 mL, 23.5 mmol) was added drop wise under stirring. After the addition was complete, 
the solution was left at 0 °C for 5 min and then at room temperature for 1 h. The solution 
was cooled again to 0 °C, and a second portion of ethyl vinyl ketone (2.3 mL, 23.5 mmol) 
was added, the solution was left under stirring for 3 h at room temperature, monitoring 
the reaction by TLC. Sodium sulfate was added and the solution was filtered and 
concentrated under reduced oressure. The crude material was purified by chromatography 
on silica gel (CH2Cl2, Rf 0.25) to give oxo-thione 222 as a light yellow oil (3.2 g, 87%); IR 
(NaCl) cm-1 3030 (m) (CH, stretch), 2942 (s) (CH, stretch), 1710 (s) (ketone C=O, stretch), 
1329 (m), 1265 (m) and 1159 (m) (C=S stretch); 1H-NMR (400 MHz, CDCl3) δH 1.03 (3H, t, J = 
7.0 Hz, COCH2CH3), 1.61 (2H, m, CH2CH2CH2CS), 1.84 (2H, m, CH2CH2CH2N), 2.44 (2H, q, J = 
7.0 Hz, CH2CH3), 2.93 (2H, t, J = 6.5 Hz, CH2CH2CO), 2.95 (2H, m, CH2C=S), 3.49 (2H, t, J = 6.0 
Hz, CH2N) and 4.10 (2H, t, J = 6.5 Hz, CH2N); 
13C-NMR (100 MHz, CDCl3) δC 7.8 (COCH2CH3), 
20.5 (CH2CH2CS), 23.0 (CH2CH2N), 36.2 (CH3CH2CO), 38.6 (CH2CH2CO), 41.9 (CH2CS), 50.3 
(COCH2CH2N), 52.2 (CH2N), 199.7 (CO ketone), and 209.7 (C=S); HRMS(EI
+) found 200.1118, 
C10H17NOS requires 200.1109.  
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(1R,9aR)-1,9a-Dimethylhexahydro-1H-quinolizin-2(6H)-one (223) 
 
To a solution of TFA salt 233 (630 mg, 2.3 mmol) in dry THF (15 mL) was added 
methylmagnesium bromide (3 M in diethyl ether, 3.7 mL, 11.3 mmol) at room temperature 
under an argon atmosphere. After the mixture was heated at reflux temperature for 24 h, 
a solution of saturated ammonium chloride (20 mL) and 10% NH4OH (20 mL) were added 
and the solution extracted with Et2O (5 x 10 mL), the combined organic layers were dried 
over anhydrous K2CO3 then filtered and concentrated under reduced pressure. The 
resulting residue was dissolved in Et2O (10 mL) and adjusted to pH 2 with 10% HCl (5 mL) 
and extracted with Et2O (3 x 10 mL). The aqueous phase was adjusted to pH 12 with NaOH 
(pellets) and extracted with Et2O (5 x 10 mL). The combined ethereal layers were dried 
(K2CO3) and filtered, and the solvent was removed under reduced pressure. The crude 
material was purified by chromatography on alumina (hexane-ethyl acetate; 1:1, Rf 0.30)  
to give compound 223 as pale yellow oil (273 mg, 65%); IR (thin film) cm-1 2790-2928 (s) 
(CH, stretch), 1718 (s) (C=O, stretch), 1326 (m) and 1252 (s) (CN, stretch); 1H-NMR (400 
MHz, CDCl3) δH 0.72 [3H, s, C(CH3)], 0.87 (3H, d, J = 6.5 Hz, (CH3)CH), 1.33 -1.50 (6H, m, 
3CH2), 1.57-1.66 (1H, dddd, J = 6.5, 6.0, 5.5 Hz, CH(CH3), 2.42-2.64 (2H, m, CH2CO), 2.63-
2.85 (4H, m, 2CH2N); 
13C-NMR (100 MHz, CDCl3) δC 8.1 (CH3)C, 10.1 (CH3CH), 20.1 
(CH2CH2CH2N), 26.2 (CH2CH2CH2N), 37.70 [CH2C(CH3)], 40.68 (COCH2CH2N), 49.33 
(CH2CH2CH2N), 50.33 (COCH2CH2N), 55.80 [CH(CH3)], 60.17 [C(CH3)], 210.90 (C=O, ketone); 
HRMS(EI+) found 182.1554, C11H19NO requires 182.1545.  
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1-Methyloctahydropyrido[1,2-a]azepin-2(1H)-one (225) 
 
CuI (80.8 mg, 0.42 mmol) was suspended in dry Et2O (3 mL) at 0 °C under argon 
atmosphere, and then MeLi (2 M in diethyl ether, 0.5 mL, 0.84 mmol) was added drop wise 
at 0 °C, a yellow precipitate appeared, and then disappeared after the complete addition of 
MeLi. Enone 193 (70 mg, 0.42 mmol) was added to the above solution of dimethyl copper 
lithium at 0 °C. After stirring for 90 min at 0˚C and 2 h at room temperature, a solution of 
ammonium chloride (10 mL) and 10% ammonium hydroxide (10 mL) were added and the 
solution was extracted with Et2O (5 × 10 mL), the combined organic layers were dried over 
anhydrous K2CO3, filtered and concentrated under reduced pressure. The resulting residue 
was adjusted to pH 2 with 10% HCl (5 mL) and extracted with Et2O (3 × 10 mL). The 
aqueous phase was adjusted to pH 12 with NaOH (pellets) and extracted with Et2O (3 x 5 
mL), the combined ethereal layers were dried (K2CO3) then filtered and the solvent was 
removed under reduced pressure. The crude material was purified by chromatography on 
alumina column (hexane-ethyl acetate; 10%, Rf 0.30)  to give compound 225 as pale yellow 
oil (40 mg, 52%): IR (thin film) cm-1 3040 (m) (CH, stretch), 2760-2800 (m) (CH, stretch), 
1718 (s) (ketone C=O, stretch): 1H-NMR (400 MHz, CDCl3) δH 0.99 (3H, d, J = 7.0 Hz, CH3CH), 
1.6-1.64 (2H, m, CH2), 1.70-1.72 (1H, m, CH3CH), 1.73-1.76 (2H, m, CH2), 2.21-2.29 (1H, m, 
CH), 2.32-2.39 (4H, m, CH2CH2CH2N), 2.70-2.2.73 (2H, m, CH2CO), 2.90-2.95 (2H, m, CH2N), 
3.01-3.09 (2H, m, CH2N); 
13C-NMR (100 MHz, CDCl3) δC 8.8 (CH3CH), 22.4 (CH2), 24.2 (CH2), 
28.2 (CH2), 30.4 (CH2), 40.2 (CH2CO), 55.60 (CHCH3), 57.7 (CH2N), 58.0 (CH2N), 67.3 (CH), 
210.0 (C=O); HRMS(EI+) found 181.1554, C11H19NO requires 181.1553.  
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8-Hydroxy-9-methyl-1,2,3,4,6,7-hexahydroquinolizin-5-ium 2,2,2-trifluoroacetate (233) 
 
To a solution of enaminone 193 (420 mg, 2.5 mmol) in dry THF (5 mL) was added 
trifluoroacetic acid (0.20 mL, 2.5 mmol) at room temperature. After stirring for 10 min, the 
solvent and excess TFA was removed under reduced pressure, and the residue placed 
under high vacuum to give salt of enone 233 as yellow-orange oil (630 mg, 90%, Rf 0.15); IR 
(thin film) cm-1 3050 (m) (CH, stretch), 2828 (s) (C-H stretch); 1H-NMR (400 MHz, CDCl3) δH 
1.71 (3H, s, CH3C=C), 1.76-1.80 (2H, m, CH2CH2CH2) 1.84-1.91 (2H, m, CH2CH2CH2N), 2.6-2.7 
(2H, t, J = 7.0 Hz, CH2COH), 2.8-2.89 (2H, t, J = 6.5 Hz, CH2C=N), 3.50-3.55 (2H, t, J = 5.5 Hz, 
HOCCH2CH2N), 3.60-3.65 (2H, t, J = 5.5 Hz, CH2CH2N); 
13C-NMR (100 MHz, CDCl3) δC 8.6 
(CH3), 16.5 (CH2CH2CH2N), 20.0 (CH2CH2CH2N), 25.8 (CH2COH), 27.5 (CH2C=N), 48.6 
(CH2CH2CH2N), 51.2 (COHCH2CH2N), 102.6 (C=COH), 111.1 (q, CF3), 158.9 (COO), 172.1 
(C=N), 174.2 (COH=C). This salt was used forward in the next step without purification.  
(1'R,9a'R)-1',9a'-Dimethyloctahydrospiro[[1,3]dithiolane-2,2'-quinolizine] (234) 
 
To a solution of amino ketone 223 (70 mg, 0.4 mmol) in dry DCM (5 mL) were added 1,2-
ethandithol (0.3 mL, 3.8 mmol) and BF3.OEt2 (2 M in diethyl ether, 0.14 mL, 1.16 mmol) at 
room temperature under a nitrogen atmosphere. The mixture was stirred for 24 h, and 
then a solution of 1N NaOH (5 mL) was added and the mixture was extracted with DCM (5 
x 3 mL). The combined organic layers were dried (K2CO3), filtered and concentrated under 
reduced pressure. The crude material was purified by chromatography on silica gel 
(hexane: ethyl acetate, 20%, Rf 0.34) to give the compound 234 as white solid (80 mg, 
80%); IR (thin film) cm-1 3060 (m) (CH, stretch), 2790-2928 (s) (CH, stretch); 1H-NMR (400 
MHz, CDCl3) δH 0.88 (3H, s, CH3C), 1.08-1.10 (3H, d, J = 7.0 Hz, CH3CH), 1.45-1.60 (6H, m, 
3CH2), 1.92-1.93 (1H, q, J = 7.0, 13.5 Hz, CHCH3), 2.00-2.01 (1H, m, HCHCS2), 2.30-2.46 (4H, 
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m, HCHCS2, CH2N, HCHN), 2.64-2.65 (1H, m, HCHN), 2.98-3.26 (4H, m, SCH2CH2S); 
13C-NMR 
(100 MHz, CDCl3) δC  6. 9 (CH3C), 11.6 (CH3CH), 19.6 (CH2), 25.8 (CH2), 38.0 (CH2), 38.3 
(CH2CS2), 40.5 (CHCH3), 46.2 (CH2S), 49.3 (CH2S), 49.5 (CH2N), 51.7 (CH2N), 58.0 (CS2), 72.5 
(CCH3); HRMS(EI
+) found 258.1359, C13H23NS2 requires 258.1350.  
(1R,2R,9aR)-1,9a-Dimethyloctahydro-1H-quinolizin-2-ol (237) and  
(1R,2S,9aR)-1,9a-Dimethyloctahydro-1H-quinolizin-2-ol (238) 
 
 
To a stirred solution of amino ketone 223 (100 mg, 0.5 mmol) in dry THF (4 mL) was added 
LiAlH4 (18 mg, 5.5 mmol) at room temperature under N2. The reaction mixture was stirred 
at room temperature for 2 h, and then a solution of 5% of NaOH (5 mL) was added slowly 
to precipitate the aluminium salt by-product. The white salt removed by filtration under 
reduced pressure and the residue washed with additional THF (5 mL). To the resulting THF 
filtrate was added 10% HCl (5 mL) and the mixture was stirred for 5 min. DCM (10 mL) was 
added and the two phases were separated. The aqueous layer was adjusted to pH 12 with 
NaOH (pellets), and extracted with Et2O (4 x 5 mL). The combined ethereal layers were 
dried (K2CO3) and filtered, and the solvent was removed under reduced pressure. The 
crude product was purified by chromatography on alumina (ethyl acetate-methanol, 10%, 
Rf 0.17) to give the amino alcohol mixture (237 and 238) as a colourless oil (92 mg, 90%); IR 
(thin film) cm-1 3396 (s) (br), (OH, stretch), 2760-2866 (s) (CH, stretch), 1220 (m) (CN, 
stretch); 1H-NMR (400 MHz, CDCl3) δH 0.74 (3H, s, CH3C, 10%) and 1.00 (3H, s, CH3C, 90%), 
0.89 (3H, d, J = 7.0 Hz, CH3CH, 10%) and  0.92 (3H, d, J = 12.0 Hz, CH3CH, 90%),  1.45-1.50 
(6H, m, 3CH2), 1.52-1.60 [1H, m, CH(CH3)], 2.00-2.44 (2H, m, CH2COH), 2.46-2.50 (2H, m, 
CH2N), 2.53-2.75 (2H, m, CH2N), 3.36-3.37 (1H, tt, J = 10.0 Hz, CHOH, 10%) and 3.80-3.82 
(1H, td, J = 11.0 Hz, CHOH, 90%); 13C-NMR (100 MHz, CDCl3) δC 12.5 (CH3C), 14.8 (CH3CH), 
19.6 (CH2CH2CH2N), 26.8 (CH2CH2N), 33.2 (CH2CH2N), 37.5 (COHCH2CH2N), 45.0 (CHCH3), 
49.6 (CH2N), 56.8 (CH2N), 60.4 (CCH3), 70.6 (COH); HRMS(EI
+) found 184.1325, C11H21NO 
requires 184.1320.  
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(1S,9aR)-1,9a-Dimethyldecahydroquinolizin-5-ium 2,4,6-trinitrophenolate (243) 
 
This salt was prepared by Dr.Juan. A. Faraldos: To a stirred solution of free amine 105 (68 
mg, 0.4 mmol) in ethanol (4 mL) was added picric acid (91.6 mg, 0.4 mmol) at room 
temperature. After stirring for 1h,  the mixture was filtered under reduced pressure to give 
the picrate salt 243 as yellow crystals (115 mg, 77%); mp 220 °C; IR (NaCl) cm-1 3060 (m) 
(CH, stretch), 2780-2940 (s) (stretch C-H), 1230 (m) (CN, stretch); 1H-NMR (500 MHz, CDCl3) 
δH 0.89-0.90 (3H, d, J = 7.0 Hz, CH3CH), 1.21 (3H, s, CH3C), 1.42-1.44 (2H, m, CH2CH2CH2N), 
1.57-1.59 (1H, m, CH3CH), 1.70-1.72 [2H, m, CH2C(CH3)N], 1.87-1.91 (2H, m, CH2CH2N), 
2.08-2.33 (4H, m, 2 x CH2CH2N), 2.80-2.90 (2H, m, CH2N), 3.22-3.24 (2H, m, CH2N), 8.83 (2H, 
s, ArH), 9.56 (broad s, NH); 13C-NMR (125 MHz, CDCl3) δC 9.3 (CH3CH), 15.7 (CH3C), 18.8 
(CH2CH2CH2N), 22.7 (CH2CH2CH2N), 22.9 (CH2CH2CH2N), 26.9 [CH2CH(CH3)], 33.7 
[CH2C(CH3)CN], 38.9 (CHCH3), 50.3 (CH2N), 50.4 (CH2N), 65.4 (CH3C), 126.6 (ArCH, ArCH), 
127.8 (ArCNO2), 141.8 (ArCNO2, ArCNO2), 161.6 (ArCO
-); HRMS(EI+) found 168.1753, 
C11H22N requires 168.1752.  
 (S)-1-(4-(Prop-1-en-2-yl)-2-thioxopiperidin-1-yl)pentan-3-one (244) 
 
Piperidine-2-thione (196) (100 mg, 0.64 mmol), anhydrous K2CO3 (190 mg, 1.4 mmol) (kept 
at 140 ˚C for 12 h before use), and 18-crown-6 (20 mg, 0.08 mmol) were suspended in 
anhydrous THF (10 mL). After cooling to 0 °C, a first portion of ethyl vinyl ketone (0.1 mL, 
0.86 mmol) was added dropwise with stirring under nitrogen. After the addition was 
complete, the solution was left at 0 °C for 5 min and then at room temperature for 1 h. The 
solution was cooled again to 0 °C, and a second portion of ethyl vinyl ketone (0.1 mL, 0.86 
mmol) was added. Stirring was continued for 1 h at room temperature, monitoring the 
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reaction by TLC. Anhydrous Na2SO4 was then added and the solution was filtered and 
concentrated under reduced pressure. The crude product was purified by chromatography 
on silica gel (DCM, Rf 0.25) to give pure oxo-piperidine-2-thione 244 as a light yellow oil 
(130 mg, 84%): IR (thin film) cm-1 3085 (m) (CH, stretch), 1712 (s) (ketone C=O, stretch), 
1645 (s) (C=C, stretch), 1348 (s) and 1161 (m) (C=S); 1H-NMR (400 MHz, CDCl3) δH 1.03 (3H, 
t, J = 5.0 Hz, COCH2CH3), 1.65 (3H, s, CH3C=C), 2.01 (1H, m, CH), 2.44 (2H, q, J = 7.0, 6.0 Hz, 
COCH2CH3), 2.65 (2H, t, J = 6.5 Hz, CH2CH2N), 2.97 (2H, dt, J = 6.5, 4.0 Hz, CH2CH2CO), 3.10 
(2H, ddd, J = 2.0, 3.0, 6.0 Hz, CH2CS), 3.59 (1H, app ddd, J = 4.0, 5.5, 13.0 Hz, CHN), 3.44 
(1H, app ddd, J = 5.0, 10.0, 13.0 Hz, CHN), 4.10- 4.20 (2H, dt, J = 6.5, 13.0 Hz, NCH2CH2CO) 
and 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 7.7 
(COCH2CH3), 20.6 (CH2CH2CN), 27.5 (CH3CH=CH2), 36.1 (CH2CHCH2), 38.4 (CH2CH2CO), 38.6 
(COCH2CH3), 46.7 (CH2CS), 49.9 (CNCH2CH2), 51.8 (CH2CN), 110.5 (CH2=CH), 145.8 (C=CH2), 
198.9 (C=O) and 209.8 (C=S); HRMS(EI+) found 239.1352, C13H21NOS requires 239.1344; 
[α]22D  = -28.4 (c 2.27, CHCl3). 
(S)-8-Hydroxy-9-methyl-2-(prop-1-en-2-yl)-1,2,3,4,6,7-hexahydroquinolizin-5-ium (246) 
 
To a solution of bicyclic enone 194 (250 mg, 1.21 mmol) in dry DCM (3 mL) was added TFA 
(0.1 mL, 1.21 mmol). After stirring for 5 min, the excess of TFA and solvent were removed 
under reduced pressure and the residue was placed under high vacuum to give the TFA salt 
246 as yellow-orange oil (350 mg, 91%); IR (thin film) cm-1 3340 (m) (OH, stretch) 3085 (m) 
(CH stretch), 2822 (m) (CH, stretch), 1640 (m) (C=C, stretch), 1346 (m) and 1241 (m) (C-N 
stretch); 1H-NMR (400 MHz, CDCl3) δH 1.82 [3H, s, C=C(CH3)CO], 1.85 (3H, s, C=CCH3), 2.11 
(1H, m, CH), 2.48 (2H, d, J = 3.5 Hz, CHCH2C), 2.61 (2H, q, J = 6.0, 5.0 Hz, CHCH2CH2), 2.92 
(2H, m, CH2CO), 3.62-3.84 (4H, m, CH2CH2NCH2), 4.75 (1H, s, CHaH=C), 5.13 (1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 8.4 (CH3C=COH), 22.5 (CH3C=C), 31.3 (CH2C=N), 32.1 
(CH2CH2N), 33.8 (CH2CH2N), 38.5 (CH), 44.6 (CH2N), 45.9 (CH2N), 105.7 (C=COH), 105.1 
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(CH2=CCH3), 111.1-115.9 (q, J = 285 Hz, CF3), 147.9 (C=CCH3), 158.9-159.9 (q, J = 38 Hz, 
COO), 172.1 (C=N), 174.2 (COH=C). This salt was used in the next step without purification. 
(1S,8S,9aR)-1,9a-Dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium 
 perchlorate (247) 
 
This salt was prepared by Dr. Juan. A. Faraldos: To a solution of the free amine 106 (20 mg, 
0.09 mmol) in dry Et2O (4 mL) was added perchloric acid (9.0 mL, 0.09 mmol) under a 
nitrogen. After stirring for 15 min, the crystals were filtered and washed with dry ether (10 
mL) to give perchlorate salt 247 (25 mg, 90%) as white crystals; IR (thin film) cm-1 3050 (m) 
(CH, stretch), 2695-2770 (s) (CH, stretch), 1660 (m) (C=C, stretch); 1H-NMR (500 MHz, D2O) 
δH 0.80-0.81 (3H, d, J = 6.5 Hz, CH3CH), 1.18 (3H, s, CH3C), 1.36-1.41 (1H, m, CHCH3), 1.45-
1.59 (4H, 2 x CH2), 1.60 (3H, s, CH3C=C), 1.73-2.05 (4H, m, CH2CH2N, CH2CH2N), 2.35 (1H, m, 
CH), 2.92-3.02 (3H, m, CH2N, CHN), 3.11-3.19 (1H, ddd, J = 3.5, 3.0, 2.0 Hz, CHN), 4.66 (1H, 
s, CHaH=C), 4.71 (1H, s, CHHb=C); 
13C-NMR (125 MHz, D2O) δC 9.8 (CH3CH), 15.4 (CH3C), 20.7 
(CH3C=C), 24.1 (CH2CHCH3), 27.5 (CH2CCH3), 29.2 (CH2CH2N), 37.7 (CH2CH2N), 41.5 (CH), 
42.3 (CHCH3), 50.8 (CH2N), 50.9 (CH2N), 66.8 (CCH3), 110.4 (CH2=C), 148.4 (CH2=C); 
HRMS(EI+) found 208.2058, C14H26N requires 208.2065.  
(4R)-Limonene oxide[(4R)-1-methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptanes] (248) 
 
A mixture of (R)-limonene (30.1 g, 220 mmol) and NaHCO3 (37.8 g, 450 mmol) in DCM (150 
mL) was stirred at 0-5 °C, as a solution of 75% m-CPBA (70.0 g, 223 mmol) in DCM (250 mL) 
was added over 50 min. The mixture was stirred at 0 °C for 30 min, and a solution of 10% 
Na2SO3 of water (100 mL) was added. The mixture was stirred for 30 min at room 
temperature and diluted with water (100 mL) before separating the organic fraction. The 
aqueous layer was extracted with DCM (6 x 100 mL). The combined organic layers were 
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dried (MgSO4), filtered and concentrated under reduced pressure. The residue was purified 
by chromatography on silica gel (hexane-ethyl acetate, 5%, Rf 0.40) to afford limonene 
oxide (248) as colourless oil which was a 60: 40 mixture of two isomers (20.5 g, 61%); IR 
(thin film) cm-1 3070 (m) (C-H, stretch), 2918 (m) (C-H, stretch), 1655 (m) (C=C, stretch); 1H-
NMR (500 MHz, CDCl3) δH 1.23 and 1.25 (3H, s, CH3CO), 1.60  and 1.64 (3H, s, CH3C=C), 
1.43-2.18 (7H, m, 3 x CH2, CH), 3.00 and 3.02 (1H, dd, J = 6.5 Hz, CHO), 4.68 (1H, s, CHaH=C), 
4.74 (1H, s, CHHb=C); 
13C-NMR (125 MHz, CDCl3) δC 17.1 (CH3CO), 21.3 (CH3C=C), 23.8 
(CH2CHO), 27.9 (CH2CCH3), 28.6 (CH2CH), 39.3 (CH), 60.3 (CH3CO), 63.7 (CHO), 110.4 
(CH2=C), 147.8 (CH2=C); HRMS(EI
+) found 152.2303, C10H16O requires 152.2301.  
(4R)-1-Methyl-4-(prop-1-en-2-yl)-cyclohexane-1,2-diol (249) 
 
A mixture of (+)-limonene oxide (248) (50 g, 0.33 mol), KOH (109 g, 1.96 mol), DMSO (165 
mL) and water (150 mL) was heated at 110 ˚C for 24 h. The mixture was cooled to room 
temperature and placed into an ice-bath to precipitate the diol as white crystals. Crystals 
were collected by filtration under reduced pressure. The filtrate was extracted with Et2O (6 
× 100 mL) and the combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The extracte diol, in addition to the crystals gave 
the diol 249 in a combined yield of 42 g (hexane-ethyl acetate, 20%, Rf 0.25, 74%); mp 70-
74 ˚C; IR (thin film) cm-1 3396 (s) (br), (OH, stretch), 3080 (m) (CH, stretch), 2924 (m) (CH, 
stretch), 1653 (m) (C=C, stretch), 1375 (m) and 1265 (m) (CN, stretch); 1H-NMR (400 MHz, 
CDCl3) δH 1.25 [3H, s, C(OH)CH3], 1.72 [3H, s, CH3C=C], 1.42-2.85 [9H, m, 3 x CH2, CH, 2 x 
OH], 3.62 [1H, s, CH(OH)] and 4.74 (2H, br s, CH2=C); 
13C-NMR (100 MHz, CDCl3) δC 21.1 
[C(OH)CH3], 26.2 (CH3C=CH2), 26.7 (CHCH2CH2), 33.6 (CH2CHCH2), 34.0 [C(OH)CH2CH], 37.4 
[C(OH)CH3CH2], 71.3 [C(OH)CH3], 73.9 [C(OH)], 109.0 (CH2=C) and 149.3 (CH2=C); HRMS(EI
+) 
found 170.1308, C10H18O2 requires 170.1307. 
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(5R)-2-Hydroxy-2-methyl-5-(prop-1-en-2-yl)-cyclohexanone (250) 
 
To a stirred suspension of PCC (25 g, 0.14 mol) in DCM (250 mL) was added drop wise at 
room temperature a solution of freshly prepared diol 249 (10 g, 0.06 mol) in DCM (250 
mL). After stirring for 2 h, the reaction mixture was filtered through a short silica- gel 
column with DCM. The filtrate was concentrated under reduced pressure. Purification of 
the residue by flash-column chromatography on silica gel (hexane-ethyl acetate, 20%, Rf 
0.30) gave the hydroxy ketone 250 as colourless oil (8 g, 83%); IR (thin film) cm-1 3423 (s) 
(OH, stretch), 3083 (m) (CH, stretch), 2973 (m) (CH, stretch), 1717 (s) (C=O, stretch), 1645 
(m) (C=C, stretch) and 1375 (m); 1H-NMR (400 MHz, CDCl3) δH 1.37 [3H, s, C(OH)CH3], 1.75 
(3H, s, CH3C=C), 1.65-2.95 [7H, m, 3 x CH2, CH], 3.62 (1H, s, OH), 4.70 (1H, s, CHaH=C), 4.86 
(1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 21.5 (CH3C=CH2), 24.9 [C(OH)CH3], 25.2 
(CH2CHCH2), 40.7 (CH2CHCH2), 44.1 [C(OH)CH3CH2], 46.2 (CH2CO), 75.6 [C(OH)CH3], 110.6 
(CH2=C), 146.13 (CH2=C) and 209.64 (C=O); HRMS(EI
+) found 168.1152, C10H16O2 requires 
168.1150.  
(R)-Methyl-6-oxo-3-(prop-1-en-2-yl)-heptanoate (251) 
 
To stirred solution of hydroxy ketone 250 (8 g, 50 mmol) in methanol (40 mL) was slowly 
added lead tetraacetate (30 g, 68 mmol) at -5 °C over 30 min. The reaction mixture was 
stirred at 0 °C for an additional 1 h and then diluted with water (40 mL) and brine solution 
(20 mL). The product was extracted with Et2O (4 × 20 ml) and the combined ethereal 
extracts were dried with Na2SO4, filtered, and concentrated under reduced pressure. The 
resulting residue was purified by silica gel column chromatography (hexane- ethyl acetate; 
10%, Rf 0.26) to give methyl ester 251 as colourless oil (8.08 g, 81%); IR (thin film) cm
-1 
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3067 (m) (CH stretch), 1738 (s) (ester C=O, stretch), 1716 (s) (ketone C=O, stretch), 1646 
(m) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.66 (3H, s, CH3C=C), 2.15 (3H, s, CH3CO), 
1.85-2.75 [7H, m, 3 x CH2, CH), 3.65 (3H, s, OCH3) and 4.74 (1H, s, CHaH=C), 4.80 (1H, s, 
CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 18.7 (CH3C=CH2), 26.6 (CH3CO), 30.4 (CH2CHCH2), 
39.3 (CH2CHCH2), 41.5 (CH2COO), 43.4 (CH2CO), 51.9 (OCH3), 113.3 (C=CH2), 145.7 (CH2=C), 
173.1(CO ester) and 208.8 (CO ketone); HRMS(EI+) found 199.1328, C11H18O3requires 
199.1334. 
(R)-Methyl-6-(hydroxyimino)-3-(prop-1-en-2-yl)-heptanoate (252) 
 
Hydroxylamine hydrochloride (3.16 g, 49 mmol) was added in one portion to a stirred 
solution of methyl ester 251 (8.08 g, 40.8 mmol) in pyridine (30 mL) and ethanol (20 mL).  
The resulting mixture was stirred for 6 h and then diluted with water (100 mL) and 
extracted with ethyl acetate (6 × 20 mL). The combined organic extracts were washed with 
aqueous hydrochloric acid (10%, 20 mL), saturated sodium hydrogen carbonate (30 mL) 
and brine (20 mL). The organic layer was dried (Na2SO4), filtered and concentrated under 
reduced pressure. The residue was purified by silica-gel column chromatography (hexane-
ethyl acetate; 10%, Rf 0.30) to give a mixture of E/Z oximes 252 as a colourless oil (7.98 g, 
91%); IR (thin film) cm-1 3377 (s) (OH, stretch), 3086 (m) (CH, stretch), 2931 (m) (CH, 
stretch), 1716 (s) (ester C=O, stretch), 1645 (s) (C=N, stretch), 1656 (m) (C=C, stretch); 1H-
NMR (400 MHz, CDCl3) δH 1.56 and 1.57 (3H minor and major isomers, 2 x s, CH3C=C), 1.75 
and 1.76 (3H, minor and major isomers, 2 x s, N=CCH3), 1.80-2.72 (7H, minor and major 
isomers, m, 3 x CH2, CH ), 3.64 and 3.65 (3H, minor and major isomers, 2 x s, OCH3), 4.70, 
4.74 and 4.75 (2H, br s, minor and major isomers, CH2=C);
 13C-NMR (100 MHz, CDCl3) δC 
14.0 (CH3C), 18.9 and 18.8 (major and minor isomer, CH3CN), 29.4 and 28.6 (major and 
minor isomer, CHCH2CH2), 33.9 (CHCH2CH2), 39.9 and 39.4 (CH2CHCH2), 43.6 and 44.2 
(major and minor isomer, CH2COOCH3), 51.2 (OCH3), 113.2 and 113.1 (C=CH2), 145.7 
(C=CH2), 158.9 and 158.5 (major and minor isomer, C=N) and 173.3 (CO ester); HRMS(EI
+) 
found 213.1360, C11H19NO3 requires 213.1365. 
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(R)-Methyl 3-(2-acetamidoethyl)-4-methylpent-4-enoate (253) 
 
p-Toluene sulfonyl chloride (12.8 g, 67.3 mmol) was added in one portion to a stirred 
solution of freshly prepared oxime 252 (7.9 g, 37.4 mmol) in dry benzene (20 mL) and 
pyridine (15 mL). The mixture was stirred at room temperature in the dark for 7 days under 
nitrogen. The solvent was removed under reduced pressure and the residue was dissolved 
in ethyl acetate (50 mL) and washed with 10% hydrochloric acid (100 mL). The organic 
layer was dried over Na2SO4, filtered, and the solvent was removed under reduced 
pressure. The residue was purified by chromatography on silica gel (ethyl acetate, Rf 0.18) 
to give acetamide 253 as a colourless oil (5.10 g, 64%); IR (thin film) cm-1 3296 (s) (NH, 
stretch), 3078 (m) (CH, stretch), 2950 (m) (CH, stretch), 1739 (s) (ester C=O, stretch), 1647 
(s) (amide, C=O, stretch), 1658 (m) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.65 (3H, s, 
CCH3), 1.99 (3H, s, COCH3), 2.35-2.65 (3H, m, CH2, CH), 3.01-3.25 (2H, m, CH2NH ), 3.65 (3H, 
s, OCH3), 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C) and 5.56 (1H, br s, NH); 
13C-NMR (100 
MHz, CDCl3) δC 18.6 (CH3C), 23.4 (COCH3), 38.4 (CH), 39.2 (CH2COO), 41.8 (CH2NH), 52.1 
(OCH3), 113.3 (C=CH2), 145.7 (C=CH2), 170.7 (C=O amide) and 173.7 (CO ester); HRMS(EI
+) 
found 214.1446, C10H20NO3 requires 214.1443; [α]
22
D  = + 6.6 (c 2.07, CHCl3). 
 (4R)-(Prop-1-ene-2yl) -2-piperidone (254) 
 
A stirred mixture of acetamide 253 (5.10 g, 23 mmol) and 3 M sodium hydroxide solution 
(30 mL, 90 mmol) was heated under reflux for 3 h. The solution was cooled, and 
neutralized to pH 6 with 1M HCl. The resulting mixture was evaporated under reduced 
pressure to dryness, and the residue was heated at 130 °C for 3 h. The solid was extracted 
with petroleum ether (12 × 25 ml). The combined ethereal extracts were evaporated under 
reduced pressure. The residue was purified by chromatography on silica gel (diethyl ether, 
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Rf 0.35) to give the lactam 254 as white crystals (3.17 g, 95%); mp 53-55˚C; IR (NaCl) cm
-1 
3212 (s) (NH, stretch), 3083 (m) (CH, stretch), 2923 (m) (CH, stretch), 1668 (s) (lactam C=O, 
stretch), 1646 (s) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.69 (3H, s, CCH3), 1.18-1.88 
(1H, m, CH2CHCH2), 2.15-2.23 (2H, q, J = 6.0, 5.5 Hz, CHCH2CH2), 2.37-2.46 (2H, m, 
CHCH2CO), 3.27-3.28 (2H, m, CH2N), 4.68 (1H, s, CHaH=C), 4.76 (1H, s, CHHb=C) and 6.38 
(1H, br s, NH); 13C-NMR (100 MHz, CDCl3) δC 21.0 (CH3C), 27.2 (CH2CHCH2), 36.8 
(CH2CHCH2), 39.6 (CH2CO), 41.5 (CH2NH), 110.6 (C=CH2), 146.8 (C=CH2) and 173.0 (C=O 
lactam); HRMS(EI+) found 139.0996, C8H13NO requires 139.0997; [α]
22
D  = + 5.8 (c 3.22, 
CHCl3). 
(4R)-(Prop-1-ene-2yl) piperidine-2-thione (255) 
 
A mixture of lactam 254 (3.17 g, 22.8 mmol) and Lawesson,s reagent (4.16 g, 11.4 mmol) 
was suspended in anhydrous toluene (30 mL), and heated under reflux for 1 h under 
nitrogen. The resulting mixture was cooled to room temperature, and then the solvent was 
removed under reduced pressure. The residue was purified by slica-gel column 
chromatography (DCM: petroleum ether, 2:1, Rf 0.33) to give a yellow powder. 
Recrystallisation from i-PrOH produced analytically pure white needles of thiolactam 255 
(2.80 g, 78%); mp 93-95 ˚C; IR (NaCl) cm-1 3169 (s) (NH, stretch), 3086 (m) (CH, stretch), 
2952 (m) (CH, stretch), 1645 (s) (C=C, stretch), 1258 (m) and 1119 (s) (C=S); 1H-NMR (400 
MHz, CDCl3) δH 1.65 (3H, s, CH3C=C), 1.70-1.89 (1H, m, CH2CHCH2), 2.32 (2H, m, CHCH2CH2), 
2.69 (1H, dd, J = 4.0, 8.0 Hz, HCHC=S), 3.06 (1H, dd, J = 4.0, 8.0 Hz, HCHC=S), 3.27-3.40 (2H, 
m, CH2N), 4.85 (1H, s, CHaH=C), 4.94 (1H, s, CHHb=C) and 8.85 (1H, br s, NH); 
13C-NMR (100 
MHz, CDCl3) δC 20.2 (CH3C), 26.3 (CH2CHCH2), 38.7 (CHCH2CH2), 41.2 (CH2NH), 45.7 
(CH2C=S), 112.8 (C=CH2), 145.7 (C=CH2) and 206.9 (C=S); HRMS(EI
+) found, 156.0847 
C8H13NS requires 156.0847 [α]
22
D  = + 3.4 (c 0.62, CHCl3).  
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(4R)-(Prop-1-ene-2yl)-(3-oxopentyl) piperidine-2-thione (256) 
 
Piperidine-2-thione 255 (1.4 g, 9.02 mmol), anhydrous K2CO3 (2.75 g, 19.85 mmol) (kept at 
140 °C for 12 h before use), and 18-crown-6 (0.30g, 1.13 mmol) were suspended in 
anhydrous THF (20 mL). After cooling to 0 °C, a first portion of ethyl vinyl ketone (1.2 mL, 
12.09 mmol) was added dropwise with stirring under nitrogen. After the addition was 
complete, the solution was left at 0 °C for 5 min and then at room temperature for 1 h. The 
solution was cooled again to 0 °C, and a second portion of ethyl vinyl ketone (1.2 mL, 12.09 
mmol) was added. Stirring was continued for 1 h at room temperature, monitoring the 
reaction by TLC. Sodium sulfate was then added, and the solution filtered and 
concentrated under reduced pressure. The resulting crude material was purified by silica 
column chromatography (eluent DCM, Rf 0.25) to give pure oxo-piperidine-2-thione 256 as 
a light yellow oil (1.82 g, 84.3%): IR (thin film) cm-1 3085 (m) (CH, stretch), 1712 (s) (ketone 
C=O, stretch), 1645 (s (C=C, stretch), 1348 (s) and 1161 (m)(C=S); 1H-NMR (400 MHz, CDCl3) 
δH 1.03 (3H, t, J = 5.0 Hz, COCH2CH3), 1.65 (3H, s, CH3C=C), 2.01 (1H, m, CH2CHCH2), 2.44 
(2H, q, J = 7.5, 6.0 Hz, COCH2CH3), 2.65 (2H, t, J = 6.5 Hz, CH2CH2N), 2.97 (2H, dt, J = 6.5, 4.0 
Hz, CH2CH2CO), 3.10 (2H, ddd, J = 2.0, 3.5, 6.0 Hz, CH2CS), 3.59 (1H, app ddd, J = 4.0, 5.5, 
13.0 Hz, CHN), 3.44 (1H, app ddd, J = 5.0, 10.0, 13.0 Hz, CHN), 4.10- 4.20 (2H, dt, J = 6.5, 
13.0 Hz, NCH2CH2CO) and 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C); 
13C-NMR (100 MHz, 
CDCl3) δC 7.7 (COCH2CH3), 20.6 (CH2CH2CN), 27.5 (CH3CH=CH2), 36.1 (CH2CHCH2), 38.4 
(CH2CH2CO), 38.6 (COCH2CH3), 46.7 (CH2CS), 49.9 (CNCH2CH2), 51.8 (CH2CN), 110.5 
(CH2=CH), 145.8 (C=CH2), 198.9 (C=O) and 209.8 (C=S); HRMS(EI
+) found 239.1352, 
C13H21NOS requires 239.1344;. [α]
22
D =  + 7.8 (c 2.27, CHCl3). 
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(R)-9-methyl-2-(prop-1-en-2-yl)-3,4,6,7-tetrahydro-1H-quinolizin-8(2H)-one (257) 
 
To a stirred suspension of oxo-piperidine-2-thione 256 (750 mg, 3.13 mmol) in anhydrous 
benzene (10 mL) under nitrogen was added freshly distilled Me2SO4 (0.49 mL, 5.33 mmol) 
drop wise by a syringe. The mixture was heated under reflux. After 1 h, 1, 8-diazabicyclo 
[5.4.0] undec-7-ene (DBU) (0.80 mL, 5.33 mmol) was added drop wise by a syringe; the 
resulting solution was heated under reflux for further 1 h. After cooling to room 
temperature, the solution was diluted with DCM (100 mL), and washed with water (100 
mL). The combined organic extracts were dried over Na2SO4 then filtered and concentrated 
under reduced pressure. The residue was adjusted to pH 2 with 10% HCl (10 mL) and 
extracted with Et2O (3× 10 mL). The aqueous phase was adjusted to pH 12 with NaOH 
(pellets) and extracted with Et2O (5 x 10 mL). The combined ethereal layers were dried 
(K2CO3) and filtered, and the solvent was removed under reduced pressure. The crude was 
purified by chromatography on alumina (hexane: diethyl ether, 10%, Rf 0.35). The by-
product eluted first and was isolated as a yellow oil (185 mg, 41%). Further elution with 
(hexane: diethyl ether, 30%, Rf 0.27) to give bicyclic enone 257 as colourless oil (360 mg, 
40%); IR (thin film) cm-1 3080 (m) (CH, stretch), 2925 (m) (CH, stretch), 1660 (m) (C=C, 
stretch), 1643 (m) (ketone C=O, stretch), 1656 (m) (C=C, stretch), 1346 (m) and 1241 (m) 
(CN, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.52 [3H, s, C=C(CH3)CO], 1.55 (3H, s, C=CCH3), 
1.81 (1H, m, CH), 2.08 (2H, d, J = 3.5 Hz, CHCH2C), 2.252 (2H, q, J = 6.0, 5.5 Hz, CHCH2CH2), 
2.52 (2H, m, CH2CO), 3.02-3.14 (4H, m, CH2CH2NCH2), 4.63 (1H, s, CHaH=C), 4.73 (1H, s, 
CHHb=C); 
13C-NMR (100MHz, CDCl3) δC 9.6 (CH2=CCH3), 20.6 [C=C(CH3)CO], 27.4 
(CH2CHCH2), 32.2 (CHCH2CH2N), 35.1 (CHCH2C), 38.1 (COCH2CH2), 50.2 (COCH2CH2N), 50.6 
(CH2CH2N), 103.0 (CH2=CCH3), 110.5 [C=C(CH3)CO], 146.9 (C=CCH3), 160.3 [C=C(CH3)CO] and 
189.0 (CO ketone); HRMS(EI+) found, 206.1540. C13H19NO requires 206.1545; [α]
22
D  = + 9.1 
(c 4.6, CHCl3). 
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(R)-8-hydroxy-9-methyl-2-(prop-1-en-2-yl)-1,2,3,4,6,7-hexahydroquinolizin-5-ium (258) 
 
To a stirred solution of bicyclic enone 257 (250 mg, 1.21 mmol) in dry DCM (3 mL) was 
added TFA (0.1 mL, 1.21 mmol). After stirring for 5 min, the excess of TFA and solvent were 
removed under reduced pressure and the residue was placed under high vacuum to give 
the TFA salt 258 as yellow-orange oil (350 mg, 91%); IR (thin film) cm-1 3340 (m) (OH, 
stretch) 3085 (m) (CH stretch), 2822 (m) (CH, stretch), 1640 (m) (C=C, stretch), 1346 (m) 
and 1241 (m) (C-N stretch); 1H-NMR (400 MHz, CDCl3) δH 1.82 [3H, s, C=C(CH3)CO], 1.85 
(3H, s, C=CCH3), 2.11 (1H, m, CH), 2.48 (2H, d, J = 3.5 Hz, CHCH2C), 2.61 (2H, q, J = 6.0, 5.0 
Hz, CHCH2CH2), 2.92 (2H, m, CH2CO), 3.62-3.84 (4H, m, CH2CH2NCH2), 4.75 (1H, s, CHaH=C), 
5.13 (1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 8.4 (CH3C=COH), 22.5 (CH3C=C), 31.3 
(CH2C=N), 32.1 (CH2CH2N), 33.8 (CH2CH2N), 38.5 (CH), 44.6 (CH2N), 45.9 (CH2N), 105.7 
(C=COH), 105.1 (CH2=CCH3), 111.1-115.9 (q, J = 285 Hz, CF3), 147.9 (C=CCH3), 158.9-159.9 
(q, J = 38 Hz, COO), 172.1 (C=N), 174.2 (COH=C). This salt was used in the next step without 
purification. 
(1S,8R,9aS)-1,9a-Dimethyl-8-(prop-1-en-2-yl)hexahydro-1H-quinolizin-2(6H)-one (259) 
 
To a stirred solution of freshly prepared TFA salt 258 in dry THF (5 mL) was added 
methylmagnesium bromide (3 M in diethyl ether, 2.1 mL, 4.8 mmol) at room temperatur 
under argon. The mixture was heated under reflux for 24 h and then, after cooling to room 
temperature, a solution of saturated NH4Cl (10 mL) and 10% NH4OH (10 mL) were added 
and the resulting mixture was extracted with Et2O (3 × 10 mL). The resulting residue was 
adjusted to pH 2 with 10% HCl (5 mL) and extracted with Et2O (3 × 10 mL). The aqueous 
phase was adjusted to pH 12 with NaOH (pellets) and extracted with Et2O (5 x 10 mL). The 
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combined ethereal layers were dried (K2CO3) then filtered and the solvent was removed 
under reduced pressure. The crude product was purified by chromatography on alumina 
(hexane-ethyl acetate; 20%, Rf 0.26) to give amino ketone 259 as pale yellow oil (145 mg, 
63%); IR (thin film) cm-1 3050 (m) (CH, stretch), 2790-2966 (s) (CH, stretch), 1718 (s) (C=O, 
stretch), 1670 (m) (C=C, stretch), 1326 (m) and 1252 (s) (CN, stretch); 1H-NMR (500 MHz, 
CDCl3) δH 0.71 (3H, s, CCH3), 0.90 (3H, d, J = 7.0 Hz, CH3CH), 1.12-1.15 [2H, m, 
C(CH3)CH2CH], 1.17-1.25 (2H, m, CH2CH), 1.50-1.55 (2H, ddd, J = 7.0, 6.5, 5.0 Hz, CH2CO), 
1.63 (3H, s, CH3C=C), 1.95-2.01 (1H, m, CH2CHCH2), 2.41-2.50 (1H, dddd, J = 8.0, 7.5, 6.0 Hz, 
CHCH3), 2.62-2.69 (2H, m, CH2N), 2.80-2.86 (2H, m, CH2N), 4.65 (1H, s, CHaH=C), 4.69 (1H, s, 
CHHb=C); 
13C-NMR (125 MHz, CDCl3) δC 14.0 (CH3C), 15.2 (CH3CH), 20.6 (CH3C=C), 31.9 
(CH2CH2N), 37.6 (CH2CCH3), 41.2 (CH2CO), 43.3 (CH2CHCH2), 49.7 (CH2N), 50.0 (CH2N), 56.5 
(CHCH3), 60.0 (CCH3), 109.1 (CH2=C), 149.1 (CH2=C), 210.6 (C=O); HRMS(EI
+) found 
221.1783, C14H23NO requires 221.1781. 
(1R,8R,9aS)-1,9a-Dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-ium2,4,6-
trinitrophenolate (260) 
 
This salt was prepared by Dr. Juan. A. Faraldos: To a solution of the free amine 107 (20 mg, 
0.09 mmol) in ethanol (4 mL) was added picric acid (20.6 mg, 0.09 mmol). After stirring for 
1 h, the crystals were filtered and washed with ethanol (10 mL) to give picrate salt 260 (28 
mg, 90%) as yellow crystals; IR (thin film) cm-1 3070 (m) (CH, stretch), 2825 (m) (CH, 
stretch), 1660 (m) (C=C, stretch), 1619 (m), 1346 (m) and 1241 (m) (CN, stretch); 1H-NMR 
δH (500 MHz, CDCl3) 0.76 (1H, m, HCHCHCH3), 0.80 (3H, d, J = 6.5, CH3CH), 1.24 (3H, s, 
CH3C), 1.41 (1H, m, HCHCHCH3), 1.72 (3H, s, CH3C=C), 1.74-1.87 (3H, m, CH2CCH3, CHCH3), 
1.87-1.91 (2H, m, CH2CH2N), 2.12-2.16 (1H, t, J = 12.0 Hz, CH), 2.33-2.38 (2H, m, CH2CH2N), 
2.95-3.00 (2H, m, CH2N), 3.30-3.37 (2H, m, CH2N), 4.74 (1H, s, CHaH=C), 4.80 (1H, s, 
CHHb=C), 8.86 (2H, s, ArH), 9.69 (1H, br s, NH); 
13C-NMR (125 MHz, CDCl3) δC 9.35 (CH3CH), 
15.72 (CH3C), 20.50 (CH3C=C), 22.78 (CH2CHCH3), 23.91 (CH2CCH3), 26.93 (CH2CH2N), 33.76 
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(CH2CH2N), 37.80 (CH), 38.95 (CHCH3), 50.36 (CH2N), 50.41 (CH2N), 65.49 (CH3C), 110.16 
(CH2=C), 126.61 (ArCH, ArCH), 127.89 (ArCNO2), 141.80 (ArCNO2, ArCNO2), 146.92 (CH2=C), 
161.65 (ArCO-); HRMS(EI+) found 208.2066. C14H26N requires 208.2065. 
(1R,8R,9aS)-1,9a-Dimethyl-8-(prop-1-en-2-yl)decahydroquinolizin-5-iumperchlorate (261) 
 
This salt was prepared by Dr. Juan. A. Faraldos: To a solution of the free amine 107 (20 mg, 
0.09 mmol) in dry Et2O (4 mL) was added perchloric acid (9.0 mL, 0.09 mmol) under a 
nitrogen. After stirring for 15 min, the crystals were filtered and washed with dry ether (10 
mL) to give perchlorate salt 261 (35 mg, 88%) as white crystals ; IR (thin film) cm-1 3068 (m) 
(CH, stretch), 2825 (m) (CH, stretch), 1665 (m) (C=C, stretch), 1619 (m), 1346 (m) and 1241 
(m) (CN, stretch); 1H-NMR (500 MHz, D2O) δH 0.80-0.81 (3H, d, J = 6.5 Hz, CH3CH), 1.18 (3H, 
s, CH3C), 1.36-1.41 (1H, m, CHCH3), 1.45-1.59 (4H, 2 x CH2), 1.60 (3H, s, CH3C=C), 1.73-2.05 
(4H, m, CH2CH2N, CH2CH2N), 2.35 (1H, m, CH), 2.92-3.02 (3H, m, CH2N, CHN), 3.11-3.19 (1H, 
ddd, J = 3.5, 3.0, 2.0 Hz, CHN), 4.66 (1H, s, CHaH=C), 4.71 (1H, s, CHHb=C); 
13C-NMR (125 
MHz, D2O) δC 9.8 (CH3CH), 15.4 (CH3C), 20.7 (CH3C=C), 24.1 (CH2CHCH3), 27.5 (CH2CCH3), 
29.2 (CH2CH2N), 37.7 (CH2CH2N), 41.5 (CH), 42.3 (CHCH3), 50.8 (CH2N), 50.9 (CH2N), 66.8 
(CCH3), 110.4 (CH2=C), 148.4 (CH2=C); HRMS(EI
+) found 208.2058, C14H26N requires 
208.2065.  
(3R)-6-Methyl-3-(prop-1-en-2-yl)-1,2,3,4,6,7,8,9-octahydroquinolizin-5-ium bromide (262) 
 
To a stirred solution of LDA (2 M in THF, 2 mL, 4.01 mmol) in dry THF (8 mL) at -35 °C under 
argon was added 3S-(prop-1-en-2-yl)-6-methyl-2,3,4,5-tetrahydropyridine (182) (500 mg, 
3.6 mmol) in dry THF (5 mL) and the resulting mixture was stirred at this temperature for 
45 min. After cooling to -78° C, a solution of 1,3-dibromo butane (0.46 mL, 4.01 mmol) in 
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dry THF (3 mL) was added, then the reaction mixture was stirred overnight at room 
temperature. The solvent was evaporated under reduced pressure and residual solvent 
was removed under high vacuum to yield a yellow-orange oil of dehydroquinolizinium 
bromide 262 (512 mg, 74%) that was used for the next step without purification;. IR (NaCl) 
cm-1 3060 (m) (CH, stretch), 2850 (m) (CH, stretch), 1665 (m) (C=C, stretch), 1672 (m) 
(stretch, C=N); 1H-NMR (400 MHz, CDCl3) δH 1.64 (3H, d, J = 7.0 Hz, CH3), 1.69 (3H, s, CH3), 
1.80-1.95 (6H, m, 3CH2), 2.09 (1H, m, CHN), 2.40-2.92 (4H, m, 2CH2C=N
+), 3.55-3.77 (1H, m, 
HCHN+), 4.11-4.20 ( 1H, m, HCHN+), 4.30-4.42 (1H, CHN+), 4.67 (1H, s, CHaH=C), 4.78 (1H, s, 
CHHb=C); HRMS(EI
+) found, 192.1283 C13H22N requires 192.1280. 
(3R,6S,9aS)-6,9a-Dimethyl-3-(prop-1-en-2-yl)decahydroquinolizine 5-oxide (282) 
 
To a stirred solution of free amine 108 (15 mg, 0.07 mmol) in DCM (2 mL) were added 
K2CO3 (28 mg, 0.20 mmol) and mCPBA (77% in H2O, 8.06 mg, 0.105 mmol) at 0 °C. After 
stirring for 2h at the same temperature, the mixture was filtered through a short pad of 
silica gel. The filtrate was concentrated under reduced pressure and the residue was 
purified by basic alumina-column (diethyl ether-methanol, 50%, Rf 0.20) to afford N-oxide 
282 as a yellow oil (12.1 mg, 76%); IR (NaCl) cm-1 3376 (N-O, stretch), 2735-2822 (CH, 
stretch), 1658 (m) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.07-1.09 (2H, m, H9eq + 
H1eq), 1.17-1.19 (3H, d, J = 6.0 Hz, CH3CH), 1.30-1.38 (1H, m, H7eq), 1.42 (3H, s, CH3C), 
1.45-1.68 (4H, m, H8 +H2), 1.71 (3H, s, CH3C=CH), 2.25 (1H, ddd, J = 6.0, 5.5, 4.0 Hz, H7ax), 
2.45-2.48 (1H, ddd, J = 5.5, 4.5, 4.0 Hz, H9ax), 2.55-2.62 (1H, ddd, J = 6.0, 4.5, 4.0 Hz, H1ax), 
2.82 (1H, t, J = 6.5 Hz, H4), 3.18 (2H, m, H3+H4), 3.39 (1H, m, H6), 4.69 (1H, s, CHaH=C), 
4.78 (1H, s, CHHb=C); 
13C-NMR (100MHz, CDCl3) δC 15.0 (CH3CH), 18.2 (CH2), 18.9 (CH3C), 
21.4 (CH3C=C), 23.6 (CH2), 28.6 (CH2), 32.4 (CH2), 33.5 (CH2), 37.7 (CH), 60.1 (CH2N), 63.4 
(CHN), 69.5 ( CH3C), 110.4 (CH2=C), 146.4 (CH2=C) HRMS(EI
+) found 224.2005, C14H25NO 
requires 224.2014.  
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(3S,6R,9aR)-6,9a-Dimethyl-3-(prop-1-en-2-yl)decahydroquinolizin-5-iumtrifluoroacetate 
(292) 
 
To a stirred solution of free amine 110 (20 mg, 0.096 mmol) in dry DCM (2 mL) was added 
TFA (8 µL, 0.096 mmol). After 15 min the solvent was evaporated under reduced pressure, 
and the residue was purified by column chromatography on alumina (ethyl acetate-
methanol, 15%, Rf 0.16) to afford pure TFA salt 292 as yellow-orange oil (25 mg, 82%); IR 
(thin film) cm-1 3060 (m) (CH, stretch), 2750-2876 (m) (CH, stretch), 1672 (m) (C=N, stretch 
), 1650 (m) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.27-1.28 (3H, d, J = 6.0 Hz, CH3CH), 
1.30 (3H, s, CH3C), 1.70 (3H, s, CH3C=C), 1.73-1.85 (10H, m, 5 x CH2), 2.43 (1H, m, CH), 2.57 
(1H, m, HCHN), 3.15 (1H, m, HCHN), 3.42 (1H, m, CHN), 4.68 (1H, s, CHaH=C), 4.81 (1H, s, 
CHHb=C), 7.25 (1H, br s, NH); 
13C-NMR (100 MHz, CDCl3) δC 13.6 (CH3CH), 16.7 (CH3C=C), 
19.4 (CH3C), 22.2 (CH2CH2CCH3), 28.7 (CH2CHCH3), 31.3 (CH2CH2CCH3), 36.1 (CH2CCH3), 36.5 
(CH2CCH3), 40.5 (CH), 47.6 (CH2N), 55.7 (CH3CHN), 61.9 (CN
+), 110.6 (CH2=C), 111.3-117.5 
(q, J = 286.0 Hz, CF3), 142.4 (CH2=C), 158.6-159.6 (q, J = 40.0 Hz, COO); HRMS(EI
+) found 
208.2066. C14H26N requires 208.2065. 
Jones oxidation of diol 249 to (R)-6-oxo-3-(prop-1-en-2-yl)-heptanoic acid (294) 
 
To a stirred solution of diol 249 (16.2 g, 0.09 mol) in acetone (200 mL) was added Jones 
reagent (~50 mL) slowly with stirring at 0 ˚C for 20 min. The addition was continued until 
the characteristic orange colour of the reagent persisted for about 20 min. A solution of 
NaHCO3 (100 mL) was added, and the suspension was stirred vigorously until the pH of 
reaction mixture was neutral. The suspension was filtered and the residue was washed 
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with acetone (100 mL). H2O (150 mL) was added to filtrate solution which was then 
extracted with DCM (5 x 100 mL). The organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by silica-gel column 
chromatography (hexane-ethyl acetate; 15%, Rf 0.21) to give pure keto acid 294 as 
colourless oil (12.1 g, 69%); IR (thin film) cm-1 3300 (vs) (OH, stretch), 2845 (m) (C-H, 
stretch), 1738 (s) (acid C=O, stretch), 1715 (s) (ketone C=O, stretch), 1660 (m) (C=C, 
stretch); 1H-NMR (400 MHz, CDCl3) δH 1.56 (3H, s, CCH3), 1.8-2.7 (7H, m, 3 x CH2, CH), 2.15 
(3H, s, COCH3) and 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C); 
13C-NMR (100 MHz, CDCl3) δC 
18.8 (CH3C), 26.6 (CH3CO), 30.4 (CH2CH2CO), 39.2 (CH2CHCH2), 41.5 (CH2COO), 43.1 
(CH2CO), 113.5 (C=CH2), 145.4 (CH2=C), 178.5 (CO acid), 209.3 (CO ketone); HRMS(EI
+) 
found 185.1178, C10H16O3 requires 185.1178. 
(S)-4-Methoxybenzyl (5-oxo-2-(prop-1-en-2-yl)hexyl)carbamate (297) 
 
To stirred solution of keto acid 294 (12.1 g, 0.06 mol) in dry toluene (30 mL) was added 
Et3N (25 mL, 0.143 mol) followed by diphenylphosphoryl azide (21 mL, 0.143 mol). After 15 
min at room temperature the solution was heated at reflux for 2.5 h, after which time the 
starting material was converted completely to the isocyanate as judged by TLC (eluent 
hexane-ethyl acetate, 25%, Rf 0.37). p-Methoxybenzyl alcohol (15.1 mL, 0.143 mol) was 
then  added and heated under reflux for 24 h. The solvent was evaporated under reduced 
pressure to give a black oil that was purified by chromatography on silica gel (hexane-ethyl 
acetate, 25%, Rf 0.28) to give the urethane 297 as pale yellow oil (10.5 g, 60%); IR (NaCl)
 
cm-1 3120 (m) (NH urethane, stretch), 2975 (m) (CH, stretch), 1716 (C=O, stretch), 1660 (m) 
(C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.52 (3H, s, CH3C=C), 2.14 (3H, s, CH3C=O), 
1.80-2.72 [5H, m, (CH2)2CH], 2.91-3.10 (1H, m, CHNH), 3.20-3.31 (1H, m, HCNH), 3.75 (3H, 
s, OCH3), 4.74 (1H, s, CHaH=C), 4.80 (1H, s, CHHb=C), 5.25 (2H, s, OCH2), 6.85 (2H, d, J = 8.5 
Hz), 7.27 (2H, d, J = 8.5 Hz); 13C-NMR (100 MHz, CDCl3) δC 18.2 (CH3C=C), 23.9 (CH3CO), 30.0 
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(CH2CH), 40.9 (CH2CO), 43.1 (CH), 46.6 (CH2N), 55.2 (OCH3), 66.4 (OCH2), 113.9 (CH2=C), 
114.2 (ArCH, ArCH), 128.7 (ArCCH2O), 129.9 (ArCH, ArCH), 144.3 (CH2=C), 156.3 (COO), 
159.6 (ArCOCH3), 208.3 (C=O);HRMS(EI
+) found 319.1812, C18H25NO4 requires 319.1811. 
 (S)-6-Methyl-3-(prop-1-en-2-yl)-2,3,4,5-tetrahydropyridine (298) 
 
To a stirred solution of urethane 297 (10.5 g, 0.03 mol) in DCM (50 mL) was added, 
dropwise, a solution of TFA (20 mL) in DCM (50 mL) to give a bright orange solution. After 
10 min, triisopropylsilane (3.2 mL) was added and stirring was continued for 5 min before 
ice-water (100 mL) was added. The aqueous phase was washed with DCM (2 x 20 mL) and 
then adjusted with KOH (pellets) until the pH reached 12. The equeous layer was extracted 
with DCM (4 x 20 mL). The combined DCM extracts were dried over K2CO3 and 
concentrated under redued pressure. The crude was purified by chromatography on basic 
alumina (hexane-diethyl ether, 50%, Rf 0.35) to give cyclic imine 298 as yellow oil (3 g, 
72%); IR (NaCl) cm-1 3035 (m) (CH, stretch), 2975 (s) (CH, stretch), 1667 (m) (C=C, stretch), 
1612 (m) (C-N, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.42-1.60 (1H, m, HCHCH2C=N), 1.65 
(3H, s, CH3C=C), 1.70-1.81 (1H, m, HCHCH2C=N), 1.87 (3H, s, CH3C=N), 2.01-2.11 (1H, m, 
CH), 2.15-2.25 (2H, m, CH2C=N), 3.10-3.25 (1H, m, HCHN), 3.65-3.78 (1H, m, HCHN), 4.67 
(1H, s, CHaH=C), 4.78 (1H, s, CHHb=C); 
13C-NMR (100MHz, CDCl3) δC 20.0 (CH3C=C), 24.4 
(CH3C=N), 27.0 (CH2CH2C=N), 30.3 (CH2C=N), 39.7 (CHCH2), 54.1 (CH2N), 110.0 (CH2=C), 
147.2 (CH2=C), 167.5 (C=N); HRMS(EI
+) found 138.1283, C9H16N requires 138.1280. 
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(3S)-6-Methyl-3-(prop-1-en-2-yl)-1,2,3,4,6,7,8,9-octahydroquinolizin-5-ium bromide (299) 
 
To a stirred solution of LDA (2 M in THF, 5 mL, 10.4 mmol) in dry THF (10 mL) at -35 °C 
under argon was added 3R-(prop-1-en-2-yl)-6-methyl-2,3,4,5-tetrahydropyridine (298) (1.3 
g, 9.4 mmol) in dry THF (5 mL) and the resulting mixture stirred at this temperature for 45 
min. After cooling to -78° C, a solution of 1,3-dibromo butane (0.50 mL, 10.4 mmol) in dry 
THF (3 mL) was added, then, the reaction mixture was stirred for 24 h at room 
temperature. The solvent was evaporated under reduced pressure, and residual solvent 
was removed under high vacuum to yield 299 as an orange solid (900 mg, 57%) that was 
used for the next step without purification;. IR (NaCl) cm-1 3030 (m) (CH, stretch), 2850 (m) 
(CH, stretch), 1672 (m) (stretch, C=N), 1665 (m) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 
1.64 (3H, d, J = 7.0 Hz, CH3), 1.69 (3H, s, CH3), 1.80-1.95 (6H, m, 3CH2), 2.09 (1H, m, CHN), 
2.40-2.92 (4H, m, 2CH2C=N
+), 3.55-3.77 (1H, m, HCHN+), 4.11-4.20 ( 1H, m, HCHN+), 4.30-
4.42 (1H, CHN+), 4.67 (1H, s, CHaH=C), 4.78 (1H, s, CHHb=C); HRMS(EI
+) found, 192.1283. 
C13H22N requires 192.1280. 
 (3S,6S,9aS)-6,9a-Dimethyl-3-(prop-1-en-2-yl)decahydroquinolizin-5-iumtrifluoroacetate 
(300) 
 
To a stirred solution of free amine 111 (12 mg, 0.057 mmol) in dry DCM (2 mL) was added 
TFA (5 µL, 0.057 mmol). After 15 min the solvent was evaporated under reduced pressure, 
and the residue was purified by column chromatography on alumina using (ethyl acetate-
methanol, 15%, Rf 0.150) to afford pure TFA salt 300 as yellow-orange oil (15 mg, 82%); IR 
(NaCl) cm-1 3040 (m) (CH, stretch), 2830-2740 (m) (CH, stretch), 1672 (m) (C=N, stretch), 
1665 (m) (C=C, stretch); 1H-NMR (400 MHz, CDCl3) δH 1.27-1.29 (3H, d, J = 6.5 Hz, CH3CH), 
1.53 (3H, s, CH3C), 1.70 (3H, s, CH3C=C), 1.29-1.1.79 (10H, m, 5 x CH2), 2.09 (1H, m, CH), 
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2.72 (1H, m, HCHN), 3.20 (1H, m, HCHN), 3.87 (1H, m, CHN), 4.70 (1H, s, CHaH=C), 4.81 (1H, 
s, CHHb=C), 6.50 (1H, br s, NH); 
13C-NMR (100 MHz, CDCl3) δC 17.6 (CH3CH), 18.5 (CH3C=C), 
21.2 (CH3C), 23.3 (CH2CH2CCH3), 23.6 (CH2CH2CCH3), 25.4 (CH2CCH3), 25.8 (CH2CCH3), 37.3 
(CH2CHN), 40.0 (CH), 34.2 (CH2N), 53.2 (CH3CHN), 60.6 (CN
+), 111.5 (CH2=C), 112.2-117.3 (q, 
J = 287.0 Hz, CF3), 144.8 (CH2=C), 160.2-160.9 (q, J = 40.0 Hz, COO); HRMS(EI
+) found 
208.2066. C14H26N requires 208.2065. 
(R)-6-(3-(2-Methyl-1,3-dioxolan-2-yl)propyl)-3-(prop-1-en-2-yl)-2,3,4,5-
tetrahydropyridine (302)  
 
A stirred solution of LDA (0.8 mL, 2 M in THF, 1.59 mmol) in dry THF (5 mL) under argon 
was cooled to -78 °C and a solution of 3S-(prop-1-en-2-yl)-2, 3, 4, 5-6-methyl-
tetrahydropyridine (182) (200 mg, 1.45 mmol) in dry THF (3 mL) was added. The solution 
was allowed to warm slowly to -35 °C and was stirred at this temperature for 30 min. The 
bright orange solution was then cooled to -78˚C and a solution of 1-bromo-3-butane 
ethylene acetal (301) (0.20 mL, 1.59 mmol) in dry THF (3 mL) was added dropwise. After 
the addition, the reaction was allowed to warm to room temperature over 2 h. As the 
temperature reached to  -15 °C the orange colour disappeared. The reaction was then 
stirred for 24 h at room temperature, before quenching with water (10 mL). The aqueous 
phase was extracted with ether (3 x 5 mL) and the combined organic layers dried over 
K2CO3 and filtered. The filtrate was evaporated under reduced pressure affording crude of 
product as a yellow oil. This was purified by chromatography on basic alumina (hexane-
diethyl ether, 50%, Rf 0.37) to give pure imine acetall (302) as pale yellow oil (175 mg, 70% 
yield); IR (NaCl) cm-1 3060 (m) (CH, stretch), 1660 (m) (C=C, stretch), 1672 (m) (C=N, 
stretch); 1H-NMR (400 MHz, CDCl3) δH 1.33 [3H, s, CH3C(OCH2)2], 1.60-1.64 (6H, m, 3 x CH2), 
1.73 (3H, s, CH3C=C), 2.17 (4H, m, 2CH2C=N), 2.19 (1H, m, CH), 3.19 (1H, m, HCHN), 3.73 
(1H, m, HCHN), 3.96 (4H, m, OCH2CH2O), 4.71 (1H, s, CHaH=C), 4.78 (1H, s, CHHb=C); 
13C-
NMR (100MHz, CDCl3) δC 20.9 (CH3C=C), 23.8 [CH3(CH2O)2], 26.4 (CH2), 35.4 (CH2), 37.1 
(CH2), 39.5 (CH2), 40.5 [CH2C(CH2O)2], 41.1 (CH), 54.0 (CH2N), 64.6 (CH2O), 64.7 (CH2O), 
    181 
 
109.7 (CH2=C), 109.8 [CH2C(CH2O)2], 147.1 (CH2=C), 171.2 (C=N); HRMS(EI
+) found 
251.1283,. C15H25NO2 requires 251.1280. 
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